DGK targeting compounds and uses thereof

By developing compounds that selectively inhibit or degrade DGKα, the problem of tumor evasion of the immune system is solved, the anti-cancer immune response is enhanced, and effective treatment of a variety of cancers is achieved.

CN118946556APending Publication Date: 2024-11-12ARVINAS OPERATIONS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380030720.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-01
Filing Date
2023-02-01
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prior art is difficult to effectively activate and maintain the anti-cancer immune response. Tumors lead to immune system tolerance through various mechanisms (such as dysfunctional T cell signaling, inhibitory regulatory cells and endogenous 'immune checkpoints'), and then Escape from the destruction of the epidemic.

Method used

Develop active compounds with the ability to act as inhibitors of diacylglycerol kinase alpha (DGKα) selectively inhibit or degrade DGKα, thereby enhancing T cell signaling and activation, and overcoming the inhibition of immune checkpoints.

Benefits of technology

By inhibiting or degrading DGKα, it enhances the anti-tumor immune response, improves T cell activation, and improves anti-cancer efficacy. It is especially suitable for a variety of cancers such as colon cancer, pancreatic cancer, breast cancer, etc.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118946556A_ABST
    Figure CN118946556A_ABST
Patent Text Reader

Abstract

Disclosed herein are compounds of Formula (A), or pharmaceutically acceptable salts thereof, which inhibit the activity of one or both of diacylglycerol kinase alpha (DGK alpha). These compounds are useful in the treatment of proliferative diseases (e.g., cancer) and viral infections. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Related applications

[0002] This application claims priority to U.S. Provisional Application No. 63 / 305,668, filed February 1, 2022, the entire contents of which are incorporated herein by reference. Background Art

[0003] Human cancers involve numerous genetic and epigenetic alterations that generate neoantigens that the immune system may recognize (Sjoblom et al. (2006) Science 314:268-74). The adaptive immune system, composed of T lymphocytes and B lymphocytes, possesses potent anti-cancer potential, exhibiting broad responsiveness and high specificity to a wide range of tumor antigens. Furthermore, the immune system displays considerable plasticity and a memory component. Successfully utilizing all these properties of the adaptive immune system would make immunotherapy unique among all cancer treatment modalities. However, despite the observation of endogenous immune responses to cancer in preclinical models and patients, these responses are often ineffective, and identified cancers are perceived as “self” and tolerated by the immune system. This tolerance arises because tumors may actively disrupt anti-tumor immunity using several different mechanisms. These mechanisms include the combined effects of dysfunctional T-cell signaling (Mizoguchi et al. (1992) Science 258:1795-98), inhibitory regulatory cells (Facciabene et al. (2012) Cancer Res. 72:2162-71), and endogenous “immune checkpoints,” which downregulate the intensity of adaptive immune responses and protect normal tissues from collateral damage caused by tumors escaping immune destruction (Topalian et al. (2012) Curr. Opin. Immunol. 24:1-6; Mellman et al. (2011) Nature 480:480-89). Therefore, in the field of cancer treatment, there is a need for novel, safe, and effective anticancer agents that restore T-cell activation, lower antigen thresholds, enhance antitumor function, and / or overcome the inhibitory effects of one or more endogenous immune checkpoints. Summary of the Invention

[0004] This document discloses compounds having activity as inhibitors of diacylglycerol kinase α (DGKα). Furthermore, in embodiments, the disclosed compounds induce the degradation of DGKα.

[0005] In the implementation scheme, the compounds described herein possess desirable efficacy, stability, bioavailability, therapeutic index, and toxicity values, which are important for their use as pharmaceuticals.

[0006] In some respects, this paper provides compounds having the structure of formula (A):

[0007]

[0008] Or its pharmaceutically acceptable salt, wherein:

[0009] Ring A is a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaromatic ring fused with ring B;

[0010] Ring C is a heterocyclic ring, except for R. 3 and R 4 In addition, it can be replaced;

[0011] R 1 It is a C1-C4 alkyl group;

[0012] R 2 It is an H or an electron-withdrawing functional group;

[0013] Each R 3 Independently is NR 5 R 6 ;

[0014] Each R 4 It is independently a C1-C4 alkyl or C1-C4 alkoxy, or

[0015] An R 3 and an R 4 Together with the atoms of the C rings to which they are attached, they form substituted or unsubstituted rings;

[0016] R 5 and R 6 Each is independently H, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group, or

[0017] R 5 and R 6 Together with the nitrogen to which they are attached, they form substituted or unsubstituted rings;

[0018] m and n are each independently 0, 1, 2, 3 or 4.

[0019] In the embodiments, compounds having the structure of formula (A) are disclosed herein:

[0020]

[0021] Or a pharmaceutically acceptable salt thereof, wherein ring A is a substituted or unsubstituted heteroaromatic ring fused with ring B.

[0022] In embodiments of the compound of formula (I), the compound has the structure of formula (II):

[0023]

[0024]

[0025] Or a pharmaceutically acceptable salt thereof, wherein R 9 It is H or C1-C4 alkyl.

[0026] In the implementation scheme of Formula II, R 9 It is a straight-chain or branched C1-C4 alkyl group. In the embodiments of formula II, R 9 It is a methyl group.

[0027] In embodiments of the compound of formula (I), the compound has the structure of formula (III):

[0028]

[0029] Or a pharmaceutically acceptable salt thereof, wherein R 10 It is a C1-C4 alkyl group or an electron-withdrawing functional group.

[0030] In the implementation of formula (III), R 10 It is a straight-chain or branched C1-C4 alkyl group.

[0031] In embodiments of the compound of formula (III), the compound has the structure of formula (IIIa):

[0032]

[0033] or a pharmaceutically acceptable salt thereof.

[0034] In embodiments of compounds of formula (III) or (IIIa), R 10 Selected from halogens, -CH3, -SO2CF3, -N(R) 11 )2、-NO2、-SO2R 12 -C≡N, -C(R) 13 3. -COR 14 -CO2R 16 、-CON(R 17 )2 and -N = 0, where:

[0035] R 11 、R 12 、R 14 、R 15 、R 16 or R 17 Each of them is independently H or a C1-C4 alkyl group (e.g., straight-chain or branched C1-C4 alkyl); and

[0036] Each R 13 It is halogen.

[0037] In embodiments of compounds of formula (III) and (IIIa), R10 It is -Cl. In the embodiments of compounds of formula (III) and (IIIa), R 10 It is -C≡N.

[0038] In embodiments of any of the compounds of formulas (I), (II), (III), and (IIIa), R 1 It is a straight-chain or branched C1-C4 alkyl group. In embodiments of any of the compounds of formulas (I), (II), (III), and (IIIa), R 1 It is a methyl group.

[0039] In embodiments of any of the compounds of formulas (I), (II), (III), and (IIIa), R 2 Selected from H, halogens, -SO2CF3, -N(R) 32 )2、-NO2、-SO2R 26 -C≡N, -C(R) 27 3. -COR 28 -CO2R 30 、-CON(R 31 )2 and -N = 0, where:

[0040] R 32 、R 26 、R 28 、R 30 and R 31 Each of them is independently H or a C1-C4 alkyl group (e.g., straight-chain or branched C1-C4 alkyl); and

[0041] Each R 33 It is halogen.

[0042] In embodiments of any of the compounds of formulas (I), (II), (III), and (IIIa), R 2 It is H. In the embodiments of compounds of formula (I), (II), (III) and (IIIa), R 2 It is -C≡N.

[0043] In embodiments of any of the compounds of formulas (I), (II), (III), and (IIIa), R 4 It is a C1-C4 alkyl group (e.g., straight-chain or branched C1-C4 alkyl group).

[0044] In embodiments of any of the compounds of formulas (I), (II), (III), and (IIIa), R 4 It is a C1-C4 alkoxy group.

[0045] In embodiments of any of the compounds of formulas (I), (II), (III), and (IIIa), the ring C is further composed of one or more components selected from R 15 、R 18 、R 19 、R 20 、R 21 and R 22 substituted by a substituent.

[0046] In embodiments of any of the compounds of formulas (I), (II), (III), and (IIIa), ring C is selected from...

[0047]

[0048] in:

[0049] R 18 and R 19 Each of the following is independently H, OH, C1-C4 alkoxy, C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl) or -NR 23 R 24 ,or

[0050] R 18 and R 19 Together with the carbon atoms they are attached to, they form substituted or unsubstituted rings;

[0051] R 20 It is H or C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl), or

[0052] R 18 and R 20 Or R 19 and R 20 Together with the carbon atoms they are attached to, they form substituted or unsubstituted rings;

[0053] R 21 It is H, C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl), substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;

[0054] R 22 It is a C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl), a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl;

[0055] R 23 and R 24 Each is independently H, C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl), substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;

[0056] R 15It is a C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl), a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl; and

[0057] Indicates the connection point between ring C and ring B.

[0058] In the implementation scheme of ring C, R 21 It is a straight-chain or branched C1-C4 alkyl group. In the embodiments, R 22 It is a straight-chain or branched C1-C4 alkyl group. In cyclic C embodiments, R 23 and R 24 Each is independently H, a straight-chain or branched C1-C4 alkyl, aryl, or heteroaryl. In embodiments with cyclic C, R 15 It is a straight-chain or branched C1-C4 alkyl group.

[0059] In any embodiment of compounds of formulas (I), (II), (III), and (IIIa), ring C is where R 18 and R 19 Together with the carbon atoms they are attached to, they form 5- or 6-membered substituted or unsubstituted carbon rings or 5- or 6-membered substituted or unsubstituted heterocycles.

[0060] In any embodiment of compounds of formulas (I), (II), (III), and (IIIa), ring C is where R 18 and R 20 Or R 19 and R 20 Together with the carbon atoms they are attached to, they form substituted or unsubstituted 5-, 6-, or 7-membered carbon rings or substituted or unsubstituted 5-, 6-, or 7-membered heterocycles.

[0061] In the implementation scheme of ring C, R 20 It is a straight-chain or branched C1-C4 alkyl group.

[0062] In embodiments of any of the compounds of formulas (I), (II), (III), and (IIIa), ring C is selected from...

[0063]

[0064] In any embodiment of compounds of formulas (I), (II), (III), and (IIIa), ring C is

[0065] where R 21 yes in:

[0066] R 25Selected from OH, halogens, C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl), C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, aryl and heteroaryl;

[0067] t is 0, 1, or 2; and

[0068] Instruction R 21 The connection point with N.

[0069] In any embodiment of compounds of formulas (I), (II), (III), and (IIIa), ring C is

[0070] where R 21 yes in:

[0071] R 25 Selected from OH, halogens, C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl), C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, aryl and heteroaryl;

[0072] t is 0, 1, or 2; and

[0073] Instruction R 21 The connection point with N.

[0074] In the implementation of ring C, each R 25 It is selected from OH, halogen, C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl), C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, aryl and heteroaryl.

[0075] In any embodiment of compounds of formulas (I), (II), (III), and (IIIa), ring C is

[0076] where R 21 Selected from

[0077]

[0078] In any embodiment of compounds of formulas (I), (II), (III), and (IIIa), ring C is

[0079] where R 21 Selected from

[0080]

[0081] In embodiments of any of the compounds of formulas (I), (II), (III), and (IIIa), ring C is selected from...

[0082]

[0083] In the implementation scheme of ring C, R 22 It is a C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl), a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl. In embodiments with cyclic C, R 22 It is a straight-chain or branched C1-C4 alkyl group.

[0084] In any embodiment of compounds of formulas (I), (II), (III), and (IIIa), ring C is where R 18 and R 19 Each is independently selected from -H, -OH, C1-C4 alkoxy, C1-C4 alkyl (straight-chain or branched C1-C4 alkyl) and And among them:

[0085] R 26 It is H, C1-C4 alkyl (straight-chain or branched C1-C4 alkyl), substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;

[0086] Each R 27 It is -OH, C1-C4 alkyl (straight-chain or branched C1-C4 alkyl), halogen, C1-C4 alkoxy or C1-C4 haloalkoxy, or

[0087] Two adjacent R 27 The groups and the two carbon atoms to which they are attached form substituted or unsubstituted 5- or 6-membered rings;

[0088] q is 0, 1, or 2; and

[0089] Instruction R 18 and R 19 The connection point of one or both of them with ring C.

[0090] In embodiments of any of the compounds of formulas (I), (II), (III), and (IIIa), ring C is selected from... where R 18 and R 19 Each is independently selected from -H, -OH, C1-C4 alkyl groups and in:

[0091] R 26It is H, C1-C4 alkyl (straight-chain or branched C1-C4 alkyl), substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;

[0092] Each R 27 It is -OH, C1-C4 alkyl (straight-chain or branched C1-C4 alkyl), halogen, C1-C4 alkoxy or C1-C4 haloalkoxy, or

[0093] Two adjacent R 27 The groups and the two carbon atoms to which they are attached form substituted or unsubstituted 5- or 6-membered rings;

[0094] q is 0, 1, or 2; and

[0095] Instruction R 18 and R 19 The connection point of one or both of them with ring C.

[0096] In the implementation scheme of ring C, R 26 It is a straight-chain or branched C1-C4 alkyl group.

[0097] In the implementation of ring C, each R 27 It is -OH, straight-chain or branched C1-C4 alkyl, C1-C4 alkoxy or C1-C4 haloalkoxy.

[0098] In embodiments of any of the compounds of formulas (I), (II), (III), and (IIIa), ring C is selected from...

[0099]

[0100]

[0101]

[0102]

[0103]

[0104] In embodiments of any of the compounds of formulas (I), (II), (III), and (IIIa), ring C is selected from...

[0105]

[0106] In any embodiment of compounds of formulas (I), (II), (III), and (IIIa), ring C is where R 18 and R 19 Together with the carbon atoms they are attached to form in:

[0107] X and Y are independently CH2 and NR, respectively. 29 O or C=O;

[0108] R 28 It is -OH, halogen, C1-C4 alkyl (straight-chain or branched C1-C4 alkyl), C1-C4 haloalkyl, C1-C4 alkoxy, or C1-C4 haloalkoxy; R 29 It is H or C1-C4 alkyl (straight-chain or branched C1-C4 alkyl); and

[0109] w is 0, 1, or 2.

[0110] In the implementation of ring C, each R 28 It is independently selected from -OH, halogen, straight-chain or branched C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy and C1-C4 haloalkoxy.

[0111] In the implementation scheme of ring C, R 29 It is a straight-chain or branched C1-C4 alkyl group.

[0112] In embodiments of any of the compounds of formulas (I), (II), (III), and (IIIa), ring C is selected from...

[0113]

[0114] In embodiments of any of the compounds of formulas (I), (II), (III), and (IIIa), ring C is selected from...

[0115]

[0116] where R 34 It is a C1-C4 alkyl group.

[0117] In the implementation scheme of ring C, R 34 It is a straight-chain or branched C1-C4 alkyl group.

[0118] In any embodiment of compounds of formulas (I), (II), (III), and (IIIa), ring C is

[0119] where R 32 yes

[0120] In any embodiment of compounds of formulas (I), (II), (III), and (IIIa), ring C is where R 22 It is a C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl), a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl.

[0121] In embodiments of compounds of formulas (I), (II), (III), and (IIIa), ring C is selected from...

[0122]

[0123]

[0124] In the implementation plan, ring C is

[0125] In the implementation scheme, compounds selected from the following are disclosed:

[0126]

[0127]

[0128]

[0129]

[0130]

[0131]

[0132]

[0133]

[0134]

[0135]

[0136]

[0137]

[0138]

[0139]

[0140]

[0141]

[0142]

[0143]

[0144]

[0145]

[0146]

[0147] or a pharmaceutically acceptable salt thereof.

[0148] In the implementation scheme, compounds selected from the following are disclosed:

[0149]

[0150]

[0151]

[0152]

[0153]

[0154]

[0155]

[0156]

[0157]

[0158]

[0159] Or its pharmaceutically acceptable salt, wherein:

[0160] X is CH2, O, or NR. 29 ;as well as

[0161] R 29 It is an H or C1-C4 alkyl group (e.g., straight-chain or branched C1-C4 alkyl). In embodiments, compounds selected from the following are disclosed herein:

[0162]

[0163]

[0164]

[0165]

[0166]

[0167]

[0168]

[0169]

[0170]

[0171]

[0172]

[0173]

[0174]

[0175]

[0176]

[0177]

[0178]

[0179]

[0180]

[0181]

[0182]

[0183]

[0184]

[0185]

[0186]

[0187]

[0188]

[0189] or a pharmaceutically acceptable salt thereof.

[0190] This document also discloses pharmaceutical compositions comprising one or more of the compounds disclosed herein and pharmaceutically acceptable excipients. In embodiments, the pharmaceutical compositions further comprise one or more additional anticancer agents. In embodiments, at least one of the additional anticancer agents is an immune checkpoint inhibitor.

[0191] In some aspects, this document discloses methods for treating cancer, comprising administering to a subject in need a therapeutically effective amount of one or more of the compounds disclosed herein or pharmaceutical compositions thereof. In embodiments, the cancer is selected from colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, cervical cancer, kidney cancer, head and neck cancer, lymphoma, leukemia, and melanoma.

[0192] In some respects, this document discloses methods for inhibiting the activity of diacylglycerol kinase α (DGKα), comprising administering to a subject in need a therapeutically effective amount of one or more of the compounds disclosed herein or pharmaceutical compositions thereof. DETAILED DESCRIPTION

[0193] Diacylglycerol kinase (DGK) is a lipid kinase that mediates the conversion of diacylglycerol to phosphatidic acid, thereby terminating T cell function transmitted through the TCR signaling pathway. Therefore, DGKs act as intracellular checkpoints, and inhibition of DGK is expected to enhance T cell signaling pathways and T cell activation. DGKα knockout mouse models have shown a hyperresponsive T cell phenotype and improved antitumor immune activity (Zha Y et al., Nature Immunology, (2006) 12:1343; Olenchock B.A. et al., Nature (2006) 11:1174-81). Furthermore, overexpression of DGKα has been observed in tumor-infiltrating lymphocytes isolated from human renal cell carcinoma patients, leading to suppression of T cell function (Prinz, PU et al., J Immunology (2012) 12:5990-6000). Therefore, DGKα can be considered a target for cancer immunotherapy (Riese MJ et al. Front Cell Dev Biol. (2016) 4:108; Chen, SS et al. Front Cell Dev Biol. (2016) 4:130; Avila-Flores, A. et al. Immunology and Cell Biology (2017) 95:549-563; Noessner, E. Front Cell Dev Biol. (2017) 5:16; Krishna, S. et al. Front Immunology (2013) 4:178; Jing, W. et al. Cancer Research (2017) 77:5676-86). Compounds that can be used as inhibitors of DGKα are still needed.

[0194] Therefore, this document discloses compounds having activity as DGKα inhibitors. In embodiments, the disclosed compounds selectively inhibit DGKα. In embodiments, the disclosed compounds are selective inhibitors of DGKα relative to other diacylglycerol kinases (e.g., DGKζ).

[0195] In the embodiments, the disclosed compounds cause the degradation of DGKα. In the embodiments, the disclosed compounds cause the selective degradation of DGKα. In the embodiments, the disclosed compounds cause the selective degradation of DGKα relative to other diacylglycerol kinases (e.g., DGKζ).

[0196] The disclosed compounds can be used to treat certain diseases or conditions. In embodiments, the disclosed compounds can be used to treat certain cancers (e.g., colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, cervical cancer, kidney cancer, head and neck cancer, lymphoma, leukemia, and melanoma).

[0197] definition

[0198] Unless otherwise defined herein, the scientific and technical terms used in this application shall have the meanings commonly understood by one of ordinary skill in the art. Generally, the terms and techniques relating to chemistry, cell and tissue culture, molecular biology, cell and cancer biology, neurobiology, neurochemistry, virology, immunology, microbiology, pharmacology, genetics, and protein and nucleic acid chemistry described herein are well known and commonly used in the art.

[0199] Unless otherwise stated, the methods and techniques disclosed herein are generally practiced according to conventional methods well known in the art and as described in the various general and more specific references cited and discussed in this specification. See, for example, “Principles of Neural Science,” McGraw-Hill Medical, New York, NY (2000); Motulsky, “Intuitive Biostatistics,” Oxford University Press, Inc. (1995); Lodish et al., “Molecular Cell Biology, 4th Edition,” WH Freeman & Co., New York (2000); Griffiths et al., “Introduction to Genetic Analysis, 7th Edition,” WH Freeman & Co., NY (1999); and Gilbert et al., “Developmental Biology, 6th Edition,” Sinauer Associates, Inc., Sunderland, MA (2000).

[0200] Chemical terms used herein are used in accordance with the usual usage in the field, as illustrated in "The McGraw-Hill Dictionary of Chemical Terms," ​​edited by Parker S., McGraw-Hill, San Francisco, Calif. (1985).

[0201] All the foregoing references in this application, as well as all other publications, patents, and published patent applications, are specifically incorporated herein by reference. In case of conflict, this specification (including its specific definitions) shall prevail.

[0202] As used herein, the term "cell" refers to a cell in vitro, ex vivo, or in vivo. In embodiments, an ex vivo cell may be a portion of a tissue sample excised from an organism such as a mammal. In embodiments, an in vitro cell may be a cell in a cell culture. In embodiments, an in vivo cell is a cell living in an organism such as a mammal.

[0203] As used herein, the term "contact" means bringing together the indicated portions in an in vitro or in vivo system. For example, "contacting" a DGKα enzyme with a compound of the present invention includes administering a compound of the present invention to a subject (such as a human) having DGKα, and, for example, introducing a compound of the present invention into a sample containing cells or a purified formulation containing a DGKα enzyme.

[0204] The term "DGKα degrader" refers to a reagent that targets the DGKα enzyme, thereby causing its degradation.

[0205] The term "DGKα inhibitor" refers to an agent that enhances T cell stimulation by inhibiting the enzymatic activity of diacylglycerol kinase α (DGKα) in T cells. DGKα inhibitors can be reversible. A "reversible DGKα inhibitor" is a compound that reversibly inhibits DGKα enzyme activity at either the catalytic or non-catalytic site.

[0206] The terms “patient,” “subject,” and “individual” are used interchangeably herein and refer to human or non-human animals. These terms include mammals such as humans, primates, livestock (including cattle, pigs, etc.), companion animals (e.g., canines, felines, etc.), and rodents (e.g., mice and rats). In this implementation, the subject is a human.

[0207] As used herein, the term "selective inhibitor of DGKα" refers to a compound that selectively inhibits the activity of DGKα compared to other diacylglycerol kinases (e.g., DGKζ).

[0208] As used herein, the term “selective degrader of DGKα” refers to a compound that selectively degrades DGKα compared to other diacylglycerol kinases (e.g., DGKζ).

[0209] "Treatment" refers to a condition or patient and "treatment" means taking steps by applying the compounds or compositions of the present invention to obtain a beneficial or desired outcome, including clinical outcomes. Beneficial or desired outcomes include, but are not limited to, relief or improvement of one or more symptoms or conditions, reduction of disease severity, stabilization of the disease state (i.e., no worsening), prevention of disease spread, delay or slowing of disease progression, improvement or reduction of the disease state, and remission (whether partial or complete). "Treatment" may also refer to prolonged survival compared to expected survival without treatment.

[0210] The "administering" or "administration of" of the compounds or compositions of the present invention to a subject may be performed under the guidance of an attending physician using any of a variety of routes and methods known to those skilled in the art. For example, the compounds or pharmaceutical compositions of the present invention may be administered to a subject requiring such treatment via any of the following routes: intravenous, intra-arterial, intradermal, intramuscular, intraperitoneal, subcutaneous, intraocular, sublingual, oral (by ingestion), intranasal (by inhalation), intravaginal, intraspinal, intrathecal, intracerebral, and percutaneous (by skin absorption). The compounds or compositions of the present invention may also be suitably introduced via rechargeable or biodegradable polymer devices or other devices (e.g., patches and pumps) or formulations, providing extended, slowed, delayed, or controlled release of the compound or composition. Administration may also be performed, for example, once, multiple times, and / or over one or more extended periods.

[0211] The appropriate method of administering the compounds or pharmaceutical compositions of the present invention to a subject will also depend on a variety of factors, such as the subject's age, weight, sex and physical condition, as well as the chemical and biological properties of the compounds or pharmaceutical compositions (e.g., solubility, absorption, bioavailability, metabolism, stability and toxicity).

[0212] In embodiments, the compounds or pharmaceutical compositions of the present invention are administered orally, for example, by ingestion, to a subject. In embodiments, the orally administered compounds or pharmaceutical compositions are controlled-release formulations (e.g., delayed-release, prolonged-release, or slow-release).

[0213] As used herein, the phrase "combined administration" refers to any form of administration of two or more different therapeutic agents such that the previously administered therapeutic agent remains effective in the body while the second therapeutic agent is being administered (e.g., both drugs are effective simultaneously in the patient, which may include synergistic effects between the two drugs). For example, different therapeutic compounds may be administered simultaneously or sequentially in the same formulation or in separate formulations. Thus, individuals receiving such treatment may benefit from the combined effect of different therapeutic agents.

[0214] The "therapeutic effective amount" or "therapeutic dose" of the compound or pharmaceutical composition of the present invention is the amount of the drug or composition that will have the expected therapeutic effect when administered to a subject. A complete therapeutic effect does not necessarily occur with a single dose, but may occur only after a series of doses. Therefore, a therapeutic effective amount can be administered in one or more doses. The effective amount required by the subject will depend on factors such as the subject's age, weight, health status, sex, and the nature and extent of the condition being treated (e.g., cancer). The attending physician will typically determine the effective amount for a given situation based on these and other factors.

[0215] The term "alkyl" refers to a saturated aliphatic group, including straight-chain alkyl, branched alkyl, cycloalkyl (alicyclic) groups, alkyl-substituted cycloalkyl, and cycloalkyl-substituted alkyl. In a preferred embodiment, the straight-chain or branched alkyl group has six or fewer carbon atoms in its main chain (e.g., straight chain C1-C6, branched chain C3-C6), more preferably four or fewer carbon atoms in its main chain.

[0216] The term "alkoxy" refers to an alkyl group attached to an oxygen atom, represented by -O-alkyl. For example, "C1-C4 alkoxy" includes methoxy, ethoxy, propoxy, isopropoxy, and butoxy.

[0217] When used in conjunction with a chemical moiety (e.g., alkyl, alkenyl, alkoxy), the term "C" is used. x -C y "" refers to groups containing x to y carbon atoms in the chain. For example, C1-C6 alkyl groups contain one to six carbon atoms in the chain; C1-C4 alkyl groups contain one to four carbon atoms in the chain.

[0218] As used herein, the term "aryl" includes substituted or unsubstituted monocyclic aromatic groups, wherein each ring atom is a carbon. Preferably, the ring is a 5- to 7-membered ring. The term "aryl" also includes polycyclic systems having two or more cyclic rings, wherein the two or more carbons are shared by two adjacent rings, and wherein at least one ring is aromatic, i.e., the other cyclic rings may be selected from cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclic, and combinations thereof. Aryl groups include benzene, naphthalene, phenanthrene, phenol, aniline, etc.

[0219] As used herein, the term "carbocyclic ring" refers to a non-aromatic saturated or unsaturated ring, wherein each atom of the ring is a substituted or unsubstituted carbon atom. Preferably, the carbocyclic ring contains 3 to 10 atoms, more preferably 3 to 8 atoms, including 5 to 7 atoms, such as 5 or 6 atoms.

[0220] As used herein, the term "electron-withdrawing group" refers to an atom or functional group that typically attracts electron density from neighboring atoms to itself through resonance or induction effects. Exemplary electron-withdrawing groups include, but are not limited to, trifluoromethanesulfonyl (-SO2CF3) and substituted or unsubstituted ammonium groups (-NR3). + The following groups are represented as follows: (where each R is H or alkyl), nitro (-NO2), sulfonic acid (-SO3H), sulfonyl (SO2R, where R is alkyl), cyano (-C≡N), haloformyl (-COX, where X is Cl, Br or I), formyl (-CHO), acyl (-COR, where R is alkyl), carboxyl (-CO2H), alkoxycarboxyl (-CO2R, where R is alkyl), substituted or unsubstituted aminocarbonyl (-CONH2, -CONHR, -CONR2, where R is alkyl), halogen groups and nitroso (-N=O).

[0221] As used herein, the terms “halogenated group,” “halogen,” and “halogen group” refer to substituents in Group 17 of the periodic table and include fluorine (-F), chlorine (-Cl), bromine (-Br), and iodine (-I) substituents.

[0222] The terms “halogenated alkyl” and “halogenated alkoxy” refer to alkyl or alkoxy groups that are substituted with one or more halogen atoms, respectively.

[0223] The term "heteroaryl" or "heteroaromatic" includes substituted or unsubstituted aromatic monocyclic structures, preferably 5- to 7-membered rings, more preferably 5- to 6-membered rings, whose ring structure includes at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms. The term "heteroaryl" also includes polycyclic systems having two or more rings, wherein two or more carbons are shared by two adjacent rings, wherein at least one ring is heteroaromatic; for example, the other rings may be selected from cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, and heterocyclic groups. Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, and pyrimidine.

[0224] As used herein, the term "heteroatom" refers to an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, and sulfur.

[0225] The term "heterocyclic" refers to a substituted or unsubstituted non-aromatic ring structure, preferably a 3- to 10-membered ring, more preferably a 3- to 7-membered ring, whose ring structure includes at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms. The term "heterocyclic" also includes polycyclic systems having two or more rings, wherein two or more carbons are shared by two adjacent rings, and at least one ring is heterocyclic; for example, the other rings may be selected from cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, and heterocyclic groups. Heterocyclic groups include, for example, diazine, imidazoline, piperidine, piperazine, pyrrolidine, morpholine, lactone, lactam, octahydropyrrolo[3,4-c]pyrrole, etc.

[0226] The term "substituted" refers to the portion of the main chain in which one or more carbon atoms are replaced by substituents. It should be understood that "substituted" or "substituted" includes the implicit limiting condition that such substitution meets the permissible valence of the substituted atom and the substituent, and that said substitution produces a stable compound, for example, which does not spontaneously undergo transformations such as rearrangement, cyclization, or elimination. As used herein, the term "substituted" is considered to include all permissible substituents in organic compounds. In a broad sense, permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents in organic compounds. For suitable organic compounds, permissible substituents may be one or more, and may be the same or different. For the purposes of this invention, heteroatoms such as nitrogen may have hydrogen substituents and / or any permissible substituents in organic compounds that meet the heteroatom valence as described herein. Substituents may include any substituents described herein, such as halogens, hydroxyl groups, carbonyl groups (such as carboxyl, alkoxycarbonyl, formyl, or acyl), thiocarbonyl groups (such as thioesters, thioacetic acids, or thiocarbamates), alkoxy groups, phosphoryl groups, phosphate groups, phosphonates, hypophosphonates, amino groups, amide groups, amidine groups, imine groups, cyano groups, nitro groups, azide groups, mercapto groups, alkylthio groups, sulfate groups, sulfonates, aminosulfonyl groups, sulfonamide groups, sulfonyl groups, heterocyclic groups, aralkyl groups, or aromatic or heteroaromatic moieties. Those skilled in the art will understand that, where appropriate, the substituted portion of the hydrocarbon chain may itself be substituted.

[0227] The term "aromatic ring" includes aryl and heteroaryl rings.

[0228] The term "ring" includes aryl, cycloalkyl, heterocyclic, carbocyclic, and heteroaryl ring systems.

[0229] Some of the compounds described herein can exist in various stereoisomeric forms. Stereoisomers are compounds that differ only in spatial arrangement. When the disclosed compounds are named or described as having or not having a structure indicating stereochemistry, it should be understood that the name or structure includes all possible stereoisomers, geometric isomers, including substantially pure stereo or geometric isomers, and combinations thereof.

[0230] When the stereochemical configuration at the chiral center of a compound having one or more chiral centers is described by its chemical name (e.g., where the configuration is indicated by "R" or "S" in the chemical name) or structure (e.g., the configuration is indicated by a "wedge" bond), the enrichment of the indicated configuration relative to the opposite configuration is greater than 50%, 60%, 70%, 80%, 90%, 99%, or 99.9%. "Enrichment of the indicated configuration relative to the opposite configuration" is a molar percentage and is determined by dividing the number of compounds having the indicated stereochemical configuration at the chiral center by the total number of all compounds in the mixture having the same or opposite stereochemical configurations.

[0231] When the stereochemical configuration at the chiral centers in a compound having two or more chiral centers is described by its structure (e.g., indicated by a "wedge" bond) and the configuration with respect to the two or more chiral centers is labeled "or1", it means that the compound comprises a mixture of stereoisomers, and the stereochemistry is relative in the described configurations between the two or more chiral centers. For example,

[0232] This means that the compound contains A mixture.

[0233] When the stereochemical configuration at the chiral center in a compound having two or more chiral centers is described by its structure (e.g., the configuration is indicated by a “wedge” bond) and the configuration with respect to two or more chiral centers is labeled “abs”, it means that the compound is stereochemically enriched, as the stereochemistry is drawn, or conversely, one or the other stereoisomer is absolute.

[0234] For example,

[0235] This means that the compound is The indicated configuration has an enrichment of more than 50%, 60%, 70%, 80%, 90%, 99%, or 99.9% relative to the opposite configuration.

[0236] Enantiomers are a pair of mirror-image, non-overlapping stereoisomers, most commonly because they contain an asymmetrically substituted carbon atom as a chiral center. "Enantiomers" refers to one of a pair of molecules that are mirror images of each other and cannot be superimposed. Diastereomers are stereoisomers containing two or more asymmetrically substituted carbon atoms. "Geometric isomers" are stereoisomers with different substituent atom orientations associated with carbon-carbon double bonds, carbocyclic rings, or bridged bicyclic systems.

[0237] Mixtures of enantiomers and diastereomers can be resolved into their component enantiomers or stereoisomers by well-known methods, such as chiral gas chromatography, chiral high-performance liquid chromatography, crystallizing the compound into a chiral salt complex, or crystallizing the compound in a chiral solvent. Enantiomers and diastereomers can also be obtained from diastereomers or enantiomerically pure intermediates, reagents, and catalysts by well-known asymmetric synthetic methods.

[0238] Compounds of the present invention

[0239] This document discloses compounds having activity as DGKα inhibitors. In a preferred embodiment, the disclosed compounds selectively inhibit DGKα. In an embodiment, the disclosed compounds are selective inhibitors of DGKα relative to other diacylglycerol kinases (e.g., DGKζ).

[0240] In the embodiments, the disclosed compounds cause the degradation of DGKα. In the embodiments, the disclosed compounds cause the selective degradation of DGKα. In the embodiments, the disclosed compounds cause the selective degradation of DGKα relative to other diacylglycerol kinases (e.g., DGKζ).

[0241] In the implementation plan, the disclosed compounds possess desirable efficacy, stability, bioavailability, therapeutic index, and toxicity values, which are important for their use as pharmaceuticals.

[0242] In the embodiments, compounds having the structure according to formula (A) are disclosed herein:

[0243]

[0244] Or its pharmaceutically acceptable salt, wherein:

[0245] Ring A is a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaromatic ring fused with ring B;

[0246] The ring C is a substituted or unsubstituted carbon ring or a substituted or unsubstituted heterocycle;

[0247] R 1 It is an alkyl group (e.g., straight-chain or branched C1-C6 alkyl group (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, neopentyl, pentyl, hexyl));

[0248] R 2 It is an H or an electron-withdrawing functional group;

[0249] Each R 3 Independently is NR 5 R 6 ;

[0250] Each R 4 Independently, it is an alkyl group (e.g., straight-chain or branched C1-C6 alkyl groups (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, neopentyl, pentyl, hexyl)) or an alkoxy group (e.g., C1-C6 alkoxy groups (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, neopentoxy, pentoxy, hexoxy)), or

[0251] An R 3 and an R 4 Together with the atoms of the C rings to which they are attached, they form substituted or unsubstituted rings;

[0252] R 5 and R 6 Each is independently H, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group, or

[0253] R 5 and R 6 Together with the nitrogen to which they are attached, they form substituted or unsubstituted rings; and

[0254] m and n are each an independent integer that is 0 or greater than 0 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10).

[0255] In embodiments of formula (A), compounds having the structure according to formula (I) are disclosed herein:

[0256]

[0257] Or its pharmaceutically acceptable salt, wherein:

[0258] Ring A is a substituted or unsubstituted heteroaromatic ring fused with ring B;

[0259] Ring C is a substituted or unsubstituted heterocycle;

[0260] R 1 It is a C1-C4 alkyl group (e.g., straight-chain or branched C1-C4 alkyl group).

[0261] R 2 It is an H or an electron-withdrawing functional group;

[0262] Each R 3 Independently is NR 5 R 6 ;

[0263] Each R 4 Independently, it is a C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl) or a C1-C4 alkoxy, or

[0264] An R 3 and an R4 Together with the atoms of the C rings to which they are attached, they form substituted or unsubstituted rings;

[0265] R 5 and R 6 Each is independently H, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group, or

[0266] R 5 and R 6 Together with the nitrogen to which they are attached, they form substituted or unsubstituted rings;

[0267] m and n are each independently 0, 1, 2, 3 or 4.

[0268] In the embodiments, compounds having the structure according to formula (I) are disclosed herein:

[0269]

[0270] Or its pharmaceutically acceptable salt, wherein:

[0271] Ring A is a 5- or 6-membered substituted or unsubstituted heteroaromatic ring fused with ring B;

[0272] The ring C is a heterocycle with 5 to 8 substituted or unsubstituted members;

[0273] R 1 It is a C1-C4 alkyl group (e.g., straight-chain or branched C1-C4 alkyl group).

[0274] R 2 It is an H or an electron-withdrawing functional group;

[0275] Each R 3 Independently is NR 5 R 6 ;

[0276] Each R 4 Independently, it is a C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl) or a C1-C4 alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy), or

[0277] An R 3 and an R 4 Together with the atoms of the C rings to which they are attached, they form substituted or unsubstituted rings;

[0278] R 5 and R 6 Each is independently H, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group, or

[0279] R 5 and R6 Together with the nitrogen to which they are attached, they form substituted or unsubstituted rings; and

[0280] m and n are each independently 0, 1, 2, 3 or 4.

[0281] In the embodiments, compounds of formula (A) or formula (I) are disclosed herein, wherein ring A is selected from pyridine, imidazole, thiazole, oxazole, pyrazole and isoxazole.

[0282] In the embodiments, compounds of formula (A) or formula (I) are disclosed herein, wherein ring A is selected from piperidine, diazines, octahydropyrrolo[3,4-c]pyrrole, imidazoline, and pyrrolidinyl.

[0283] In the embodiments, compounds of formula (A) or formula (I) having a structure according to formula (IIa) are disclosed herein:

[0284]

[0285] Or a pharmaceutically acceptable salt thereof, wherein Y is S or CH or CR 33 ; R 9 It is H, halogen, cyano (-CN), C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl), C1-C4 haloalkyl (e.g., fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, chloroethyl, dichloroethyl, trichloroethyl, fluoropropyl, difluoropropyl, trifluoropropyl, chloropropyl, dichloropropyl, trichloropropyl), C1-C4 alkoxy (e.g., methoxy, ethoxy, propoxy, isopropyl, butoxy), or NR. 9a , where R 9a It is a C1-C4 alkyl group (e.g., straight-chain or branched C1-C4 alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl); and R 33 It is a C1-C4 alkyl group (e.g., straight-chain or branched C1-C4 alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl), a C1-C4 haloalkyl group (e.g., fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, chloroethyl, dichloroethyl, trichloroethyl, fluoropropyl, difluoropropyl, trifluoropropyl, chloropropyl, dichloropropyl, trichloropropyl), or a C1-C4 alkoxy group (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy). In some embodiments, R 9 It is a straight-chain or branched C1-C4 alkyl group. For example, in a specific embodiment, R 9 It is methyl, ethyl, propyl, or butyl. In a specific embodiment, R 9 It is a methyl group.

[0286] In the embodiments, compounds of formula (A) or formula (I) having a structure according to formula (II) are disclosed herein:

[0287]

[0288] Or a pharmaceutically acceptable salt thereof, wherein R 9 It is H, halogen, cyano (-CN), C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl), C1-C4 haloalkyl (e.g., fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloroethyl, fluoroethyl, difluoroethyl, trifluoroethyl, chloroethyl, dichloroethyl, trichloroethyl, fluoropropyl, difluoropropyl, trifluoropropyl, chloropropyl, dichloropropyl, trichloropropyl), C1-C4 alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy), or NR. 9a , where R 9a It is a C1-C4 alkyl group (e.g., straight-chain or branched C1-C4 alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl). In the embodiments, R 9 It is a straight-chain or branched C1-C4 alkyl group. For example, in a specific embodiment, R 9 It is methyl, ethyl, propyl, or butyl. In the embodiment of formula (II), R 9 It is a methyl group.

[0289] In the embodiments, compounds of formula (A) or formula (I) having a structure according to formula (III) are disclosed herein:

[0290]

[0291] Or a pharmaceutically acceptable salt thereof, wherein R 10 It is H, a C1-C4 alkyl group (e.g., straight-chain or branched C1-C4 alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl), a carbocyclic group (e.g., C3-C7 cycloalkyl), or an electron-withdrawing functional group; and q is 1 or 2. In an embodiment of formula (III), R 10 It is a C1-C4 alkyl group (e.g., straight-chain or branched C1-C4 alkyl) or an electron-withdrawing functional group. In the embodiments, R 10 It is methyl, ethyl, propyl, isopropyl, or butyl. In the embodiment of formula III), R 10 It is a methyl group.

[0292] In the embodiments, compounds of formula (III) having the structure of formula (IIIa) are disclosed herein:

[0293]

[0294] or a pharmaceutically acceptable salt thereof.

[0295] In the implementation of formula (IIIa), R 10 It is a C1-C4 alkyl group (e.g., straight-chain or branched C1-C4 alkyl groups, such as methyl, ethyl, propyl, isopropyl, or butyl). In an embodiment of formula (IIIa), R 10 It is a straight-chain or branched C1-C4 alkyl group. In the embodiment of formula (IIIa), R 10 It is a methyl group (-CH3).

[0296] In the implementation plan, R 10 Selected from halogens (e.g., -F, -Cl), -CH3, -SO2CF3, -N(R) 11 )2、-NO2、-SO2R 12 -C≡N, -C(R) 13 3. -COR 14 -CSR 15 -CO2R 16 、-CON(R 17 )2 and -N = 0, where:

[0297] R 11 、R 12 、R 14 、R 15 、R 16 or R 17 Each of them is independently H or a C1-C4 alkyl group (e.g., straight-chain or branched C1-C4 alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl); and

[0298] Each R 13 It is a halogen (e.g., -F, -Cl).

[0299] In the implementation plan, R 10 It is -Cl. Alternatively, R 10 Yes, it is -F.

[0300] In the implementation plan, R 10 It is -C≡N.

[0301] In the implementation plan, R 10 It is -N(R) 11 )2, -SO2R 12 or -C(R) 13 3. -CSR 15 , where R 11 、R 12 and R 15 Each of them is independently either H or methyl.

[0302] In the implementation plan, R10 It is -COR 14 , where R 14 It is H or methyl. In the embodiment, R 10 Yes -CHO. In the implementation plan, R 10 It is -CO(CH3).

[0303] In the implementation plan, R 10 It is -CO2(R) 16 ), where R 16 It is H or methyl. In the embodiment, R 10 It is CO2 (CH3).

[0304] In the implementation plan, R 10 It is -CON(R) 17 )2, where each R 17 Independently, it is H or methyl. In the embodiments, R 10 It is -CONH(CH3). In the implementation scheme, R 10 It is -CON(CH3)2.

[0305] In the implementation plan, R 10 It is -N=O.

[0306] In the embodiments, compounds having a structure according to any one of formula (A), (I), (II), (III) or (IIIa) are disclosed herein, wherein R 1 It is a straight-chain or branched C1-C4 alkyl group. In any embodiment of formula (A), (I), (II), (III) or (IIIa), R 1 It is methyl, ethyl, propyl, or butyl. In embodiments of formula (A), (I), (II), (III), or (IIIa), wherein R 1 It is a methyl group.

[0307] In the embodiments, compounds having a structure according to any one of formula (A), (I), (II), (III) or (IIIa) are disclosed herein, wherein R 2 Selected from H, halogens, -SO2CF3, -N(R) 32 )2、-NO2、-SO2R 26 -C≡N, -C(R) 27 3. -COR 28 -CSR 29 -CO2R 30 、-CON(R 31 )2 and N=0, where:

[0308] R 32 、R 26 、R28 、R 29 、R 30 or R 31 Each of them is independently H or a C1-C4 alkyl group (e.g., straight-chain or branched C1-C4 alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl); and

[0309] Each R 33 It is a halogen (e.g., -F, -Cl).

[0310] In the embodiments, compounds having a structure according to any one of formula (A), (I), (II), (III) or (IIIa) are disclosed herein, wherein R 2 It’s H.

[0311] In the embodiments, compounds having a structure according to any one of formula (A), (I), (II), (III) or (IIIa) are disclosed herein, wherein R 2 It is -C≡N.

[0312] In the embodiments, compounds having a structure according to any one of formula (A), (I), (II), (III) or (IIIa) are disclosed herein, wherein R 2 It is -N(R) 32 )2, -SO2R 26 -C(R) 33 3. -COR 28 -CSR 29 -CO2R 30 or -CON(R) 31 )2, where R 32 、R 26 、R 28 、R 29 、R 30 and R 31 Each of them is independently either H or methyl; and each R 33 It is halogen.

[0313] In embodiments of any of the compounds of formulas (I), (II), (III), and (IIIa), the ring C is further composed of one or more components selected from R 15 、R 18 、R 19 、R 20 、R 21 and R 22 substituted by a substituent.

[0314] In embodiments of any of the compounds of formulas (I), (II), (III), and (IIIa), the ring C is further composed of one or more components selected from R 15 、R18 、R 19 、R 20 、R 21 and R 22 Substituents are used to replace the substituents, wherein:

[0315] R 15 It is a straight-chain or branched C1-C4 alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group;

[0316] R 18 and R 19 Each is independently a C1-C4 alkoxy, C1-C4 alkyl, or -NR 23 R 24 , or R 18 and R 19 Together with the carbon atoms they are attached to, they form substituted or unsubstituted rings;

[0317] R 20 It is a straight-chain or branched C1-C4 alkyl group or an electron-withdrawing group, or R 18 and R 20 or R 19 and R 20 Together with the carbon atoms they are attached to, they form substituted or unsubstituted rings;

[0318] R 21 It is a straight-chain or branched C1-C4 alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group;

[0319] R 22 It is a straight-chain or branched C1-C4 alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group; and

[0320] R 23 and R 24 Each is independently a straight-chain or branched C1-C4 alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group.

[0321] In embodiments of any of the compounds of formulas (I), (II), (III), and (IIIa), R 4 It is a straight-chain or branched C1-C4 alkyl group.

[0322] In embodiments of any of the compounds of formulas (I), (II), (III), and (IIIa), R 4 It is a C1-C4 alkoxy group.

[0323] In the embodiments, compounds having a structure according to any one of formula (A), (I), (II), (III) or (IIIa) are disclosed herein, wherein the ring C is selected from...

[0324]

[0325] in:

[0326] R 15 It is a straight-chain or branched C1-C4 alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group;

[0327] R 18 and R 19 Each of the following is independently H, OH, C1-C4 alkoxy, C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl) or -NR. 23 R 24 ,or

[0328] R 18 and R 19 Together with the carbon atoms to which they are attached, they form substituted or unsubstituted rings (e.g., 5- or 6-membered substituted or unsubstituted carbon rings or 5- or 6-membered substituted or unsubstituted heterocycles).

[0329] R 20 It is H, C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl) or C1-C4 alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy), or

[0330] R 18 and R 20 Or R 19 and R 20 Together with the carbon atoms to which they are attached, they form rings (e.g., 5-, 6-, or 7-membered substituted or unsubstituted carbon rings, or 5-, 6-, or 7-membered substituted or unsubstituted heterocycles).

[0331] R 21 It is an H or C1-C4 alkyl group (e.g., straight-chain or branched C1-C4 alkyl group, such as methyl, ethyl, propyl, isopropyl, butyl), a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group;

[0332] R 22 It is a C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl), substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

[0333] R 23 and R 24 Each of these elements is independently H, a C1-C4 alkyl group (e.g., straight-chain or branched C1-C4 alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl), a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group; and

[0334] Indicates the connection point between ring C and ring B.

[0335] In the embodiments, compounds having a structure according to any one of formula (A), (I), (II), (III) or (IIIa) are disclosed herein, wherein the ring C is selected from...

[0336]

[0337] in:

[0338] R 15 It is a straight-chain or branched C1-C4 alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group;

[0339] R 18 and R 19 Each of these can be independently OH, C1-C4 alkoxy, C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl) or -NR. 23 R 24 ,or

[0340] R 18 and R 19 Together with the carbon atoms to which they are attached, they form substituted or unsubstituted rings (e.g., 5- or 6-membered substituted or unsubstituted carbon rings or 5- or 6-membered substituted or unsubstituted heterocycles).

[0341] R 20 It is a C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl) or a C1-C4 alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy), or

[0342] R 18 and R 20 Or R 19 and R 20 Together with the carbon atoms to which they are attached, they form rings (e.g., 5-, 6-, or 7-membered substituted or unsubstituted carbon rings, or 5-, 6-, or 7-membered substituted or unsubstituted heterocycles).

[0343] R 21 It is a C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl), substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

[0344] R 22It is a C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl), substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

[0345] R 23 and R 24 Each of these elements is independently H, a C1-C4 alkyl group (e.g., straight-chain or branched C1-C4 alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl), a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group; and

[0346] Indicates the connection point between ring C and ring B.

[0347] In the implementation scheme of ring C, R 32 、R 26 、R 28 、R 29 、R 30 or R 31 Any one of them is a straight-chain or branched C1-C4 alkyl group.

[0348] In the embodiments, compounds having a structure according to any one of formula (A), (I), (II), (III) or (IIIa) are disclosed herein, wherein the ring C is selected from...

[0349]

[0350] in:

[0351] R 18 and R 19 Each of the following is independently H, OH, C1-C4 alkoxy, C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl) or -NR. 23 R 24 ,or

[0352] R 18 and R 19 Together with the carbon atoms to which they are attached, they form substituted or unsubstituted rings (e.g., 5- or 6-membered substituted or unsubstituted carbon rings or 5- or 6-membered substituted or unsubstituted heterocycles).

[0353] R 20 It is H or C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl), or

[0354] R 18 and R 20 Or R 19 and R 20Together with the carbon atoms to which they are attached, they form rings (e.g., 5-, 6-, or 7-membered substituted or unsubstituted carbon rings, or 5-, 6-, or 7-membered substituted or unsubstituted heterocycles).

[0355] R 21 It is H or C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl), aryl or heteroaryl;

[0356] R 22 It is a C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl), substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

[0357] R 23 and R 24 Each of them is independently H, C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl), substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;

[0358] R 15 It is a C1-C4 alkyl group (e.g., straight-chain or branched C1-C4 alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl), a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group; and

[0359] Indicates the connection point between ring C and ring B.

[0360] In the implementation scheme of ring C, R 21 It is a straight-chain or branched C1-C4 alkyl group.

[0361] In the implementation scheme of ring C, R 22 It is a straight-chain or branched C1-C4 alkyl group.

[0362] In the implementation scheme of ring C, R 15 It is an unsubstituted C1-C4 alkyl group.

[0363] In the embodiments, compounds having a structure according to any one of formula (A), (I), (II), (III) or (IIIa) are disclosed herein, wherein the ring C is where R 18 and R 19 Together with the carbon atoms they are attached to, they form substituted or unsubstituted 5- or 6-membered carbon rings or substituted or unsubstituted 5- or 6-membered heterocycles.

[0364] In the embodiments, compounds having a structure according to any one of formula (A), (I), (II), (III) or (IIIa) are disclosed herein, wherein the ring C is where R 18 and R 20 Or R 19 and R 20 Together with the carbon atoms they are attached to, they form substituted or unsubstituted 5-, 6-, or 7-membered carbon rings or substituted or unsubstituted 5-, 6-, or 7-membered heterocycles.

[0365] In the embodiments, compounds having a structure according to any one of formula (A), (I), (II), (III) or (IIIa) are disclosed herein, wherein the ring C is selected from...

[0366]

[0367] In the embodiments, compounds having a structure according to any one of formula (A), (I), (II), (III) or (IIIa) are disclosed herein, wherein the ring C is where R 21 yes in

[0368] R 25 Selected from OH, halogens (-Cl, -F), C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl), C1-C4 alkoxy (e.g., methoxy, ethoxy, propoxy, butoxy), C1-C4 haloalkyl (e.g., -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2CF3, -(CH2)2CH2F, -(CH2)2CHF2, -(CH2)2CF3, -(CH2)3CH 2F, -(CH2)3CHF2, -(CH2)3CF3), C1-C4 haloalkoxy groups (e.g., -OCH2F, -OCHF2, -OCF3, -OCH2CH2F, -OCH2CHF2, -OCH2CF3, -O(CH2)2CH2F, -O(CH2)2CHF2, -O(CH2)2CF3, -O(CH2)3CH2F, -O(CH2)3CHF2, -O(CH2)3CF3), substituted or unsubstituted aryl groups and substituted or unsubstituted heteroaryl groups;

[0369] t is 0, 1, or 2; and

[0370] Instruction R 21 The connection point with N.

[0371] In the embodiments, compounds having a structure according to any one of formula (A), (I), (II), (III) or (IIIa) are disclosed herein, wherein the ring C is where R 21 yes in

[0372] Each R 25 Independently selected from OH, halogens (-Cl, -F), C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl), C1-C4 alkoxy (e.g., methoxy, ethoxy, propoxy, butoxy), C1-C4 haloalkyl (e.g., -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2CF3, -(CH2)2CH2F, -(CH2)2CHF2, -(CH2)2CF3, -(CH2)3 CH2F, -(CH2)3CHF2, -(CH2)3CF3), C1-C4 haloalkoxy groups (e.g., -OCH2F, -OCHF2, -OCF3, -OCH2CH2F, -OCH2CHF2, -OCH2CF3, -O(CH2)2CH2F, -O(CH2)2CHF2, -O(CH2)2CF3, -O(CH2)3CH2F, -O(CH2)3CHF2, -O(CH2)3CF3), substituted or unsubstituted aryl groups and substituted or unsubstituted heteroaryl groups;

[0373] t is 0, 1, or 2; and

[0374] Instruction R 21 The connection point with N.

[0375] In the embodiments, compounds having a structure according to any one of formula (A), (I), (II), (III) or (IIIa) are disclosed herein, wherein the ring C is where R 21 Selected from

[0376]

[0377] In the embodiments, compounds having a structure according to any one of formula (A), (I), (II), (III) or (IIIa) are disclosed herein, wherein the ring C is where R 21 Selected from

[0378]

[0379] In the embodiments, compounds having a structure according to any one of formula (A), (I), (II), (III) or (IIIa) are disclosed herein, wherein the ring C is selected from...

[0380]

[0381] In the implementation scheme of ring C, R22 It is a straight-chain or branched C1-C4 alkyl group.

[0382] In the embodiments, compounds having a structure according to any one of formula (A), (I), (II), (III) or (IIIa) are disclosed herein, wherein the ring C is where R 18 and R 19 Each is independently selected from -H, -OH, alkyl (e.g., straight-chain or branched C1-C4 alkyl) and in:

[0383] R 26 It is H, C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl), substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;

[0384] Each R 27 It is -OH, halogen (-Cl, -F), C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl), halogen (-Cl, -F), C1-C4 alkoxy (e.g., methoxy, ethoxy, propoxy, butoxy), or C1-C4 haloalkyl (e.g., -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2CF3, -(CH2)2CH2F, -(CH2)2CHF2 ... 2) 2CF3, -(CH2)3CH2F, -(CH2)3CHF2, -(CH2)3CF3), C1-C4 haloalkoxy groups (e.g., -OCH2F, -OCHF2, -OCF3, -OCH2CH2F, -OCH2CHF2, -OCH2CF3, -O(CH2)2CH2F, -O(CH2)2CHF2, -O(CH2)2CF3, -O(CH2)3CH2F, -O(CH2)3CHF2, -O(CH2)3CF3), or

[0385] Two adjacent R 27 The groups and the two carbon atoms to which they are attached form 5- or 6-membered substituted or unsubstituted rings;

[0386] q is 0, 1, or 2; and

[0387] ---Instruction R 18 and R 19 The connection point of one or both of them with ring C.

[0388] In the embodiments, compounds having a structure according to any one of formula (A), (I), (II), (III) or (IIIa) are disclosed herein, wherein the ring C is where R 18 and R 19 Each is independently selected from -H, -OH, alkyl (e.g., straight-chain or branched C1-C4 alkyl) and in:

[0389] R 26 It is H, C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl), substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;

[0390] Each R 27 It is -OH, halogen (-Cl, -F), C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl), halogen (-Cl, -F), C1-C4 alkoxy (e.g., methoxy, ethoxy, propoxy, butoxy), or C1-C4 haloalkyl (e.g., -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2CF3, -(CH2)2CH2F, -(CH2)2CHF2 ... 2) 2CF3, -(CH2)3CH2F, -(CH2)3CHF2, -(CH2)3CF3), C1-C4 haloalkoxy groups (e.g., -OCH2F, -OCHF2, -OCF3, -OCH2CH2F, -OCH2CHF2, -OCH2CF3, -O(CH2)2CH2F, -O(CH2)2CHF2, -O(CH2)2CF3, -O(CH2)3CH2F, -O(CH2)3CHF2, -O(CH2)3CF3), or

[0391] Two adjacent R 27 Groups and the two carbon atoms to which they are attached form 5- or 6-membered substituted or unsubstituted rings; and

[0392] q is 0, 1, or 2.

[0393] In the implementation scheme of ring C, R 26 It is a straight-chain or branched C1-C4 alkyl group.

[0394] In the embodiments, compounds having a structure according to any one of formula (A), (I), (II), (III) or (IIIa) are disclosed herein, wherein the ring C is selected from...

[0395]

[0396]

[0397]

[0398]

[0399]

[0400] In the embodiments, compounds having a structure according to any one of formula (A), (I), (II), (III) or (IIIa) are disclosed herein, wherein the ring C is selected from...

[0401]

[0402] In the embodiments, compounds having a structure according to any one of formula (A), (I), (II), (III) or (IIIa) are disclosed herein, wherein the ring C is

[0403] where R 18 and R 19 Together with the carbon atoms they are attached to form in:

[0404] X and Y are independently CH2 and NR, respectively. 29 O or C=O;

[0405] R 28 It is -OH, halogen (-Cl, -F), C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl), C1-C4 haloalkyl (e.g., -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2CF3, -(CH2)2CH2F, -(CH2)2CHF2, -(CH2)2CF3, -(CH2)3CH2F, -(CH2)3CHF2, -(CH2)3CHF2, -(CH 2) 3CF3), C1-C4 alkoxy groups (e.g., methoxy, ethoxy, propoxy, butoxy) or C1-C4 haloalkoxy groups (e.g., -OCH2F, -OCHF2, -OCF3, -OCH2CH2F, -OCH2CHF2, -OCH2CF3, -O(CH2)2CH2F, -O(CH2)2CHF2, -O(CH2)2CF3, -O(CH2)3CH2F, -O(CH2)3CHF2, -O(CH2)3CF3); or

[0406] R 29 It is an H or C1-C4 alkyl group (e.g., straight-chain or branched C1-C4 alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl); and

[0407] w is 0, 1, or 2.

[0408] In the implementation scheme of ring C, R 29 It is a straight-chain or branched C1-C4 alkyl group.

[0409] In the embodiments, compounds having a structure according to any one of formula (A), (I), (II), (III) or (IIIa) are disclosed herein, wherein the ring C is selected from...

[0410] In the embodiments, compounds having a structure according to any one of formula (A), (I), (II), (III) or (IIIa) are disclosed herein, wherein the ring C is selected from...

[0411]

[0412] where R 34 It is a C1-C4 alkyl group (e.g., straight-chain or branched C1-C4 alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl).

[0413] In the implementation scheme of ring C, R 34 It is a straight-chain or branched C1-C4 alkyl group.

[0414] In the embodiments, compounds having a structure according to any one of formula (A), (I), (II), (III) or (IIIa) are disclosed herein, wherein the ring C is

[0415] where R 32 yes

[0416] In the embodiments, compounds having the structure of formula (A), (I), (II), (III), or (IIIa) are disclosed herein, wherein the ring C is where R 22 It is a C1-C4 alkyl (e.g., straight-chain or branched C1-C4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl), substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.

[0417] In the implementation scheme of ring C, R 22 It is a straight-chain or branched C1-C4 alkyl group.

[0418] In the embodiments, compounds having the structure of formula (A), (I), (II), (III), or (IIIa) are disclosed herein, wherein the ring C is selected from...

[0419]

[0420]

[0421] In the embodiments, compounds having a structure according to any one of formula (A), (I), (II), (III) or (IIIa) are disclosed herein, wherein the ring C is

[0422] In the embodiments, compounds having the chemical formula according to any one of compounds 1-234 are disclosed herein, as shown in Table 1.

[0423] Table 1:

[0424]

[0425]

[0426]

[0427]

[0428]

[0429]

[0430]

[0431]

[0432]

[0433]

[0434]

[0435]

[0436]

[0437]

[0438]

[0439]

[0440]

[0441]

[0442]

[0443]

[0444]

[0445]

[0446]

[0447]

[0448]

[0449]

[0450]

[0451]

[0452]

[0453]

[0454]

[0455]

[0456]

[0457]

[0458]

[0459]

[0460]

[0461]

[0462]

[0463]

[0464]

[0465]

[0466]

[0467]

[0468]

[0469]

[0470]

[0471]

[0472]

[0473]

[0474]

[0475]

[0476]

[0477]

[0478]

[0479]

[0480]

[0481]

[0482]

[0483]

[0484] or a pharmaceutically acceptable salt thereof.

[0485] In the embodiments, compounds having the chemical formula according to any one of compounds 235-311 are disclosed herein, as shown in Table 2.

[0486] Table 2:

[0487]

[0488]

[0489]

[0490]

[0491]

[0492]

[0493]

[0494]

[0495]

[0496]

[0497]

[0498]

[0499]

[0500]

[0501]

[0502]

[0503]

[0504]

[0505]

[0506]

[0507]

[0508] Or its medicinal salt.

[0509] Example 312: Exemplary Synthesis of 4-[(3aR,7aS)-5-[5-(trifluoromethoxy)-2-pyridyl]-3,3a,4,6,7,7a-hexahydro-2H-pyrrolo[3,2-c]pyridin-1-yl]-6-chloro-1-methyl-2-oxo-1,5-naphthyl-3-carboxylonite Step 1: Preparation of tert-butyl 5-[5-(trifluoromethoxy)-2-pyridyl]-3,3a,4,6,7,7a-hexahydro-2H-pyrrolo[3,2-c]pyridine-1-carboxylic acid

[0510]

[0511] To a solution of 2-bromo-5-(trifluoromethoxy)pyridine (2.67 g, 11.05 mmol, 1 equivalent) and 2,3,3a,4,5,6,7,7a-octahydropyrrolo[3,2-c]pyridine-1-carboxylic acid tert-butyl ester (2.50 g, 11.05 mmol, 1 equivalent) in dioxane (25 mL), 1,3-bis[2,6-bis(1-propylbutyl)phenyl]-4,5-dichloro-2H-imidazol-1-onthium-2-ylidene; 3-chloropyridine; palladium dichloro(1.07 g; 1.10 mmol, 0.1 equivalent) and cesium carbonate (10.80 g, 33.14 mmol, 3 equivalent) were added. The mixture was stirred at 100 °C for 3 h. Water (30 mL) was added to the reaction mixture and extracted with 60 mL of ethyl acetate (30 mL × 2). The combined organic layers were washed with saturated sodium chloride (30 mL × 2), dried over sodium sulfate, filtered, and concentrated under reduced pressure to give the residue. The residue was purified by column chromatography (silica, petroleum ether / ethyl acetate = 100 / 1 to 5 / 1) to give a yellow oil, tert-butyl 5-[5-(trifluoromethoxy)-2-pyridyl]-3,3a,4,6,7,7a-hexahydro-2H-pyrrolo[3,2-c]pyridine-1-carboxylic acid (3.74 g, 9.65 mmol, 87% yield). LC / MS: (ESI) m / z: 388.1 [M+1] + .

[0512] Step 2: Preparation of (3aR,7aS)-5-[5-(trifluoromethoxy)-2-pyridyl]-3,3a,4,6,7,7a-hexahydro-2H-pyrrolo[3,2-c]pyridine-1-carboxylic acid tert-butyl ester and (3aS,7aR)-5-[5-(trifluoromethoxy)-2-pyridyl]-3,3a,4,6,7,7a-hexahydro-2H-pyrrolo[3,2-c]pyridine-1-carboxylic acid tert-butyl ester

[0513]

[0514] Racemic (3aR,7aS)-5-[5-(trifluoromethoxy)-2-pyridyl]-3,3a,4,6,7,7a-hexahydro-2H-pyrrolo[3,2-c]pyridine-1-carboxylic acid tert-butyl ester (1.9 g, 4.90 mmol, 1 equivalent) was purified by SFC (column: REGIS(S,S)WHELK-O1 (250 mm × 25 mm, 10 μm); mobile phase: [neutral-ethanol]; 15%–15%, 200 min) to obtain a green oily (3aR,7aS)-5-[5-(trifluoromethoxy)-2- [Pyridyl]-3,3a,4,6,7,7a-hexahydro-2H-pyrrolo[3,2-c]pyridine-1-carboxylic acid tert-butyl ester (870 mg, 2.25 mmol, 45% yield) (SFC: Rt = 1.061 min) and (3aS,7aR)-5-[5-(trifluoromethoxy)-2-pyridyl]-3,3a,4,6,7,7a-hexahydro-2H-pyrrolo[3,2-c]pyridine-1-carboxylic acid tert-butyl ester (830 mg, 2.14 mmol, 43% yield) (SFC: Rt = 1.209 min), which are present as a green oil. Absolute stereochemical configurations are provisionally designated.

[0515] Step 3: Preparation of WC-ARV-JM-047-A-2a,(3aR,7aS)-5-[5-(trifluoromethoxy)-2-pyridyl]-1,2,3,3a,4,6,7,7a-octahydropyrrolo[3,2-c]pyridine

[0516]

[0517] Trifluoroacetic acid (7.70 g, 67.53 mmol, 5.00 mL, 52.32 equivalents) was added to a solution of (3aR,7aS)-5-[5-(trifluoromethoxy)-2-pyridyl]-1,2,3,3a,4,6,7,7a-hexahydro-2H-pyrrolo[3,2-c]pyridine-1-carboxylic acid tert-butyl ester (500 mg, 1.29 mmol, 1 equivalent) in dichloromethane (5 mL). The mixture was stirred at 25 °C for 1 h. The reaction mixture was concentrated under reduced pressure to give (3aR,7aS)-5-[5-(trifluoromethoxy)-2-pyridyl]-1,2,3,3a,4,6,7,7a-octahydropyrrolo[3,2-c]pyridine (517 mg, crude substance, trifluoroacetic acid) as a yellow solid. LC / MS:MS(ESI)m / z:288.3[M+1] + .

[0518] Step 4: Preparation of 4-[(3aR,7aS)-5-[5-(trifluoromethoxy)-2-pyridyl]-3,3a,4,6,7,7a-hexahydro-2H-pyrrolo[3,2-c]pyridin-1-yl]-6-chloro-1-methyl-2-oxo-1,5-naphthyl-3-carboxylonitrile

[0519]

[0520] Diisopropylethylamine (833 mg, 6.44 mmol, 1.12 mL, 5 equivalents) was added to a solution of (3aR,7aS)-5-[5-(trifluoromethoxy)-2-pyridyl]-1,2,3,3a,4,6,7,7a-octahydropyrrolo[3,2-c]pyridine (517 mg, 1.29 mmol, 1 equivalent, trifluoroacetic acid) and 4,6-dichloro-1-methyl-2-oxo-1,5-naphthyl-3-carboxynitrile (327 mg, 1.29 mmol, 1 equivalent) in acetonitrile (5 mL). The mixture was stirred at 25 °C for 12 h. The reaction mixture was concentrated under reduced pressure to obtain a residue. The residue was purified by preparative HPLC (column: Phenomenex Luna C18 150×25mm×10um; mobile phase: [water (formic acid)-acetonitrile]; 58%-88%, 58 min) to give a yellow solid 4-[(3aR,7aS)-5-[5-(trifluoromethoxy)-2-pyridinyl]-3,3a,4,6,7,7a-hexahydro-2H-pyrrolo[3,2-c]pyridin-1-yl]-6-chloro-1-methyl-2-oxo-1,5-naphthyl-3-carboxynitrile (465.7 mg, 0.89 mmol, 69% yield, 96% purity). LC / MS: (ESI) m / z: 505.2 507.3, 505.3 [M+1] + . 1 H NMR: (400MHz, DMSO-d6)δ:8.13(d,J=2.4Hz,1H),8.02(d,J=9.2Hz,1H),7.80(d,J=9.2Hz,1H),7 .58(dd,J=2.4,9.2Hz,1H),6.88(d,J=9.6Hz,1H),5.54-5.42(m,1H),4.46-4.34(m,1H),3.99-3 .89(m,2H),3.84-3.75(m,1H),3.63(dd,J=4.4,13.6Hz,1H),3.50(s,3H),3.21-3.13(m,1H),2. 57(d,J=6.4Hz,1H),2.24-2.15(m,1H),2.08-1.99(m,1H),1.96-1.86(m,1H),1.81-1.71(m,1H)

[0521] In the embodiments, compounds having the chemical formula according to any one of compounds 312-390 are disclosed herein, as shown in Table 3. These compounds were prepared using a synthetic method similar to that described for compound 312, which will be discussed in more detail below.

[0522]

[0523]

[0524]

[0525]

[0526]

[0527]

[0528]

[0529]

[0530]

[0531]

[0532]

[0533]

[0534]

[0535]

[0536]

[0537]

[0538]

[0539]

[0540]

[0541]

[0542]

[0543] In the embodiments, compounds having the chemical formula according to any one of compounds 391-449 are disclosed herein, as shown in Table 4. These compounds were prepared using a synthetic method similar to that described for compounds 397, 416 and 429, which will be discussed in more detail below.

[0544]

[0545]

[0546]

[0547]

[0548]

[0549]

[0550]

[0551]

[0552]

[0553]

[0554]

[0555]

[0556]

[0557]

[0558] Pharmaceutical composition

[0559] This document discloses pharmaceutical compositions comprising the compounds of the present invention as defined above, or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable excipients.

[0560] The compositions of the present invention may be in forms suitable for oral use (e.g., as tablets, lozenges, hard capsules or soft capsules, aqueous suspensions or oil suspensions, emulsions, dispersible powders or granules, syrups or elixirs), in forms suitable for topical use (e.g., as creams, ointments, gels or aqueous or oily solutions, suspensions or transdermal patches), in forms suitable for inhalation (e.g., as fine powders or liquid aerosols), in forms suitable for inhalation (e.g., as fine powders), or for parenteral use (e.g., as sterile aqueous or oily solutions for intravenous, subcutaneous, intramuscular, or intraperitoneal administration, or as suppositories for rectal or vaginal administration).

[0561] In view of this disclosure, the pharmaceutical compositions of the present invention can be obtained by conventional methods using conventional pharmaceutical excipients well known in the art. Therefore, compositions for oral use may contain, for example, one or more colorants, sweeteners, flavoring agents, and / or preservatives.

[0562] Pharmaceutically acceptable excipients that can be used in the pharmaceutical compositions of the present invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) (e.g., d-α-tocopherol, polyethylene glycol 1000 succinate), surfactants used in pharmaceutical dosage forms (e.g., tweens), polyoxyethylene castor oil (e.g., CREMOPHOR surfactant (BASF)) or other similar polymer delivery matrices, serum proteins (e.g., human serum albumin), buffering substances (e.g., phosphates), glycine, sorbic acid, potassium sorbate, mixtures of saturated vegetable fatty acid metaglycerides, water, salts or electrolytes (e.g., protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts), silica gel, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene block polymers, polyethylene glycol, and lanolin. Cyclodextrins (e.g., α-cyclodextrin, β-cyclodextrin, and γ-cyclodextrin), their chemically modified derivatives (e.g., hydroxyalkyl cyclodextrins, including 2-hydroxypropyl-cyclodextrin and 3-hydroxypropyl-cyclodextrin), or other solubilizing derivatives may also be advantageously used to enhance the delivery of the compounds described herein.

[0563] The amount and dosing regimen of the applicable compounds used to treat symptoms with the compounds and / or compositions of the present invention depend on a variety of factors, including the subject's age, weight, sex, medical condition, disease type, disease severity, route and frequency of administration, and the specific compound used. Therefore, dosing regimens can vary considerably, but can be routinely determined using standard methods. Daily doses can be administered once to four times daily. Other dosing regimens include once a week and once every two days.

[0564] Treatment

[0565] The compounds of the present invention as defined above, or their pharmaceutically acceptable salts, may be used to treat cancer.

[0566] In embodiments, the compounds of the present invention disclosed herein, or pharmaceutically acceptable salts thereof, may be used to treat diseases or conditions associated with DGK target inhibition in T cells. In some such embodiments, the compounds of the present invention are prepared in combination with one or more additional therapeutic agents for co-administration to treat diseases or conditions associated with DGK target inhibition in T cells.

[0567] This article also provides methods for treating subjects who have or are susceptible to medical conditions associated with DGK target inhibition in T cells. For example, the compounds described herein can be used to treat or prevent viral infections and proliferative disorders such as cancer. More specifically, diseases or conditions associated with DGK target inhibition in T cells include viral and other infections (e.g., skin infections, GI infections, urinary tract infections, genitourinary tract infections, systemic infections) and proliferative disorders (e.g., cancer).

[0568] In the implementation plan, the subjects are receiving cancer treatment. Types of cancer that can be treated with the compounds of this invention include, but are not limited to, brain cancer, skin cancer, bladder cancer, ovarian cancer, breast cancer, stomach cancer, pancreatic cancer, prostate cancer, colon cancer, leukemia, lung cancer, and bone cancer. Examples of these cancer types include neuroblastoma, colorectal cancer (such as rectal cancer, colon cancer, common adenomatous polyposis carcinoma, and hereditary nonpolyposis colorectal cancer), esophageal cancer, lip cancer, laryngeal cancer, hypopharyngeal cancer, tongue cancer, salivary gland cancer, stomach cancer, adenocarcinoma, medullary thyroid carcinoma, papillary thyroid carcinoma, kidney cancer, renal parenchymal carcinoma, ovarian cancer, cervical cancer, uterine cancer, endometrial cancer, choriocarcinoma, pancreatic cancer, prostate cancer, testicular cancer, breast cancer, urinary tract cancer, melanoma, brain tumors (such as glioblastoma, astrocytoma, meningioma, medulloblastoma, and peripheral neuroectodermal tumors), Hodgkin lymphoma, non-Hodgkin lymphoma, and Burkitt lymphoma. Lymphoma, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), adult T-cell leukemia lymphoma, diffuse large B-cell lymphoma (DLBCL), hepatocellular carcinoma, gallbladder cancer, bronchial carcinoma, small cell lung cancer, non-small cell lung cancer, multiple myeloma, basal cell carcinoma, teratoma, retinoblastoma, choroidal melanoma, seminoma, rhabdomyosarcoma, craniopharyngioma, osteosarcoma, chondrosarcoma, myosarcoma, liposarcoma, fibrosarcoma, Ewing sarcoma, and plasmacytoma. In a preferred embodiment, the compounds of the present invention treat colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, cervical cancer, kidney cancer, head and neck cancer, lymphoma, leukemia, and melanoma.

[0569] In embodiments, the compounds of the present invention can inhibit the activity of diacylglycerol kinase α (DGKα). For example, by administering a therapeutically effective amount of the compounds of the present invention or salts thereof, the compounds of the present invention can be used to inhibit DGKα activity in cells or subjects requiring DGKα regulation.

[0570] In embodiments, the compounds of the present invention can cause the degradation of DGKα. For example, by administering a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof, the compounds of the present invention can be used to degrade DGKα in cells or subjects requiring said treatment. This document also discloses methods for treating diseases or conditions associated with the activity or expression (including aberrant activity and / or overexpression) of DGKα in a subject by administering a therapeutically effective amount or dose of any one or more compounds of the present invention or pharmaceutical compositions thereof to a subject requiring such treatment. Exemplary diseases may include any disease, condition, or symptom directly or indirectly related to the expression or activity of the DGKα enzyme, such as overexpression or aberrant activity. DGKα-related diseases may also include any disease, condition, or symptom that can be prevented, improved, or cured by modulating DGKα enzyme activity. Examples of DGKα-related diseases include cancer and viral infections such as HIV infection, hepatitis B, and hepatitis C.

[0571] Combination therapy

[0572] In embodiments, the compounds of the present invention can be administered in combination with other anticancer agents (such as immunotumor agents). In some embodiments, the compounds of the present invention are administered simultaneously with other anticancer agents. Alternatively, the compounds of the present invention can be co-formulated with anticancer agents.

[0573] Exemplary anticancer agents include, but are not limited to, small molecule drugs, antibodies, or other biological agents or small molecules. Exemplary biological agents include, but are not limited to, cancer vaccines, antibodies, and cytokines. In some embodiments, the antibody is a monoclonal antibody. In some such embodiments, the monoclonal antibody is humanized or human-derived.

[0574] In the implementation, the anticancer agent is an immunotumor agent. In some such implementations, the immunotumor agent is either an agonist of stimulatory (including co-stimulatory) receptors on T cells or an antagonist of inhibitory (including co-inhibitory) signals, both of which lead to an amplification of antigen-specific T cell responses (commonly referred to as immune checkpoint modulators).

[0575] Certain stimulatory and inhibitory molecules are members of the immunoglobulin superfamily (IgSF). An important family of membrane-bound ligands that bind to co-stimulatory or co-inhibitory receptors is the B7 family, which includes B7-1, B7-2, B7-H1 (PD-L1), B7-DC (PD-L2), B7-H2 (ICOS-L), B7-H3, B7-H4, B7-H5 (VISTA), and B7-H6. Another family of membrane-bound ligands that bind to co-stimulatory or co-inhibitory receptors is the TNF molecule family that binds to members of the relevant TNF receptor family, including CD40 and CD4OL, OX-40, OX-40L, CD70, CD27L, CD30, CD30L, 4-1BBL, CD137(4-IBB), TRAIL / Apo2-L, TRAILR1 / DR4, TRAILR2 / DRS, TRAILR3, TRAILR4, OPG, RANK, RANKL, TWEAKR / Fn14, TWEAK, BAFFR, EDAR, XEDAR, TACI, APRIL, BCMA, LTOR, LIGHT, DcR3, HVEM, VEGUTL1A, TRAMP / DR3, EDAR, EDA1, XEDAR, EDA2, TNFR1, lymphotoxin α / TNFβ, TNFR2, TNFα, LTβR, and lymphotoxin a. 1β2, FAS, FASL, RELT, DR6, TROY, NGFR.

[0576] In embodiments, T cell responses can be stimulated by combining the compounds of the present invention with one or more of the following substances: (i) antagonists of proteins that inhibit T cell activation (e.g., immune checkpoint inhibitors), such as CTLA-4, PD-1, PD-L1, PD-L2, LAG-3, TIM-3, galactoglobulin 9, CEACAM-1, BTLA, CD69, galactoglobulin-1, TIGIT, CD113, GPR56, VISTA, 2B4, CD48, GARP, PD1H, LAIR1, TIM-1, and TIM-4; and (ii) agonists of proteins that stimulate T cell activation, such as B7-1, B7-2, CD28, 4-IBB (CD137), 4-1BBL, ICOS, ICOS-L, OX40, OX4OL, GITR, GITRL, CD70, CD27, CD40, DR3, and CD28H.

[0577] Other agents that can be combined with the compounds of the present invention for the treatment of cancer include antagonists of inhibitory receptors on NK cells or agonists of activating receptors on NK cells. For example, the compounds of the present invention can be combined with antagonists of KIRs (such as lirilumab).

[0578] Other agents used in combination therapy include agents that inhibit or deplete macrophages or monocytes, including but not limited to CSF-1R antagonists, such as CSF-1R antagonist antibodies, including RG7155 (e.g., international patent publications WO11 / 70024, WO11 / 107553, WO11 / 131407, WO13 / 87699, WO13 / 119716, WO13 / 132044) or FPA-008 (e.g., international patent publications WO11 / 140249, WO13169264, WO14 / 036357).

[0579] In embodiments, the compounds of the present invention may be combined with one or more agonists of positive co-stimulatory receptors, blockers of signal transduction via inhibitory receptors, antagonists, and one or more agents that systemically increase the frequency of anti-tumor T cells, overcome unique immunosuppressive pathways in the tumor microenvironment (e.g., blocking inhibitory receptor binding (e.g., PD-L1 / PD-1 interaction), depleting or inhibiting Tregs (e.g., using anti-CD25 monoclonal antibodies (e.g., daclizumab) or through in vitro depletion of anti-CD25 beads), inhibiting metabolic enzymes (such as IDO), or reversing / preventing T cell anergy or exhaustion), and agents that induce innate immune activation and / or inflammation at the tumor site.

[0580] In the implementation plan, another anticancer agent is a CTLA-4 antagonist, such as an antagonistic CTLA-4 antibody. Suitable CTLA-4 antibodies include, for example, YERVOY (ipilimumab) or tremelimumab.

[0581] In the implementation scheme, additional anticancer agents are PD-1 antagonists, such as antagonistic PD-1 antibodies. Suitable PD-1 antibodies include, for example, OPDIVO (nivolumab), KEYTRUDA (pembrolizumab), or MEDI-0680 (AMP-514; e.g., International Patent Publication WO2012 / 145493). Immuno-oncology agents may also include pidilizumab (CT-011), although its specificity for PD-1 binding is questionable. Another approach to targeting the PD-1 receptor is a recombinant protein, called AMP-224, composed of the fusion of the extracellular domain of PD-L2 (B7-DC) with the Fc portion of IgG1.

[0582] In the implementation scheme, another anticancer agent is a PD-L1 antagonist, such as an antagonistic PD-L1 antibody. Suitable PD-L1 antibodies include, for example, MPDL3280A (RG7446; e.g., International Patent Publication WO2010 / 077634), durvalumab (MEDI4736), BMS-936559 (e.g., International Patent Publication WO2007 / 005874), and MSB0010718C (e.g., International Patent Publication WO2013 / 79174).

[0583] In the implementation scheme, another anticancer agent is a LAG-3 antagonist, such as an antagonistic LAG-3 antibody. Suitable LAG3 antibodies include, for example, BMS-986016 (e.g., International Patent Publications WO10 / 19570, WO14 / 08218) or IMP-731 or IMP-321 (e.g., International Patent Publications WO08 / 132601, WO09 / 44273).

[0584] In the implementation scheme, another anticancer agent is a CD137 (4-1BB) agonist, such as an agonist CD137 antibody. Suitable CD137 antibodies include, for example, urelumab and PF-05082566 (e.g., International Patent Publication WO12 / 32433).

[0585] In the implementation scheme, another anticancer agent is a GITR agonist, such as an agonist GITR antibody. Suitable GITR antibodies include, for example, BMS-986153, BMS-986156, TRX-518 (e.g., International Patent Publications WO06 / 105021, WO09 / 009116) and MK-4166 (e.g., International Patent Publication WO11 / 028683).

[0586] In the implementation scheme, the additional anticancer agent is an IDO antagonist. Suitable IDO antagonists include, for example, INCB-024360, as published in international patent publications (WO2006 / 122150, WO07 / 75598, WO08 / 36653, WO08 / 36642), indoximod, BMS-986205, or NLG-919 (e.g., published in international patent publications WO09 / 73620, WO09 / 1156652, WO11 / 56652, WO12 / 142237).

[0587] In the implementation scheme, another anticancer agent is an OX40 agonist, such as an agonist OX40 antibody. Suitable OX40 antibodies include, for example, MEDI-6383 or MEDI-6469.

[0588] In the implementation scheme, another anticancer agent is an OX4OL antagonist, such as an antagonistic OX40 antibody. Suitable OX4OL antagonists include, for example, RG-7888 (e.g., International Patent Publication WO06 / 029879).

[0589] In one embodiment, the additional anticancer agent is a CD40 agonist, such as an agonist CD40 antibody. In another embodiment, the anticancer agent is a CD40 antagonist, such as an antagonist CD40 antibody. Suitable CD40 antibodies include, for example, lucarumumab or dacetuzumab.

[0590] In the implementation plan, another anticancer agent is a CD27 agonist, such as an agonist CD27 antibody. Suitable CD27 antibodies include, for example, varlilumab.

[0591] In the implementation scheme, another anticancer agent is MGA271 (to B7H3) (e.g., International Patent Publication WO11 / 109400).

[0592] As disclosed herein, combination therapy is intended to include the combined administration of these therapeutic agents; for example, administration of the therapeutic agents in a sequential manner, wherein each therapeutic agent is administered at different times, and administration of the therapeutic agents or at least two therapeutic agents in a substantially simultaneous manner. Substantially simultaneous administration can be achieved, for example, by administering to the subject a single dosage form of each therapeutic agent in a fixed proportion or multiple single dosage forms of each therapeutic agent. Sequential or substantially simultaneous administration of each therapeutic agent can be achieved via any suitable route, including but not limited to oral, parenteral, intravenous, intramuscular, and direct absorption through mucosal tissue. The therapeutic agents can be administered via the same or different routes. For example, the first therapeutic agent in a selected combination can be administered intravenously, while the other therapeutic agents in the combination can be administered orally. Alternatively, for example, all therapeutic agents can be administered orally, or both therapeutic agents can be administered parenterally, for example, via intravenous injection. Combination therapy may also include further combination administration of the therapeutic agents as described above with other bioactive ingredients and non-pharmacological therapies (e.g., surgical or radiation therapy). When combination therapy further includes non-pharmacological treatment, the non-pharmacological treatment can be administered at any suitable time, provided that a beneficial effect is obtained from the combination of the therapeutic agents and the combined non-pharmacological treatment. For example, in appropriate circumstances, when non-pharmacological treatments are temporarily discontinued from the administration of therapeutic agents, beneficial effects may still be achieved for several days or even weeks.

[0593] One or more other agents or treatments, such as antiviral agents, chemotherapeutic agents or other anticancer agents, immune enhancers, immunosuppressants, radiation, antitumor and antiviral vaccines, cytokine therapy (e.g., IL2 and GM-CSF), and / or tyrosine kinase inhibitors, may optionally be used in combination with the compounds of the present invention for the treatment of DGKα-related diseases, conditions, or symptoms. The agents may be combined with the compounds of the present invention in a single dosage form, or the agents may be administered simultaneously or sequentially in separate dosage forms.

[0594] Other suitable anticancer agents include, for example, alkylating agents (including but not limited to nitrogen mustard, ethyleneimine derivatives, alkyl sulfonates, nitrosoureas, and triazines), such as uracil mustard, chlormethine, and cyclophosphamide. Ifosfamide, melphalan, chlorambucil, pipobroman, triethylene melamine, triethylene thiophosphate, busulfan, carmustine, lomustine, streptozocin, dacarbazine, and temozolomide.

[0595] In embodiments, suitable additional agents used in combination with the compounds of the present invention in the treatment of cancer (e.g., melanoma) include: dacarbazine (DTIC), optionally used in combination with other chemotherapeutic agents such as carmustine (BCNU) and cisplatin; the "Dartmouth regimen," which consists of DTIC, BCNU, cisplatin, and tamoxifen; and combinations of cisplatin, vinblastine, and DTIC, temozolomide, or YERVOY™. The compounds of the present invention can also be combined with immunotherapeutic agents, including cytokines such as interferon-alpha, interleukin-2, and tumor necrosis factor (TNF).

[0596] In embodiments, the compounds of the present invention can also be used in combination with vaccine therapy for the treatment of cancers (e.g., melanoma). In some respects, the anti-melanoma vaccine is similar to antiviral vaccines used to prevent viral diseases such as polio, measles, and mumps. A weakened melanoma cell, or a portion of a melanoma cell, referred to as an antigen, can be injected into the patient to stimulate the body's immune system to destroy the melanoma cell.

[0597] Other suitable anticancer agents include antimetabolites (including but not limited to folic acid antagonists, pyrimidine analogs, purine analogs, and adenosine deaminase inhibitors), such as methotrexate, 5-fluorouracil, fluorouridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, pentostatin, and gemcitabine.

[0598] Other suitable anticancer agents include, for example, certain natural products and their derivatives (e.g., vinca alkaloids, antitumor antibiotics, enzymes, lymphokines, and epipodophyllotoxin), such as vinblastine, vincristine, vindesine, bleomycin, dactinomycin D, daunorubicin, doxorubicin, epirubicin, idarubicin, ara-C, paclitaxel (Taxol), mithramycin, deoxyco-formycin, mitomycin-C, L-asparaginase, interferon (especially IFN-α), etoposide, and teniposide.

[0599] Other cytotoxic agents include navelbene, CPT-11, anastrozole, letrazole, capecitabine, reloxafine, and droloxafine.

[0600] Cytotoxic agents are also suitable, such as epiphytic toxins; antitumor enzymes; topoisomerase inhibitors; procarbazine; mitoxantrone; platinum coordination complexes, such as cisplatin and carboplatin; biological response modifiers; growth inhibitors; anti-hormonal therapeutic agents; folate; tegafur; and hematopoietic growth factors.

[0601] Other anticancer agents include antibody therapies, such as trastuzumab. Antibodies against co-stimulatory molecules, such as CTLA-4, 4-1BB, and PD-1, or antibodies against cytokines (IL-10 or TGF-β).

[0602] Other anticancer agents include those that block the migration of immune cells, such as antagonists of chemokine receptors, including CCR2 and CCR4.

[0603] Other anticancer agents include those that enhance the immune system, such as adjuvants or adoptive T-cell transfers.

[0604] Other anticancer agents include anticancer vaccines, such as dendritic cells, synthetic peptides, DNA vaccines, and recombinant viruses.

[0605] The treatment methods of the present invention may optionally include the combined administration of at least one signal transduction inhibitor (STI). A “signal transduction inhibitor” is an agent that selectively inhibits one or more important steps in signal transduction pathways in the normal function of cancer cells, thereby leading to apoptosis. Suitable STIs include, but are not limited to: (i) bcr / abl kinase inhibitors, such as, for example, STI571. (ii) Epidermal growth factor (EGF) receptor inhibitors, such as, for example, kinase inhibitors ORES (iii) her-2 / neu receptor inhibitors, such as farnesyltransferase inhibitors (FTIs), such as L-744,832 (Kohl et al., Nat. Med., 1(8):792-97(1995)); (iv) Akt family kinases or Akt pathway inhibitors, such as rapamycin (see, for example, Sekulic et al., Cancer Res., 60:3504-13(2000)); (v) cell cycle kinase inhibitors, such as flavopiridol and UCN-01 (see, for example, Sausville). (Curr. Med. Chem. Anti-Canc. Agents, 3:47-56 (2003)); and (vi) phosphatidylinositol kinase inhibitors, such as, for example, LY294002 (see, for example, Vlahos et al. J. Biol. Chem., 269:5241-48 (1994)). Alternatively, at least one STI and at least one compound of formula (I) may be in a separate pharmaceutical composition. In specific embodiments of the invention, at least one compound of the invention and at least one STI may be administered to a patient in combination. In other words, at least one compound of the invention may be administered first, or at least one STI may be administered first, followed by another; or at least one compound of the invention and at least one STI may be administered simultaneously. Furthermore, when using more than one compound of the invention and / or STI, the compounds may be administered in any order.

[0606] This document also discloses pharmaceutical compositions for treating chronic viral infections in subjects, comprising at least one compound of the present invention, optionally at least one chemotherapeutic agent, and optionally at least one antiviral agent administered in a pharmaceutically acceptable carrier in a therapeutically effective amount. In embodiments, one or more compounds of the present invention, one or more chemotherapeutic agents, and / or one or more antiviral agents are administered in combination. For example, in embodiments, at least one compound of the present invention may be administered first, or at least one chemotherapeutic agent may be administered first. Alternatively, at least one compound of the present invention and at least one STI may be administered simultaneously. Furthermore, when using more than one compound of the present invention and / or chemotherapeutic agent, the compounds may be administered in any order. Similarly, any antiviral agent or STI may also be administered at any point in time associated with the administration of the compound of the present invention.

[0607] Chronic viral infections that can be treated with the combination therapy of the present invention include, but are not limited to, diseases caused by hepatitis C virus (HCV), human papillomavirus (HPV), cytomegalovirus (CMV), herpes simplex virus (HSV), Epstein-Barr virus (EBV), varicella-zoster virus, coxsackie virus, and human immunodeficiency virus (HIV). It is noteworthy that parasitic infections (e.g., malaria) can also be treated using the above method, wherein optionally, a compound known for treating parasitic symptoms is added instead of an antiviral agent.

[0608] Suitable antiviral agents to be considered for use in combination with compounds of formula (I) may include nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors, and other antiviral drugs.

[0609] Examples of suitable NRTIs include zidovudine (AZT); didanosine (ddl); zalcitabine (ddC); stavudine (d4T); lamivudine (3TC); abacavir (1592U89); adefovir dipivoxil [bis(POM)-PMEA]; lobucavir; BCH-I0652; emitricitabine [(-)-FTC]; β-L-FD4 (also known as β-L-D4C, and named β-L-2',3'-double-helical oxy-5-fluorocytidine); DAPD ((-)-β-D-2,6-diamino-purine dioxolane); and iodine adenosine (FddA). Typical suitable NNRTIs include nevirapine (BI-RG-587); delaviradine (BHAP, U-90152); efavirenz (DMP-266); PNU-142721; AG-1549; MKC-442 (1-(ethoxy-methyl)-5-(1-methylethyl)-6-(phenylmethyl)-(2,4(1H,3H)-pyrimidinide); and (+)-coumarin A (NSC-675451) and B. Typical suitable protease inhibitors include saquinavir (Ro... 31-8959); ritonavir (ABT-538); indinavir (MK-639); nelfnavir (AG-1343); amprenavir (141W94); lasinavir; DMP-450; BMS-2322623; ABT-378; and AG-1549. Other antiviral drugs include hydroxyurea, ribavirin, IL-2, IL-12, pentafuside, and Yissum Project No. 11607.

[0610] This document also discloses pharmaceutical kits for, for example, treating or preventing the DGKα-related diseases or conditions mentioned herein, comprising one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of the compound of the present invention. If desired, such kits may also include one or more of various conventional pharmaceutical kit components, such as containers having, for example, one or more pharmaceutically acceptable carriers, or additional containers, as will be apparent to those skilled in the art. The kits may also include instructions, such as inserts or labels, indicating the amount of the component to be administered, administration guidelines, and / or guidelines for mixing the components.

[0611] Preparation method

[0612] In view of this disclosure, the compounds of the present invention can be synthesized by many methods available to those skilled in the art. General synthetic schemes for preparing the compounds of the present invention are described below. These schemes are illustrative and are not intended to limit the possible techniques that those skilled in the art can use to prepare the compounds disclosed herein. Different methods for preparing the compounds of the present invention will be apparent to those skilled in the art. Examples of compounds of the present invention prepared by the methods described in the general scheme are given in the Examples section set forth below. The preparation of pure chiral examples can be carried out by techniques known to those skilled in the art. For example, isochiral compounds can be prepared by separating racemic products or diastereomers by preparative HPLC of chiral phases. Alternatively, example compounds can be prepared by known methods to obtain products enriched with enantiomers or diastereomers.

[0613] The reactions and techniques described in this section are carried out in solvents suitable for the reagents and materials used, and are applicable to the transformations performed. Furthermore, in the description of the synthetic methods given below, it should be understood that all proposed reaction conditions (including the choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment, and post-treatment procedures) have been selected as criterion conditions for the reaction, which should be readily recognized by those skilled in the art. Those skilled in the art of organic synthesis will understand that functional groups present on different parts of the molecule must be compatible with the proposed reagents and reactions. This limitation on substituents compatible with the reaction conditions will be apparent to those skilled in the art, and substitutions are necessary when incompatible substituents are present. This sometimes requires judgment to modify the order of synthetic steps or to choose a particular process scheme over another to obtain the compounds of the present invention. It will also be recognized that another major consideration in planning any synthetic route in the art is the prudent selection of protecting groups for protecting the reactive functional groups present in the compounds described in the present invention. Wuts and Greene, Greene's Protective Groups in Organic Synthesis, 4th Edition, Wiley and Sons (2007) is an authoritative description that describes many alternatives for trained practitioners.

[0614] example

[0615] Synthesis and preparation of compounds according to the implementation plan

[0616] Synthesis of Compound 1

[0617] 7-[(3aR,6aR)-2-[4-(trifluoromethoxy)phenyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyridine Preparation of [5,4-[5,4-b]pyridine-6-carboxylonitrile (compound 1)]

[0618]

[0619] The title compound was prepared from (3aS,6aS)-5-[4-(trifluoromethoxy)phenyl]-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole in a manner similar to that of 2,4-dimethyl-5-oxo-7-spiro[3H-benzofuran-2,4'-piperidin]-1'-yl-thiazo[5,4-b]pyridine-6-carboxynitrile. (Off-white solid). LC / MS (ESI) m / z: 476.0 [M+H] + . 1HNMR (400MHz, DMSO-d6) δ7.16 (d, J = 8.4Hz, 2H), 6.56 (d, J = 8.8Hz, 2H), 4.22-4.14 (m, 2H), 4.11-4. 02(m,2H),3.54-3.49(m,2H),3.47(s,3H),3.30-3.29(m,2H),3.19(t,J=9.2Hz,2H),2.69(s,3H).

[0620] Synthesis of Compound 2

[0621] 7-[(3S,4R)-4-(4-fluoro-N-methyl-aniline)-3-methyl-1-piperidinyl]-2,4-dimethyl-5-oxo- Preparation of thiazo[5,4-b]pyridine-6-carboxylonitrile (compound 2)

[0622]

[0623] The title compound was prepared from (3S,4R)-N-(4-fluorophenyl)-N,3-dimethyl-piperidin-4-amine in a manner similar to that of 2,4-dimethyl-5-oxo-7-spiro[3H-benzofuran-2,4'-piperidin]-1'-yl-thiazo[5,4-b]pyridine-6-carboxynitrile. (White solid). LC / MS (ESI) m / z: 426.0 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ7.03 (t, J = 8.8 Hz, 2H), 6.87-6.81 (m, 2H), 4.50 (d, J = 12. 4Hz,1H),4.32(d,J=13.6Hz,1H),3.96(td,J=4.0,12.4Hz,1H),3.73(dd,J=2.4,1 3.2Hz,1H),3.48(s,3H),3.42-3.38(m,1H),2.79(s,3H),2.71(s,3H),2.41(dd, J=4.0,12.4Hz,1H),2.35-2.27(m,1H),1.76-1.68(m,1H),0.82(d,J=6.8Hz,3H).

[0624] Synthesis of Compound 3

[0625]

[0626] Step 1: Preparation of tert-butyl 4-[(2,5-difluorophenyl)methyl]-4-hydroxypiperidine-1-carboxylate

[0627]

[0628] A solution of 2-bromo-1,4-difluorobenzene (1.81 g, 9.38 mmol, 1 equivalent) in tetrahydrofuran was added to tetrahydrofuran containing isopropyl magnesium chloride (2 M, 6.72 mL, 1.43 equivalents), and the resulting mixture was stirred at 25 °C for 6 h. Then, copper bromo and methylthiolam (193 mg, 0.9 mmol, 0.1 equivalents) were added, and the resulting mixture was stirred at 25 °C for 10 min. Then, a solution of tert-butyl 1-oxa-6-azaspiro[2.5]octane-6-carboxylate (2 g, 9.38 mmol, 1 equivalent) in tetrahydrofuran was added over a 5 min interval, maintaining the temperature at 25 °C, and the reaction mixture was stirred at 25 °C for 12 h. A saturated aqueous solution of NH4Cl (20 mL) was added, and the resulting mixture was extracted with ethyl acetate (20 mL x 2). The combined organic extracts were washed with brine (40 mL), dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by rapid silica gel chromatography (gradient: 100 / 1 to 1:1 petroleum ether / ethyl acetate) to give tert-butyl 4-[(2,5-difluorophenyl)methyl]-4-hydroxy-piperidine-1-carboxylate (2.23 g, 6.80 mmol, 73% yield) as a yellow oil. LC / MS (ESI) m / z: 254.0 [M-73] + .

[0629] Step 2: Preparation of 5-fluorospiro[3H-benzofuran-2,4'-piperidine]

[0630]

[0631] A mixture of tert-butyl 4-[(2,5-difluorophenyl)methyl]-4-hydroxypiperidine-1-carboxylate (1 g, 3.05 mmol, 1 equivalent) and potassium tert-butoxide (1 g, 9.16 mmol, 3 equivalents) in 1,2-dimethoxyethane (15 mL) was stirred at 60 °C for 12 h. The material was collected by filtration and then treated with concentrated hydrochloric acid. The resulting mixture was concentrated, and the residue was purified by preparative HPLC (column: YMC Triart C18 250*50mm*7μm; mobile phase: [1-35% CH3CN / water (HCl)]) to give 5-fluorospiro[3H-benzofuran-2,4'-piperidine] (50 mg, 0.2 mmol, 7% yield, HCl salt) as a white solid. LC / MS (ESI) m / z: 208.2 [M+H] + . 1H NMR (400MHz, CDCl3) δ9.84-9.44(m,2H),6.92-6.80(m,2H),6.68(dd,J=4.0,8. 8Hz,1H),3.48-3.36(m,4H),3.08(s,2H),2.32-2.2(m,2H),2.16-2.12(m,2H).

[0632] Step 3: 7-(5-Fluorospiro[3H-benzofuran-2,4'-piperidin]-1'-yl)-2,4-dimethyl-5-oxo-thiazole Preparation of [5,4-b]pyridine-6-carboxynitrile (compound 3)

[0633]

[0634] The title compound was prepared starting from 5-fluorospiro[3H-benzofuran-2,4'-piperidine] in a manner similar to that of 2,4-dimethyl-5-oxo-7-spiro[3H-benzofuran-2,4'-piperidine]-1'-yl-thiazo[5,4-b]pyridine-6-carboxynitrile. (Off-white solid). LC / MS (ESI) m / z: 411.2 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ7.08(dd,J=2.8,8.4Hz,1H),6.92(dt,J=2.8,9.2Hz,1H),6.76(dd,J=4.4,8.8H z,1H),4.12-4.04(m,2H),3.96-3.88(m,2H),3.48(s,3H),3.12(s,2H),2.72(s,3H),2.04-1.96(m,4H).

[0635] Synthesis of Compound 4

[0636] 7-[(3aR,6aR)-2-(4-fluorophenyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-5-yl]- Preparation of 2,4-dimethyl-5-oxo-thiazo[5,4-b]pyridine-6-carboxylonitrile (compound 4)

[0637]

[0638] The title compound was prepared from 5-(4-fluorophenyl)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole in a manner similar to that of 2,4-dimethyl-5-oxo-7-spiro[3H-benzofuran-2,4'-piperidin]-1'-yl-thiazo[5,4-b]pyridine-6-carboxynitrile. (White solid). LC / MS (ESI) m / z: 410.2 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ7.01(t,J=8.8Hz,2H),6.49(dd,J=4.4,9.2Hz,2H),4.18(dd,J=5.6,9.2H z,2H),4.11-4.01(m,2H),3.50-3.44(m,5H),3.20-3.12(m,2H),2.69(s,3H),2.48-2.39(m,2H).

[0639] Synthesis of Compound 6

[0640]

[0641] Step 1: Preparation of tert-butyl (3S,4R)-4-(4-chloro-N-methylaniline)-3-methylpiperidine-1-carboxylate

[0642]

[0643] Acetic acid (53 mg, 0.88 mmol, 0.05 mL, 2.37 equivalents) was added to a mixture of (3S,4R)-4-(4-chloroanilino)-3-methylpiperidine-1-carboxylic acid tert-butyl ester (120 mg, 0.37 mmol, 1 equivalent), formaldehyde (149.89 mg, 1.85 mmol, 0.14 mL, 37% purity, 5 equivalents) and sodium cyanoborohydride (70 mg, 1.11 mmol, 3 equivalents) in methanol (1 mL) and tetrahydrofuran (1 mL), and the reaction mixture was stirred at 40 °C for 12 h. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel chromatography (gradient: 100 / 1 to 1:1 petroleum ether / ethyl acetate) to give (3S,4R)-4-(4-chloro-N-methylaniline)-3-methylpiperidine-1-carboxylic acid tert-butyl ester (100 mg, 0.30 mmol, 80% yield) as a colorless oil. LC / MS (ESI) m / z: 339.0 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ7.22-7.13(m,2H),6.80-6.69(m,2H),4.10(d,J=2.4Hz,1H),3.89-3.81(m,1H),3.81-3.65(m,1H),3.17-2.96(m ,1H),2.95-2.78(m,1H),2.77(s,3H),2.12(s,1H),2.04-1.96(m,1H),1.49(dd,J=2.4,12.4Hz,1H),1.40(s,9H),0.80(d,J=7.2Hz,3H).

[0644] Step 2: Preparation of (3S,4R)-N-(4-chlorophenyl)-N,3-dimethyl-piperidin-4-amine

[0645]

[0646] A mixture of (3S,4R)-4-(4-chloro-N-methylaniline)-3-methylpiperidin-1-carboxylic acid tert-butyl ester (100 mg, 0.30 mmol, 1 equivalent) and trifluoroacetic acid (1.54 g, 13.51 mmol, 1 mL, 45.77 equivalent) in dichloromethane (1 mL) was stirred at 25 °C for 0.5 h. The reaction mixture was concentrated under reduced pressure to give (3S,4R)-N-(4-chlorophenyl)-N,3-dimethylpiperidin-4-amine (100 mg, crude product, TFA salt) as a colorless oil. LC / MS (ESI) m / z: 239.0 [M+H] + .

[0647] Step 3: 6-Chloro-4-[(3S,4R)-4-(4-chloro-N-methyl-aniline)-3-methyl-1-piperidinyl]-1-methyl- Preparation of 2-oxo-1,5-naphthyl-3-carboxynitrile (compound 6)

[0648]

[0649] The title compound was prepared from (3S,4R)-N-(4-chlorophenyl)-N,3-dimethyl-piperidin-4-amine in a manner similar to that of 6-chloro-4-[4-(4-chloroanilino)-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile. (Yellow solid). LC / MS (ESI) m / z: 456.0 [M+H] + . 1 HNMR(400MHz,DMSO-d6)δ8.08(d,J=8.8Hz,1H),7.82(d,J=8.8Hz,1H),7.20(d,J=8.8 Hz,2H),6.85(d,J=9.2Hz,2H),4.34(d,J=12.4Hz,1H),4.14(td,J=3.2,12.4Hz,1H),4 .04-3.95(m,1H),3.91-3.83(m,1H),3.53(s,3H),3.45(t,J=11.6Hz,1H),2.85(s,3H ),2.78-2.69(m,1H),2.33(d,J=3.6Hz,1H),1.82-1.72(m,1H),0.87(d,J=6.8Hz,3H).

[0650] Synthesis of Compound 7

[0651]

[0652] Step 1: (3aR,4R,6aS)-4-methyl-2-[4-(trifluoromethoxy)phenyl]-1,3,3a,4,6,6a-hexahydropyridine Preparation of tert-butyl pyrrolo[3,4-c]pyrrolo-5-carboxylate

[0653]

[0654] Under a nitrogen atmosphere, tert-butyl pyrrolo[3,4-c]pyrrolo-5-carboxylate (257 mg, 1.14 mmol, 1 equivalent), 1-bromo-4-(trifluoromethoxy)benzene (274 mg, 1.14 mmol, 0.2 mL, 1 equivalent), and Cs₂CO₃ (1.11 g, 3.41 mmol, 3 equivalent) in N,N-dimethylacetamide (2.5 mL) were added to a mixture of 1,3-bis[2,6-bis(1-propylbutyl)phenyl]-4,5-dichloro-2H-imidazol-1-onthium-2-ylidene; 3-chloropyridine; and palladium dichloro(55 mg, 0.06 mmol, 0.05 equivalent). The suspension was then degassed and purged with nitrogen (3X). The reaction mixture was stirred at 80 °C for 3 h under N2. The mixture was diluted with water (6 mL) and extracted with ethyl acetate (6 mL x 2). The combined organic extracts were washed with brine (12 mL), dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by rapid silica gel chromatography (gradient: 100 / 1 to 1:1 petroleum ether / ethyl acetate) to give (3aR,4R,6aS)-4-methyl-2-[4-(trifluoromethoxy)phenyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylic acid tert-butyl ester (181 mg, 0.55 mmol, 41% yield) as a yellow oil. LC / MS (ESI) m / z: 387.2 [M+H] + .

[0655] Step 2: (3R,3aR,6aR)-3-methyl-5-[4-(trifluoromethoxy)phenyl]-2,3,3a,4,6,6a-hexahydro- Preparation of 1H-pyrrolo[3,4-c]pyrrole

[0656]

[0657] A mixture of (3aR,4R,6aS)-4-methyl-2-[4-(trifluoromethoxy)phenyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylic acid tert-butyl ester (90 mg, 0.23 mmol, 1 equivalent) and trifluoroacetic acid (1.54 g, 13.51 mmol, 1 mL, 57.99 equivalent) in dichloromethane (1 mL) was stirred at 25 °C for 15 min. The mixture was concentrated under vacuum to give a red oily (3R,3aR,6aR)-3-methyl-5-[4-(trifluoromethoxy)phenyl]-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole (100 mg, crude substance, TFA salt). LC / MS (ESI) m / z: 287.3 [M+H] + .

[0658] Step 3: 4-[(3aR,4R,6aS)-4-methyl-2-[[4-(trifluoromethoxy)phenyl]methyl]-1,3,3a,4,6, 6a-Hexahydropyrrolo[3,4-c]pyrrolo-5-yl]-6-chloro-1-methyl-1,5-naphthidine- Preparation of 2-one

[0659]

[0660] The title compound (a grayish-white solid) was prepared from (3R,3aR,6aR)-3-methyl-5-[4-(trifluoromethoxy)phenyl]-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole and trifluoromethanesulfonic acid (6-chloro-1-methyl-2-oxo-1,5-naphthidium-4-yl) ester in a manner similar to that of 6-chloro-4-[4-(4-chloroanilino)-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidium-3-carboxynitrile]. LC / MS (ESI) m / z: 479.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ7.95(d,J=9.2Hz,1H),7.68(d,J=8.8Hz,1H),7.13(d,J=8.4 Hz,2H),6.61-6.53(m,2H),5.63(s,1H),5.06-4.90(m,1H),4.00(dd,J=8.4,11.2Hz ,1H),3.56(dd,J=8.8,9.6Hz,1H),3.50-3.40(m,5H),3.27-3.23(m,1H),3.21(d,J= 4.0Hz,1H),3.13(dd,J=6.0,10.0Hz,1H),2.90-2.80(m,1H),1.21(d,J=6.4Hz,3H).

[0661] Synthesis of Compound 8

[0662]

[0663] Step 1: (3aS,6aR)-2-[4-(trifluoromethoxy)phenyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4- c] Preparation of tert-butyl pyrrole-5-carboxylate

[0664]

[0665] To a solution of (3aS,6aR)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrolo-5-carboxylic acid tert-butyl ester (150 mg, 0.71 mmol, 1 equivalent) and 1-bromo-4-(trifluoromethoxy)benzene (255 mg, 1.06 mmol, 0.16 mL, 1.5 equivalent) in diane (3 mL), Cs2CO3 (690 mg, 2.12 mmol, 3 equivalent) and 1,3-bis[2,6-bis(1-propylbutyl)phenyl]-4,5-dichloro-2H-imidazol-1-onthium-2-ylidene; 3-chloropyridine; palladium dichloro (34 mg, 0.035 mmol, 0.05 equivalent) were added, and the reaction mixture was stirred at 100 °C for 4 h. The mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel chromatography (gradient: 100 / 1 to 1:1 petroleum ether / ethyl acetate) to give (3aS,6aR)-2-[4-(trifluoromethoxy)phenyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylic acid tert-butyl ester (270 mg, crude) as a green oil. LC / MS (ESI) m / z: 372.9 [M+H] + . 1 H NMR (400MHz, CDCl3) 2H),6.51-6.46(m,2H),3.65(dd,J=7.2,11.2Hz,2H),3.51(d,J=2.8Hz,2H),3.37(d,J= 10.4Hz,1H),3.31-3.23(m,1H),3.20(dd,J=3.2,9.2Hz,2H),3.00(s,2H),1.46(s,9H).

[0666] Step 2: (3aR,6aS)-5-[4-(trifluoromethoxy)phenyl]-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo Preparation of [3,4-c]pyrrole

[0667]

[0668] A solution of (3aS,6aR)-2-[4-(trifluoromethoxy)phenyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-5-carboxylic acid tert-butyl ester (120 mg, 0.32 mmol, 1 equivalent) in dichloromethane (1 mL) was mixed with trifluoroacetic acid (770 mg, 6.75 mmol, 0.5 mL, 21 equivalents), and the reaction mixture was stirred at 25 °C for 0.25 h. The mixture was concentrated under reduced pressure to give a brown oily (3aR,6aS)-5-[4-(trifluoromethoxy)phenyl]-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole (120 mg, crude substance, TFA salt). LC / MS (ESI) m / z: 273.3 [M+H]+ .

[0669] Step 3: 4-[(3aS,6aR)-2-[4-(trifluoromethoxy)phenyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3, [4-c]pyrrolo-5-yl]-6-chloro-1-methyl-2-oxo-1,5-naphthyl-3-carboxylonitrile (Compound 8)

[0670]

[0671] The title compound was prepared from (3aR,6aS)-5-[4-(trifluoromethoxy)phenyl]-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole in a manner similar to that of 6-chloro-4-[4-(4-chloroanilino)-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile. (Yellow solid). LC / MS (ESI) m / z: 490.2 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.00(d,J=9.2Hz,1H),7.78(d,J=8.8Hz,1H),7.16(d,J=8.8Hz,2H),6.61-6.54(m,2H),4 .51(dd,J=6.8,12.4Hz,2H),4.09(s,2H),3.55-3.50(m,2H),3.48(s,3H),3.29-3.24(m,2H),3.20-3.13(m,2H).

[0672] Synthesis of Compound 9

[0673]

[0674] Step 1: WC-ARV-JM-027-C-1, (3aS,6aR)-3a,6a-dimethyl-2-[4-(trifluoromethoxy)benzene] Preparation of tert-butyl pyrrolo[3,4-c]pyrrolo-5-carboxylate [3,4-c]-1,3,4,6-tetrahydropyrrolo[3,4-c]pyrrolo-5-carboxylate

[0675]

[0676] To a solution of (3aR,6aS)-3a,6a-dimethyl-2,3,4,6-tetrahydro-1H-pyrrolo[3,4-c]pyrrolo-5-carboxylic acid tert-butyl ester (150 mg, 0.62 mmol, 1 equivalent) and 1-bromo-4-(trifluoromethoxy)benzene (225 mg, 0.93 mmol, 0.14 mL, 1.5 equivalent) in dioxane (3 mL), Cs₂CO₃ (610 mg, 1.87 mmol, 3 equivalent) and 1,3-bis[2,6-bis(1-propylbutyl)phenyl]-4,5-dichloro-2H-imidazol-1-onthium-2-ylidene; 3-chloropyridine; palladium dichloro (30 mg, 0.03 mmol, 0.05 equivalent) were added, and the reaction mixture was stirred at 100 °C for 4 h. The mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel chromatography (gradient: 100 / 1 to 1:1 petroleum ether / ethyl acetate) to give (3aS,6aR)-3a,6a-dimethyl-2-[4-(trifluoromethoxy)phenyl]-1,3,4,6-tetrahydropyrrolo[3,4-c]pyrrole-5-carboxylic acid tert-butyl ester (85 mg, 0.21 mmol, 34% yield) as a brown oil. LC / MS (ESI) m / z: 401.0 [M+H] + . 1 H NMR (400MHz, CDCl3)

[0677] δ7.07(d,J=8.8Hz,2H),6.45-6.39(m,2H),3.43-3.34(m,4H),3.31-3.26(m,2H),3.22(d,J=9.6Hz,2H),1.44(s,9H),1.13(s,6H).

[0678] Step 2: (3aR,6aS)-5-[4-(trifluoromethoxy)phenyl]-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo Preparation of [3,4-c]pyrrole

[0679]

[0680] A solution of (3aS,6aR)-3a,6a-dimethyl-2-[4-(trifluoromethoxy)phenyl]-1,3,4,6-tetrahydropyrrolo[3,4-c]pyrrolo-5-carboxylic acid tert-butyl ester (85 mg, 0.21 mmol, 1 equivalent) in dichloromethane (1 mL) was mixed with trifluoroacetic acid (77 mg, 6.8 mmol, 0.5 mL, 31.8 equivalents), and the reaction mixture was stirred at 25 °C for 0.25 h. The mixture was concentrated under reduced pressure to give a brown oily (3aR,6aS)-3a,6a-dimethyl-5-[4-(trifluoromethoxy)phenyl]-2,3,4,6-tetrahydro-1H-pyrrolo[3,4-c]pyrrole (85 mg, crude substance, TFA salt). LC / MS (ESI) m / z: 301.2 [M+H]+ .

[0681] Step 3: 4-[(3aS,6aR)-3a,6a-dimethyl-2-[4-(trifluoromethoxy)phenyl]-1,3,4,6-tetrahydropyridine Preparation of [3,4-c]pyrrolo-5-yl]-6-chloro-1-methyl-2-oxo-1,5-naphthyl-3-carboxylonitrile (compound 9)

[0682]

[0683] The title compound was prepared from (3aR,6aS)-3a,6a-dimethyl-5-[4-(trifluoromethoxy)phenyl]-2,3,4,6-tetrahydro-1H-pyrrolo[3,4-c]pyrrole in a manner similar to that of 6-chloro-4-[4-(4-chloroanilino)-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile. (Yellow solid). LC / MS (ESI) m / z: 518.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.00(d,J=9.2Hz,1H),7.77(d,J=9.2Hz,1H),7.15(d,J=8.4Hz,2H),6.55-6.49(m,2H ),4.35-4.30(m,2H),4.24-4.17(m,2H),3.50(s,1H),3.49-3.46(m,4H),3.26(d,J=10.4Hz,2H),1.17(s,6H).

[0684] Synthesis of Compound 10

[0685]

[0686] Step 1: Preparation of ethyl 2-methyl-5-(methylamino)thiazole-4-carboxylate

[0687]

[0688] Sodium hydride (4.19 g, 104.71 mmol, 60% purity, 1.3 equivalent) was added in portions to a mixture of ethyl 5-amino-2-methyl-thiazolyl-4-carboxylate (15 g, 80.55 mmol, 1 equivalent) in tetrahydrofuran (150 mL), and the mixture was stirred at 0 °C for 0.5 h. Iodimethane (19.44 g, 136.93 mmol, 8.52 mL, 1.7 equivalent) was then added, and the reaction mixture was stirred at 20 °C for 12 h under nitrogen. The mixture was diluted with saturated aqueous NH4Cl solution (300 mL) and then extracted with ethyl acetate (3 × 300 mL). The combined organic extracts were washed with brine (500 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography (gradient: 100 / 1 to 3:1 petroleum ether / ethyl acetate) to give ethyl 2-methyl-5-(methylamino)thiazole-4-carboxylate as a yellow solid (18 g, 89.88 mmol, 56% yield). LC / MS (ESI) m / z: 200.9 [M+H] + . 1 H NMR (400MHz, CDCl3) δ7.31-7.15(m,1H),4.48-4.33(m,2H),3.03-3.00(m,3H),2.63-2.50(m,3H),1.46-1.34(m,3H).

[0689] Step 2: Preparation of ethyl 5-[(2-cyanoacetyl)-methyl-amino]-2-methyl-thiazol-4-carboxylate

[0690]

[0691] A mixture of 2-cyanoacetic acid (3.06 g, 35.95 mmol, 1.2 equivalents) and acetic anhydride (32.70 g, 320.31 mmol, 30.00 mL, 10.69 equivalents) was stirred at 80 °C for 0.5 h. Then, ethyl 2-methyl-5-(methylamino)thiazole-4-carboxylate (6 g, 29.96 mmol, 1 equivalent) was added, and the reaction mixture was stirred at 80 °C for 0.5 h under nitrogen. The mixture was concentrated, and the resulting residue was purified by silica gel chromatography (gradient: 100 / 1 to 1:1 petroleum ether / ethyl acetate) to give ethyl 5-[(2-cyanoacetyl)-methyl-amino]-2-methyl-thiazole-4-carboxylate (2.5 g, 9.35 mmol, 31% yield) as a yellow solid. LC / MS (ESI) m / z: 268.1 [M+H] + .

[0692] 1H NMR (400MHz, CDCl3) δ4.47-4.40(m,2H),3.43(d,J=15.2Hz,2H),3.28(s,3H),2.81-2.74(m,3H),1.42-1.37(m,3H).

[0693] Step 3: Preparation of 7-hydroxy-2,4-dimethyl-5-oxo-thiazo[5,4-b]pyridine-6-carboxylonitrile

[0694]

[0695] A mixture of ethyl 5-[(2-cyanoacetyl)-methyl-amino]-2-methyl-thiazolyl-4-carboxylate (2.5 g, 9.35 mmol, 1 equivalent) and 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azapyrrolidone (1.71 g, 11.22 mmol, 1.69 mL, 1.2 equivalent) in ethanol (20 mL) was stirred at 20 °C for 0.5 h under nitrogen atmosphere. The mixture was concentrated, and the resulting residue was purified by preparative HPLC (column: Welch Xtimate C18 250*70mm#10μm; mobile phase: [0-30% CH3CN / water (0.225% formic acid)]) to give 7-hydroxy-2,4-dimethyl-5-oxo-thiazo[5,4-b]pyridine-6-carboxynitrile (1.1 g, 4.97 mmol, 53% yield) as a white solid. LC / MS (ESI) m / z: 221.9 [M+1] + . 1 H NMR(400MHz,DMSO-d6)δ3.50(s,3H),2.74(s,3H).

[0696] Step 4: Preparation of trifluoromethanesulfonic acid (6-cyano-2,4-dimethyl-5-oxo-thiazo[5,4-b]pyridin-7-yl) ester

[0697]

[0698] At 0 °C, trifluoromethanesulfonyl trifluoromethanesulfonate (2.81 g, 9.94 mmol, 1.64 mL, 2 equivalents) was added to a mixture of 7-hydroxy-2,4-dimethyl-5-oxo-thiazo[5,4-b]pyridine-6-carboxynitrile (1.1 g, 4.97 mmol, 1 equivalent), triethylamine (1.51 g, 14.92 mmol, 2.08 mL, 3 equivalents) and 4-dimethylaminopyridine (61 mg, 0.50 mmol, 0.1 equivalents) in dichloromethane (10 mL), and the reaction mixture was stirred at 0 °C under nitrogen for 1 h. The mixture was diluted with water (30 mL) and extracted with dichloromethane (30 mL x 2). The combined organic extracts were washed with brine (50 mL), dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (gradient: 10 / 1 to 1:1 petroleum ether / ethyl acetate) to give trifluoromethanesulfonic acid (6-cyano-2,4-dimethyl-5-oxo-thiazo[5,4-b]pyridin-7-yl) ester (1.2 g, 3.40 mmol, 68% yield) as a yellow solid. LC / MS (ESI) m / z: 354.0 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ3.50(s,3H),2.74(s,3H).

[0699] Step 5: 2,4-Dimethyl-5-oxo-7-spiro[3H-benzofuran-2,4'-piperidine]-1'-yl-thiazo[5,4- b] Preparation of pyridine-6-carboxynitrile (compound 10)

[0700]

[0701] The mixture of trifluoromethanesulfonic acid (6-cyano-2,4-dimethyl-5-oxo-thiazo[5,4-b]pyridin-7-yl) ester (80 mg, 0.23 mmol, 1 equivalent), spiro[3H-benzofuran-2,4'-piperidine] (51 mg, 0.23 mmol, 1 equivalent of hydrogen chloride) and diisopropylethylamine (88 mg, 0.68 mmol, 0.12 mL, 3 equivalents) in acetonitrile (2 mL) was degassed and purged with nitrogen (3X), and then stirred at 40 °C for 4 hours under a nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure, and the resulting residue was prepared at 25 °C with DMF (0.1 mL) and acetonitrile (0.2 mL), then collected by filtration to give 2,4-dimethyl-5-oxo-7-spiro[3H-benzofuran-2,4'-piperidin]-1'-yl-thiazo[5,4-b]pyridine-6-carboxynitrile (33 mg, 0.082 mmol, 36% yield) as a white solid. LC / MS (ESI) m / z: 393.3 [M+H] + . 1H NMR(400MHz,DMSO-d6)δ7.21(d,J=7.2Hz,1H),7.10(t,J=7.2Hz,1H),6.86-6.77(m,2H),4.1 3-4.04(m,2H),3.97-3.88(m,2H),3.49(s,3H),3.11(s,2H),2.70(s,3H),2.03-1.95(m,4H).

[0702] Synthesis of Compound 11

[0703]

[0704] Step 1: (3R,4R)-4-(4-chloro-2-methyl-aniline)-3-methyl-piperidine-1-carboxylic acid tert-butyl ester and (3S, Preparation of tert-butyl 4R)-4-(4-chloro-2-methyl-aniline)-3-methyl-piperidine-1-carboxylate

[0705]

[0706] To a mixture of tert-butyl 3-methyl-4-oxo-piperidine-1-carboxylate (3 g, 14.07 mmol, 1 equivalent) and 4-chloro-2-methylaniline (2.39 g, 16.88 mmol, 1.2 equivalent) in methanol (15 mL) and acetic acid (15 mL), borane-2-methylpyridine (3.01 g, 28.13 mmol, 2 equivalent) was added, and the reaction mixture was stirred at 25 °C for 12 h under nitrogen. The mixture was concentrated under vacuum, and the resulting residue was purified by preparative HPLC (column: Welch Xtimate C18 250*70mm, 10um; mobile phase: [53-88% CH3CN / water (NH4HCO3)]) followed by preparative SFC (column: DAICL CHIRALPAK AD-H (250mm*30mm, 5um); mobile phase: 20% isopropanol (0.1% NH4OH) / CO2) to obtain two diastereomers.

[0707] The compound (3R,4R)-4-(4-chloro-2-methyl-aniline)-3-methyl-piperidine-1-carboxylic acid tert-butyl ester (600 mg, 1.77 mmol, 21% yield) was obtained as a white solid. 1H NMR (400MHz, DMSO-d6) δ7.02-6.97(m,2H),6.61(d,J=8.4Hz,1H),4.35-4.31(m,1H),3.94-3.78(m,1H),3.70-3.56(m,2H),3.13 -2.83(m,2H),2.09(s,3H),2.06(d,J=3.6Hz,1H),1.74-1.62(m,1H),1.54(d,J=3.6Hz,1H),1.39(s,9H),0.76(d,J=7.2Hz,3H).

[0708] (3S,4R)-4-(4-chloro-2-methyl-aniline)-3-methyl-piperidine-1-carboxylic acid tert-butyl ester was obtained as a white solid (1.2 g, 3.54 mmol, 43% yield). 1 H NMR (400MHz, DMSO-d6) δ7.01-6.91(m,2H),6.58(d,J=9.2Hz,1H),4.54(d,J=9.2Hz,1H),3.91(d,J=11.6Hz,2H),3.12–3.08(m,1H),2.8 5(d,J=1.6Hz,1H),2.06(s,3H),1.88(dd,J=3.2,13.2Hz,1H),1.75-1.59(m,1H),1.40(s,9H),1.26-1.15(m,1H),0.88(d,J=6.4Hz,3H).

[0709] Step 2: (3S,4R)-4-(4-chloro-2-methylaniline)-3-methylpiperidine-1-carboxylic acid tert-butyl ester and (3R, Preparation of tert-butyl 4-(4-chloro-2-methyl-aniline)-3-methyl-piperidine-1-carboxylate

[0710]

[0711] Enantiomers were separated using a preparative SFC (column: DAICEL CHIRALCEL OD (250mm*30mm, 10um); mobile phase: 20% isopropanol (0.1% NH4OH) / CO2).

[0712] The absolute configuration is arbitrarily specified.

[0713] (3S,4R)-4-(4-chloro-2-methylaniline)-3-methylpiperidine-1-carboxylic acid tert-butyl ester (780 mg) was obtained as a white solid. LC / MS (ESI) m / z: 339.0 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ7.03-6.97(m,2H),6.61(d,J=8.4Hz,1H),4.38-4.32(m,1H),3.92-3.75(m,1H),3.71-3.56(m,2H),3.34(s,3H),3.17 (d,J=5.2Hz,1H),3.10(d,J=12.0Hz,1H),3.04-2.79(m,1H),1.76-1.63(m,1H),1.57-1.50(m,1H),1.42-1.38(m,9H),0.76(d,J=7.2Hz,3H).

[0714] (3R,4S)-4-(4-chloro-2-methylaniline)-3-methylpiperidine-1-carboxylic acid tert-butyl ester (630 mg) was obtained as a white solid. LC / MS (ESI) m / z: 339.0 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ7.03-6.97(m,2H),6.61(d,J=8.4Hz,1H),4.34(d,J=7.6Hz,1H),3.93-3.73(m,1H),3.70-3.57(m,2H),3.34(s,3 H),3.17(d,J=4.8Hz,1H),3.10(d,J=12.0Hz,1H),2.89(s,1H),1.74-1.62(m,1H),1.57-1.49(m,1H),1.39(s,9H),0.76(d,J=7.2Hz,3H).

[0715] Step 3: Preparation of (3S,4R)-N-(4-chloro-2-methyl-phenyl)-3-methyl-piperidin-4-amine

[0716]

[0717] A solution of (3S,4R)-4-(4-chloro-2-methyl-aniline)-3-methyl-piperidin-1-carboxylic acid tert-butyl ester (100 mg, 0.29 mmol, 1 equivalent) in dichloromethane (1 mL) was mixed with trifluoroacetic acid (770 mg, 6.75 mmol, 0.5 mL, 23 equivalents), and the reaction mixture was stirred at 25 °C for 0.25 h. The mixture was concentrated under vacuum to give (3S,4R)-N-(4-chloro-2-methyl-phenyl)-3-methyl-piperidin-4-amine (100 mg, crude substance, TFA salt) as a colorless oil. LC / MS (ESI) m / z: 239.0 [M+H] + .

[0718] Step 4: 6-Chloro-4-[(3S,4R)-4-(4-chloro-2-methyl-aniline)-3-methyl-1-piperidinyl]-1-methyl- Preparation of 2-oxo-1,5-naphthidine-3-carboxynitrile (compound 11)

[0719]

[0720] The title compound was prepared in a manner similar to that of 6-chloro-4-[4-(4-chloroanilino)-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile. (Yellow solid). LC / MS (ESI) m / z: 456.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ8.07(d,J=9.2Hz,1H),7.81(d,J=8.8Hz,1H),7.04-6.9 9(m,2H),6.72(d,J=9.2Hz,1H),4.55(d,J=8.0Hz,1H),4.18(d,J=13.8Hz,1H), 4.00-3.93(m,1H),3.89-3.81(m,2H),3.63-3.54(m,1H),3.53(s,3H),2.28-2. 18(m,1H),2.15(s,3H),2.07(s,1H),1.89-1.79(m,1H),0.86(d,J=6.8Hz,3H).

[0721] Synthesis of Compound 12

[0722] 6-Chloro-4-[(3S,4S)-4-(4-chloro-2-methyl-aniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo Synthesis of 1,5-naphthyl-3-carboxynitrile (compound 12)

[0723]

[0724] The title compound was prepared from (3S,4S)-4-(4-chloro-2-methyl-aniline)-3-methyl-piperidin-1-carboxylate tert-butyl ester in a manner similar to that of 6-chloro-4-[(3S,4R)-4-(4-chloro-2-methyl-aniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile. (Yellow solid). LC / MS (ESI) m / z: 456.0 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ8.06(d,J=9.2Hz,1H),7.81(d,J=9.2Hz,1H),7.05-6.93(m,2H),6.75-6.65(m,1H),4.75(d,J=9.2Hz,1H),4.37-4.2 0(m,2H),3.66-3.55(m,1H),3.53(s,3H),3.19-3.11(m,1H),2.26-2.1 6(m,1H),2.13-2.06(m,4H),1.69-1.55(m,1H),0.97(d,J=6.4Hz,3H).

[0725] Synthesis of Compound 13

[0726] 6-Chloro-4-[(3S,4S)-4-(4-chloro-2-methoxy-aniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo Preparation of 1,5-naphthyl-3-carboxynitrile (compound 13)

[0727]

[0728] The title compound was prepared from (3S,4S)-4-(4-chloro-2-methoxy-anilino)-3-methyl-piperidin-1-carboxylic acid tert-butyl ester in a manner similar to that of 6-chloro-4-[(3S,4R)-4-(4-chloro-2-methoxy-anilino)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile (yellow solid). LC / MS (ESI) m / z: 472.1 [M+H] + . 1 HNMR (400MHz, DMSO-d6) δ8.08(d,J=9.2Hz,1H),7.8(d,J=9.2Hz,1H),6.84(d,J=2. 4Hz,1H),6.80-6.76(m,1H),6.68(d,J=8.4Hz,1H),4.76(d,J=9.6Hz,1H),4.32-4. 2(m,2H),3.80(s,3H),3.64-3.56(m,1H),3.52(s,3H),3.4-3.32(m,1H),3.16(dd, J=11.2,12.8Hz,1H),2.16-2.04(m,2H),1.64-1.52(m,1H),0.96(d,J=6.4Hz,3H).

[0729] Synthesis of Compound 14

[0730] 6-Chloro-4-[(3R,4R)-4-(4-chloro-2-methoxy-aniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo Preparation of 1,5-naphthyl-3-carboxynitrile (compound 14)

[0731]

[0732] The title compound was prepared from (3R,4R)-4-(4-chloro-2-methoxy-anilino)-3-methyl-piperidin-1-carboxylic acid tert-butyl ester in a manner similar to that of 6-chloro-4-[(3S,4R)-4-(4-chloro-2-methoxy-anilino)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile. (Yellow solid). LC / MS (ESI) m / z: 472.1 [M+H] + . 1 HNMR(400MHz,DMSO-d6)δ8.08(d,J=8.8Hz,1H),7.80(d,J=9.2Hz,1H),6.84(d,J= 2.0Hz,1H),6.80-6.76(m,1H),6.68(d,J=8.4Hz,1H),4.76(d,J=9.6Hz,1H),4.24( t,J=13.6Hz,2H),3.80(s,3H),3.6-3.56(m,1H),3.52(s,3H),3.4-3.36(m,1H),3. 16(t,J=12.0Hz,1H),2.16-2.04(m,2H),1.64-1.52(m,1H),0.96(d,J=6.4Hz,3H).

[0733] Synthesis of Compound 15

[0734] 2,4-Dimethyl-5-oxo-7-spiro[indan-2,4-] ' -piperidine]-1 ' --Thiazo[5,4-b]pyridine-6-carboxynitrile Preparation of (Compound 15)

[0735]

[0736] The title compound was prepared from 1,3-dihydrospiro[indene-2,4'-piperidine]trifluoromethanesulfonic acid and (6-cyano-2,4-dimethyl-5-oxo-thiazo[5,4-b]pyridin-7-yl) esters in a manner similar to that of 2,4-dimethyl-5-oxo-7-spiro[3H-benzofuran-2,4'-piperidine]-1'-yl-thiazo[5,4-b]pyridin-6-carboxynitrile. (Grayish-white solid). LC / MS (ESI) m / z: 391.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ7.24-7.17(m,2H),7.15-7.09(m,2H),3.94(s,4H),3.48(s,3H),2.88(s,4H),2.69(s,3H),1.78-1.72(m,4H).

[0737] Synthesis of Compound 16

[0738] 6-Chloro-4-[(3R,4R)-4-(4-chloro-2-methyl-aniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo Preparation of 1,5-naphthyl-3-carboxynitrile (compound 16)

[0739]

[0740] The title compound was prepared from (3R,4R)-4-(4-chloro-2-methyl-aniline)-3-methyl-piperidin-1-carboxylate tert-butyl ester in a manner similar to that of 6-chloro-4-[(3S,4R)-4-(4-chloro-2-methyl-aniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthyl-3-carboxynitrile. (Yellow solid). LC / MS (ESI) m / z: 456.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ8.07(d,J=9.2Hz,1H),7.81(d,J=9.2Hz,1H),7.06-6 .92(m,2H),6.73-6.67(m,1H),4.75(d,J=9.2Hz,1H),4.35-4.21(m,2H),3.6 4-3.56(m,1H),3.53(s,3H),3.15(dd,J=11.2,12.8Hz,1H),2.28-2.17(m,1H ),2.16-2.10(m,1H),2.09(s,3H),1.67-1.55(m,1H),0.97(d,J=6.8Hz,3H).

[0741] Synthesis of Compound 17

[0742] 6-Chloro-4-[(3R,4S)-4-(4-chloro-2-methoxy-aniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo Preparation of 1,5-naphthyl-3-carboxynitrile (compound 17)

[0743]

[0744] The title compound was prepared from (3R,4S)-4-(4-chloro-2-methoxy-anilino)-3-methyl-piperidin-1-carboxylic acid tert-butyl ester in a manner similar to that of 6-chloro-4-[(3S,4R)-4-(4-chloro-2-methoxy-anilino)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile. (Off-white solid). LC / MS (ESI) m / z: 472.0 [M+H] + . 1 HNMR (400MHz, DMSO-d6)

[0745] δ8.08(d,J=9.2Hz,1H),7.80(d,J=8.8Hz,1H),6.88(d,J

[0746] =2.4Hz,1H),6.84-6.76(m,1H),6.76-6.68(m,1H),4.6(d,J=8.8Hz,1H),4.16-4.04(m,1H),3.92-3.8(m,6H),3.6(t,J =10Hz,1H),3.52(s,3H),2.32(dd,J=1.6,3.6Hz,1H),2.08(d,J=2.8Hz,1H),1.88(td,J=4.4,8.8Hz,1H),0.76(s,3H).

[0747] Synthesis of Compound 18

[0748] 6-Chloro-4-[(3S,4R)-4-(4-chloro-2-methyl-aniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo Preparation of 1,5-naphthyl-3-carboxynitrile (compound 18)

[0749]

[0750] The title compound was prepared in a manner similar to that of 6-chloro-4-[4-(4-chloroanilino)-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile. (Yellow solid). LC / MS (ESI) m / z: 456.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ8.07(d,J=9.2Hz,1H),7.81(d,J=8.8Hz,1H),7.04-6.9 9(m,2H),6.72(d,J=9.2Hz,1H),4.55(d,J=8.0Hz,1H),4.18(d,J=13.8Hz,1H), 4.00-3.93(m,1H),3.89-3.81(m,2H),3.63-3.54(m,1H),3.53(s,3H),2.28-2. 18(m,1H),2.15(s,3H),2.07(s,1H),1.89-1.79(m,1H),0.86(d,J=6.8Hz,3H).

[0751] Synthesis of Compound 19

[0752]

[0753] Step 1: (3S,4R)-4-(4-chloro-2-methoxy-aniline)-3-methyl-piperidine-1-carboxylic acid tert-butyl ester and (3R, Preparation of tert-butyl 4R)-4-(4-chloro-2-methoxy-aniline)-3-methyl-piperidine-1-carboxylic acid

[0754]

[0755] A mixture of tert-butyl 3-methyl-4-oxo-piperidine-1-carboxylate (3 g, 14.07 mmol, 1 equivalent), 4-chloro-2-methoxyaniline (2.22 g, 14.07 mmol, 1 equivalent), and borane-2-methylpyridine (3 g, 28.13 mmol, 2 equivalent) in methanol (15 mL) and acetic acid (15 mL) was stirred at 25 °C for 12 h. The mixture was concentrated under vacuum, and the crude product was diluted with water (40 mL) and extracted with ethyl acetate (40 mL x 2). The combined organic extracts were washed with brine (80 mL), dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by preparative HPLC (column: YMC Triart C18 70*250mm*7μm; mobile phase: [51-81% CH3CN / water(NH4HCO3)]) followed by SFC (column: DAICEL CHIRALPAK AD-H (250mm*30mm, 5um); mobile phase: 20% isopropanol / (0.1% NH4OH) / CO2) to obtain diastereomers.

[0756] (3S,4R)-4-(4-chloro-2-methoxy-aniline)-3-methyl-piperidine-1-carboxylic acid tert-butyl ester (1.57 g, 4.42 mmol, 31% yield) was obtained as a grayish-white oil. 1 H NMR (400MHz, DMSO-d6) δ6.88(d,J=2.4Hz,1H),6.80(dd,J=2.4,8.4Hz,1H),6.64(d,J=8.8Hz,1H),4.48(d,J=8.8Hz,1H),3.8(s,3H),3.6 8-3.52(m,2H),3.32(s,1H),3.16-3.08(m,1H),3-2.84(m,1H),2.12-2.0(m,1H),1.68-1.48(m,2H),1.40(s,9H),0.76(d,J=7.2Hz,3H).

[0757] (3R,4R)-4-(4-chloro-2-methoxy-aniline)-3-methyl-piperidine-1-carboxylic acid tert-butyl ester (624 mg, 1.76 mmol, 13% yield) was obtained as a grayish-white oil. 1H NMR (400MHz, DMSO-d6) δ6.84(d,J=2.4Hz,1H),6.76(dd,J=2.4,8.4Hz,1H),6.60(d,J=8.8Hz,1H),4.68(d,J=9.6Hz,1H),3.88(d,J=11.6Hz,2H) ,3.80(s,3H),3.12-3.00(m,1H),2.88-2.76(m,1H),1.88-1.8(m,1H),1 .68-1.52(m,1H),1.40(s,9H),1.24-1.08(m,2H),0.84(d,J=6.4Hz,3H).

[0758] Step 2: (3S,4R)-4-(4-chloro-2-methoxy-aniline)-3-methyl-piperidine-1-carboxylic acid tert-butyl ester and (3R, Preparation of tert-butyl 4-(4-chloro-2-methoxy-aniline)-3-methyl-piperidine-1-carboxylate

[0759]

[0760] Enantiomers were separated by SFC (column: DAICEL CHIRALCEL OD (250mm*30mm, 10um); mobile phase: 20% isopropanol / CO2).

[0761] The absolute configuration is arbitrarily specified.

[0762] (3S,4R)-4-(4-chloro-2-methoxy-aniline)-3-methyl-piperidin-1-carboxylic acid tert-butyl ester was obtained as a grayish-white oil (731 mg, 2.06 mmol, 46% yield). LC / MS (ESI) m / z: 299.0 [M-55] + .

[0763] (3R,4S)-4-(4-chloro-2-methoxy-aniline)-3-methyl-piperidin-1-carboxylic acid tert-butyl ester was obtained as a grayish-white oil (758 mg, 2.14 mmol, 48% yield). LC / MS (ESI) m / z: 299.0 [M-55] + .

[0764] Step 3: Preparation of (3S,4R)-N-(4-chloro-2-methoxy-phenyl)-3-methyl-piperidine-4-amine

[0765]

[0766] A mixture of (3S,4R)-4-(4-chloro-2-methoxy-aniline)-3-methyl-piperidin-1-carboxylic acid tert-butyl ester (100 mg, 0.28 mmol, 1 equivalent) and trifluoroacetic acid (1.54 g, 13.51 mmol, 1 mL, 47.93 equivalent) in dichloromethane (1 mL) was stirred at 25 °C for 15 min. The mixture was concentrated under vacuum to give (3S,4R)-N-(4-chloro-2-methoxy-phenyl)-3-methyl-piperidin-4-amine (120 mg, crude substance, TFA salt) as a red oil. LC / MS (ESI) m / z: 255.1 [M+H] +

[0767] Step 4: 6-Chloro-4-[(3S,4R)-4-(4-chloro-2-methoxy-aniline)-3-methyl-1-piperidinyl]-1-methyl Preparation of 2-oxo-1,5-naphthidium-3-carboxynitrile (compound 19)

[0768]

[0769] The title compound was prepared from (3S,4R)-N-(4-chloro-2-methoxy-phenyl)-3-methylpiperidin-4-amine in a manner similar to that of 6-chloro-4-[4-(4-chloroanilino)-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile. (White solid). LC / MS (ESI) m / z: 472.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.08(d,J=9.2Hz,1H),7.8(d,J=9.2Hz,1H),6.88(d,J=2.4Hz,1H),6.84-6.76(m,1H),6.76-6.72(m,1H),4.6(d,J=8.8Hz,1H ),4.08(d,J=12.4Hz,1H),3.88-3.8(m,6H),3.64-3.56(m,1H),3.52(s,3H ),2.32(s,1H),2.2-2.08(m,1H),1.92-1.80(m,1H),0.84(d,J=7.2Hz,3H).

[0770] Synthesis of Compounds 21 and 20

[0771]

[0772]

[0773] Step 1: (3S,4R)-4-(4-fluoro-2-hydroxyaniline)-3-methyl-piperidine-1-carboxylic acid tert-butyl ester and (3R, Preparation of tert-butyl 4R)-4-(4-fluoro-2-hydroxy-aniline)-3-methyl-piperidine-1-carboxylic acid

[0774]

[0775] A mixture of tert-butyl 3-methyl-4-oxo-piperidin-1-carboxylate (3 g, 14.1 mmol, 1 equivalent), 2-amino-5-fluorophenol (2.68 g, 21 mmol, 1.5 equivalent), and acetic acid (84.47 mg, 1.41 mmol, 0.08 mL, 0.1 equivalent) in CH3OH (30 mL) was stirred at 50 °C for 0.5 h. Sodium cyanoborohydride (2.65 g, 42 mmol, 3 equivalent) was then added, and the reaction mixture was stirred at 50 °C for 12 h. The mixture was diluted with water (150 mL) and extracted with ethyl acetate (150 mL × 4). The combined organic extracts were washed with brine (300 mL × 2), dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by preparative HPLC (column: YMC Triart C18250*50mm*7um; mobile phase: [37-67% CH3CN / water(NH4HCO3)]) to obtain the desired product.

[0776] (3S,4R)-4-(4-fluoro-2-hydroxy-aniline)-3-methyl-piperidine-1-carboxylic acid tert-butyl ester (1 g, 3 mmol, 22% yield) was obtained as a brown oil. 1 H NMR (400MHz, DMSO-d6) δ9.84 (d, J = 2.0Hz, 1H), 6.56-6.49 (m, 2H), 6.47-6.40 (m, 1H), 4.12-4.01 (m, 2H), 3.63- 3.50(m,2H),3.09(d,J=12.0Hz,1H),2.08-2.00(m,1H),1.60-1.49(m,2H),1.39(s,9H),0.75(d,J=6.8Hz,3H).

[0777] (3R,4R)-4-(4-fluoro-2-hydroxyaniline)-3-methylpiperidine-1-carboxylic acid tert-butyl ester was obtained as a brown oil (480 mg, 1.48 mmol, 11% yield). LC / MS (ESI) m / z: 269.0 (M-55) + . 1 H NMR (400MHz, DMSO-d6) δ9.74(s,1H),6.52-6.46(m,2H),6.45-6.39(m,1H),4.11(d,J=9.2Hz,1H),3.88(d,J=12.4Hz,2H),3.04-2.9 2(m,1H),2.90-2.73(m,1H),1.88(dd,J=3.2,13.2Hz,1H),1.59-1.52(m,1H),1.40(s,9H),1.14-1.06(m,1H),0.89(d,J=6.4Hz,3H).

[0778] Step 2: Preparation of 5-fluoro-2-[[(3S,4R)-3-methyl-4-piperidinyl]amino]phenol

[0779]

[0780] A solution of (3S,4R)-4-(4-fluoro-2-hydroxyaniline)-3-methyl-piperidin-1-carboxylic acid tert-butyl ester (400 mg, 1.23 mmol, 1 equivalent) in dichloromethane (4 mL) was mixed with trifluoroacetic acid (3.08 g, 27 mmol, 2 mL, 22 equivalents), and the reaction mixture was stirred at 25 °C for 0.25 h. The mixture was concentrated under reduced pressure to give 5-fluoro-2-[[(3S,4R)-3-methyl-4-piperidinyl]amino]phenol (400 mg, crude product, TFA salt) as a brown oil. LC / MS (ESI) m / z: 225.1 [M+H] + .

[0781] Step 3: 6-Chloro-4-[(3S,4R)-4-(4-fluoro-2-hydroxy-aniline)-3-methyl-1-piperidinyl]-1-methyl- Preparation of 2-oxo-1,5-naphthyl-3-carboxynitrile

[0782]

[0783] The title compound was prepared in a manner similar to that of 6-chloro-4-[4-(4-chloroanilino)-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile. (Yellow solid). LC / MS (ESI) m / z: 442.0 [M+H] + .

[0784] Step 4: 6-Chloro-4-[(3S,4R)-4-(4-fluoro-2-hydroxy-aniline)-3-methyl-1-piperidinyl]-1-methyl- 2-O-1,5-Naphtho-3-carboxynitrile (compound 21) and 6-chloro-4-[(3R,4S)-4-(4-fluoro-2-hydroxy-aniline)-3-methyl Preparation of compound 20: [1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidium-3-carboxynitrile

[0785]

[0786] Enantiomers were separated by preparative HPLC (column: DAICL CHIRALPAK AD (250 mm * 30 mm, 10 μm); mobile phase: [0.1% NH4OH / ethanol]; B%: 50%-50%, 3.2; 30 min). The enantiomers were further purified by preparative HPLC (column: Phenomenex luna C18 150 * 25 mm * 10 μm; mobile phase: [31-61% CH3CN / water (0.225% formic acid)]).

[0787] The absolute configuration is arbitrarily specified.

[0788] A yellow solid, 6-chloro-4-[(3S,4R)-4-(4-fluoro-2-hydroxyaniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile (30 mg, 0.07 mmol, 29% yield) was obtained. LC / MS (ESI) m / z: 442.2 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ10.04-9.64(m,1H),8.07(d,J=8.8Hz,1H),7.81(d,J=9.2H z,1H),6.64(d,J=6.0,8.8Hz,1H),6.57-6.51(m,1H),6.47(t,J=2.8,8.8Hz,1H),4 .18(d,J=9.2Hz,1H),4.11-4.00(m,1H),3.92-3.74(m,3H),3.63-3.55(m,1H),3.5 2(s,3H),2.30(s,1H),2.12-2.02(m,1H),1.90-1.82(m,1H),0.84(d,J=7.2Hz,3H).

[0789] A yellow solid, 6-chloro-4-[(3R,4S)-4-(4-fluoro-2-hydroxy-aniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidium-3-carboxynitrile (40 mg, 0.09 μmol, 39% yield) was obtained. LC / MS (ESI) m / z: 442.0 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ7.2(dd,J=2.4,12.0Hz,1H),7.0(dd,J=1.2,8.8Hz,1H),6.8(t,J=9.2Hz,1H),5.2(d,J=7.2Hz,1H),3.72-3.56( m,2H),3.2-3.00(m,1H),2.96-2.8(m,1H),2.08-2.00(m,1H),1.76-1.60(m,1H),1.56-1.48(m,2H),1.40(s,9H),0.76(d,J=6.8Hz,3H).

[0790] Synthesis of Compound 22

[0791] 6-Chloro-4-[(3R,4S)-4-(4-chloro-2-fluoro-aniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo- Preparation of 1,5-naphthidine-3-carboxynitrile (compound 22)

[0792]

[0793] The title compound was prepared from (3R,4S)-4-(4-chloro-2-fluoro-aniline)-3-methyl-piperidin-1-carboxylate tert-butyl ester in a manner similar to that of 6-chloro-4-[(3S,4R)-4-(4-chloro-2-fluoro-aniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthyl-3-carboxynitrile. (Off-white solid). LC / MS (ESI) m / z: 460 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.08(d,J=9.2Hz,1H),7.80(d,J=8.8Hz,1H),7.20(dd,J=2.4,11 .6Hz,1H),7.00(dd,J=1.6,8.8Hz,1H),6.96-6.88(m,1H),5.52-5.44(m,1H),4.20-4.08 (m,1H),3.96(dd,J=5.2,13.2Hz,1H),3.92-3.76(m,2H),3.60(t,J=10.4Hz,1H),3.52(s ,3H),2.32(d,J=2.0Hz,1H),2.28-2.16(m,1H),1.92-1.76(m,1H),0.84(d,J=6.8Hz,3H).

[0794] Synthesis of Compound 23

[0795]

[0796] Step 1: (3S,4R)-4-(4-chloro-2-fluoro-aniline)-3-methyl-piperidine-1-carboxylic acid tert-butyl ester, (3R,4S)- 4-(4-chloro-2-fluoro-aniline)-3-methyl-piperidin-1-carboxylic acid tert-butyl ester, (3R,4R)-4-(4-chloro-2-fluoro-aniline)-3- tert-butyl methylpiperidine-1-carboxylate, (3S,4S)-4-(4-chloro-2-fluoro-aniline)-3-methylpiperidine-1-carboxylate Preparation

[0797]

[0798] A mixture of tert-butyl 3-methyl-4-oxo-piperidine-1-carboxylate (3 g, 14.07 mmol, 1 equivalent), 4-chloro-2-fluoroaniline (2 g, 14.07 mmol, 1 equivalent), and borane-2-methylpyridine (3 g, 28.13 mmol, 2 equivalent) in acetic acid (15 mL) and methanol (15 mL) was stirred at 25 °C for 12 h. The mixture was concentrated under vacuum, and the crude product was diluted with water (40 mL) and extracted with ethyl acetate (40 mL x 2). The combined organic extracts were washed with brine (80 mL), dried over sodium sulfate, and concentrated under reduced pressure. The residue was obtained by preparative HPLC (column: YMC Triart C18 70*250mm*7μm; mobile phase: [51-81% CH3CN / water (NH4HCO3)]), followed by SFC (column: DAICL CHIRALPAK AD-H (250mm*30mm, 5μm); mobile phase: 20% methanol (0.1% NH4OH) / CO2) to obtain the four desired isomers. (3R,4S)-4-(4-chloro-2-fluoro-aniline)-3-methyl-piperidine-1-carboxylic acid tert-butyl ester was further purified by SFC (column: DAICL CHIRALPAK AD-H (250mm*30mm, 5μm); mobile phase: 20% methanol (0.1% NH4OH) / CO2). (3S,4S)-4-(4-chloro-2-fluoro-aniline)-3-methyl-piperidine-1-carboxylic acid tert-butyl ester was purified by SFC (column: DAICEL CHIRALPAKAD-H (250mm*30mm, 5μm); mobile phase: 25% methanol (0.1% NH4OH) / CO2).

[0799] The absolute configuration is arbitrarily specified.

[0800] (3S,4R)-4-(4-chloro-2-fluoro-aniline)-3-methyl-piperidine-1-carboxylic acid tert-butyl ester (333 mg, 0.97 mmol, 7% yield) was obtained as a grayish-white oil. 1H NMR (400MHz, DMSO-d6) δ7.2 (dd, J=2.4, 11.6Hz, 1H), 7.20 (td, J=1.2, 8.8Hz, 1H), 6.8 0(t,J=9.2Hz,1H),5.20(d,J=7.2Hz,1H),3.92-3.76(m,1H),3.68(dd,J=2.8,13.2Hz ,1H),3.64-3.56(m,1H),3.08(d,J=12.0Hz,1H),2.96-2.76(m,1H),2.04(dd,J=3.6, 6.8Hz,1H),1.76-1.6(m,1H),1.52-1.48(m,1H),1.40(s,9H),0.76(d,J=7.2Hz,3H).

[0801] (3R,4S)-4-(4-chloro-2-fluoro-aniline)-3-methyl-piperidine-1-carboxylic acid tert-butyl ester (260 mg, 0.76 mmol, 5% yield) was obtained as a grayish-white oil. 1 H NMR (400MHz, DMSO-d6) δ7.2(dd,J=2.4,11.8Hz,1H),7.0(dd,J=1.2,8.8Hz,1H),6.8(t,J=9.2Hz,1H),5.2(d,J=7.2Hz,1H),3.72-3.56( m,2H),3.2-3.00(m,1H),2.96-2.8(m,1H),2.08-2.00(m,1H),1.76-1.60(m,1H),1.56-1.48(m,2H),1.40(s,9H),0.76(d,J=6.8Hz,3H).

[0802] (3R,4R)-4-(4-chloro-2-fluoro-aniline)-3-methyl-piperidine-1-carboxylic acid tert-butyl ester (107 mg, 0.31 mmol, 2% yield) was obtained as a grayish-white oil. 1 H NMR (400MHz, DMSO-d6) δ7.2(dd,J=2.4,12.0Hz,1H),6.96(d,J=8.4Hz,1H),6.8(t,J=9.2Hz,1H),5.4(dd,J=2.2,9.2Hz,1H),4.0-3.84(m,2H),3.1 2(dq,J=3.6,9.9Hz,1H),2.92-2.72(m,1H),1.84(dd,J=3.2,13.2Hz,1H) ,1.68-1.56(m,1H),1.40(s,9H),1.32-1.2(m,1H),0.88(d,J=6.8Hz,3H).

[0803] (3S,4S)-4-(4-chloro-2-fluoro-aniline)-3-methyl-piperidine-1-carboxylic acid tert-butyl ester (88 mg, 0.26 mmol, 2% yield) was obtained as a grayish-white oil. 1 H NMR(400MHz, DMSO-d6)δ7.2(dd,J=2.4,12.0Hz,1H),6.96(td,J=1.2,8.8Hz,1H),6.80-6.72(m,1H),5.36(dd,J=2.0,9.2Hz,1H),3.96-3.80(m,2H),3 .12(dq,J=4.0,9.92Hz,1H),2.92-2.72(m,1H),1.84(dd,J=3.2,12.8Hz,1 H),1.72-1.6(m,1H),1.40(s,9H),1.28-1.20(m,1H),0.84(d,J=6.4Hz,3H)

[0804] Step 2: Preparation of (3S,4R)-N-(4-chloro-2-fluoro-phenyl)-3-methyl-piperidin-4-amine

[0805]

[0806] A mixture of (3S,4R)-4-(4-chloro-2-fluoro-aniline)-3-methyl-piperidin-1-carboxylic acid tert-butyl ester (100 mg, 0.29 mmol, 1 equivalent) and trifluoroacetic acid (1.54 g, 13.51 mmol, 1 mL, 46.30 equivalent) in dichloromethane (1 mL) was stirred at 25 °C for 15 min. The mixture was concentrated under vacuum to give (3S,4R)-N-(4-chloro-2-fluoro-phenyl)-3-methyl-piperidin-4-amine (120 mg, crude substance, TFA salt) as a red oil. LC / MS (ESI) m / z: 243.1 [M+H] + .

[0807] Step 3: 6-Chloro-4-[(3S,4R)-4-(4-chloro-2-fluoro-aniline)-3-methyl-1-piperidinyl]-1-methyl-2- Preparation of oxo-1,5-naphthyl-3-carboxynitrile (compound 23)

[0808]

[0809] A mixture of (3S,4R)-N-(4-chloro-2-fluoro-phenyl)-3-methylpiperidin-4-amine (120 mg, 0.34 mmol, 1 equivalent, trifluoroacetic acid), 4,6-dichloro-1-methyl-2-oxo-1,5-naphthyl-3-carboxynitrile (70 mg, 0.28 mmol, 8.19 e-1 equivalent) and diisopropylethylamine (371.00 mg, 2.87 mmol, 0.5 mL, 8.53 equivalent) in acetonitrile (1.5 mL) was stirred at 40 °C for 3 h. The mixture was concentrated, and the crude product was prepared in DMF (1 mL), washed with acetonitrile (1 mL x 2), and collected by filtration to give 6-chloro-4-[(3S,4R)-4-(4-chloro-2-fluoro-aniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidium-3-carboxynitrile (90.1 mg, 0.19 mmol, 57% yield) as a white solid. LC / MS (ESI) m / z: 460.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.08(d,J=9.2Hz,1H),7.60(d,J=9.2Hz,1H),7.20(dd,J=2.4, 11.6Hz,1H),7.2(dd,J=2.0,8.8Hz,1H),6.96-6.88(m,1H),5.48(dd,J=2.0,8.4Hz,1H ),4.20-4.08(m,1H),4.00-3.92(m,1H),3.88-3.76(m,2H),3.60-3.56(m,1H),3.52(s ,3H),2.32-2.28(m,1H),2.28-2.16(m,1H),1.88-1.76(m,1H),0.84(d,J=6.8Hz,3H).

[0810] Synthesis of Compound 24

[0811] 1,6-Dimethyl-2-oxo-4-spiro[3H-benzofuran-2,4- ' -piperidine]-1 ' -1,5-Naphthoid-3-carboxynitrile Preparation of (Compound 24)

[0812]

[0813] The title compound was prepared from 6-chloro-1-methyl-2-oxo-4-spiro[3H-benzofuran-2,4'-piperidine]-1'-yl-1,5-naphthidine-3-carboxynitrile in a manner similar to that of 1,6-dimethyl-2-oxo-4-spiro[indan-2,4'-piperidine]-1'-yl-1,5-naphthidine-3-carboxynitrile. (Brown solid). LC / MS (ESI) m / z: 387.1 [M+H] + .1 H NMR (400MHz, DMSO-d6) δ7.92(d,J=8.8Hz,1H),7.60(d,J=8.8Hz,1H),7.20(d,J=7.6Hz,1H),7.12(t,J=7.6H z,1H),6.88-6.76(m,2H),4.04-3.88(m,4H),3.52(s,3H),3.16(s,2H),2.56(s,3H),2.08(t,J=5.6Hz,4H).

[0814] Synthesis of Compound 25

[0815] 6-Chloro-4-[(3S,4R)-4-(4-fluoroanilino)-3-methoxy-1-piperidinyl]-1-methyl-2-oxo-1,5- Preparation of naphthidine-3-carboxynitrile (compound 25)

[0816]

[0817] Step 1: Preparation of (3S,4R)-N-(4-fluorophenyl)-3-methoxy-piperidine-4-amine

[0818]

[0819] A mixture of (3S,4R)-4-(4-fluoroaniline)-3-methoxy-piperidine-1-carboxylic acid tert-butyl ester (100 mg, 0.31 mmol, 1 equivalent) and trifluoroacetic acid (1.54 g, 13.51 mmol, 1 mL, 43.81 equivalent) in dichloromethane (1 mL) was stirred at 25 °C for 15 min. The mixture was concentrated under vacuum to give (3S,4R)-N-(4-fluorophenyl)-3-methoxy-piperidine-4-amine (125 mg, crude product, TFA salt) as a red oil. LC / MS (ESI) m / z: 255.1 [M+H] + .

[0820] Step 2: 6-Chloro-4-[(3S,4R)-4-(4-fluoroaniline)-3-methoxy-1-piperidinyl]-1-methyl-2-oxo Preparation of 1,5-naphthyl-3-carboxynitrile (compound 25)

[0821]

[0822] The title compound was prepared from (3S,4R)-N-(4-fluorophenyl)-3-methoxy-piperidin-4-amine in a manner similar to that of 6-chloro-4-[4-(4-chloroanilino)-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile. (Off-white solid). LC / MS (ESI) m / z: 442.1 [M+H] + . 1HNMR (400MHz, DMSO-d6) δ8.08(d,J=9.2Hz,1H),7.80(d,J=9.2Hz,1H),6.92(t,J=8.8Hz,2H),6.80-6.64(m,2H),5.44(d,J=8.8Hz,1H),4. 32-4.12(m,2H),3.84(d,J=12.4Hz,2H),3.64(s,1H),3.52(s,3H),3.52-3.48(m,1H),3.20(s,3H),2.28-2.16(m,1H),1.88-1.76(m,1H).

[0823] Synthesis of Compound 26

[0824] 1,6-Dimethyl-2-oxo-4-spiro[indan-2,4-] ' -piperidine]-1 ' -1,5-Naphthoid-3-carboxynitrile (compound) Preparation of 26)

[0825]

[0826] Under nitrogen atmosphere, cyclopentyl(diphenyl)phosphine, dichloropalladium, and iron (36 mg, 0.05 mmol, 0.1 equivalent) were added to a mixture of 6-chloro-1-methyl-2-oxo-4-spiro[indan-2,4'-piperidin]-1'-yl-1,5-naphthid-3-carboxynitrile (200 mg, 0.49 mmol, 1 equivalent), 2,4,6-trimethyl-1,3,5,2,4,6-trioxaborane (372 mg, 1.48 mmol, 0.41 mL, 50% purity, 3 equivalents), and potassium carbonate (137 mg, 0.99 mmol, 2 equivalents) in dioxane (2 mL) and water (0.4 mL). The suspension was degassed under vacuum and purged three times with nitrogen. The mixture was then stirred under nitrogen atmosphere at 90 °C for 12 h. The mixture was collected by filtration, and the residue was purified by preparative HPLC (column: Phenomenex C18 150*25mm*10um; mobile phase: [49-79% CH3CN / water (NH4HCO3)]) to obtain 1,6-dimethyl-2-oxo-4-spiro[indan-2,4'-piperidin]-1'-yl-1,5-naphthidine-3-carboxynitrile (17.9 mg, 0.05 mmol, 9% yield) as a grayish-white solid. LC / MS (ESI) m / z: 385.1 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ7.92(d,J=8.8Hz,1H),7.56(d,J=8.8Hz,1H),7.24-7.20(m,2H),7. 16-7.12(m,2H),3.92(s,4H),3.52(s,3H),2.92(s,4H),2.54(s,3H),1.84(t,J=5.2Hz,4H).

[0827] Synthesis of Compound 27

[0828]

[0829] Step 1: 6-Chloro-4-[(3R,4R)-4-(4-fluoro-2-hydroxy-aniline)-3-methyl-1-piperidinyl]-1-methyl- Preparation of 2-oxo-1,5-naphthyl-3-carboxynitrile

[0830]

[0831] The title compound was prepared from (3R,4R)-4-(4-fluoro-2-hydroxy-aniline)-3-methyl-piperidin-1-carboxylate tert-butyl ester in a manner similar to that of 6-chloro-4-[(3S,4R)-4-(4-fluoro-2-hydroxy-aniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile (yellow solid). LC / MS (ESI) m / z: 441.9 [M+H] + .

[0832] Step 2: 6-Chloro-4-[(3R,4R)-4-(4-fluoro-2-hydroxy-aniline)-3-methyl-1-piperidinyl]-1-methyl- Preparation of 2-oxo-1,5-naphthyl-3-carboxynitrile

[0833]

[0834] Enantiomers were separated by SFC (column: DAICL CHIRALPAK AD (250 mm * 30 mm, 10 μm); mobile phase: 50% ethanol (0.1% NH4OH) / CO2) followed by preparative HPLC (column: Welch Ultimate C18 150 * 25 mm * 5 μm; mobile phase: [32-62% CH3CN / water (0.225% formic acid)]) to give a yellow solid, 6-chloro-4-[(3R,4R)-4-(4-fluoro-2-hydroxy-aniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile (48 mg, 0.11 mmol, 40% yield). Absolute configuration was arbitrarily specified. LC / MS (ESI) m / z: 442.0 [M+H] + . 1HNMR(400MHz,DMSO-d6)δ9.77(s,1H),8.06(d,J=8.8Hz,1H),7.80(d,J=8.8Hz,1H),6.63-6.41(m,3H),4.30-4 .12(m,3H),3.61-3.50(m,4H),3.21-3.12(m,1H),2.16-2.00(m,2H),1.59-1.43(m,1H),0.98(d,J=6.8Hz,3H).

[0835] Synthesis of Compounds 29 and 28

[0836] 6-Chloro-4-[(3R,4R)-4-(4-chloroanilino)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthalene 3-Pyridine-carboxynitrile (compound 29) and 6-chloro-4-[(3S,4S)-4-(4-chloroanilino)-3-methyl-1-piperidinyl]-1-methyl- Preparation of 2-oxo-1,5-naphthidine-3-carboxynitrile (compound 28)

[0837]

[0838] The title compound was prepared starting with (3R,4R)-4-(4-chloroanilino)-3-methyl-piperidin-1-carboxylic acid tert-butyl ester in a manner similar to that of 6-chloro-4-[(3S,4R)-4-(4-chloroanilino)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphtho-3-carboxylonitrile and 6-chloro-4-[(3R,4S)-4-(4-chloroanilino)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphtho-3-carboxylonitrile.

[0839] 6-Chloro-4-[(3R,4R)-4-(4-chloroanilino)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxylonitrile (53.7 mg, 0.121 mmol, 27% yield) (Compound 29). (Yellow solid). LC / MS (ESI) m / z: 442.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ8.06(d,J=9.2Hz,1H),7.81(d,J=9.2Hz,1H),7.17 -6.97(m,2H),6.78-6.55(m,2H),5.80(d,J=8.8Hz,1H),4.33-4.15(m,2H), 3.62-3.54(m,1H),3.52(s,3H),3.29-3.23(m,1H),3.21-3.10(m,1H),2.17 -2.09(m,1H),2.06-1.96(m,1H),1.57-1.43(m,1H),0.97(d,J=6.4Hz,3H).

[0840] 6-Chloro-4-[(3S,4S)-4-(4-chloroanilino)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile (50.2 mg, 0.112 mmol, 25% yield, 98% purity) (Compound 28). (Yellow solid). LC / MS (ESI) m / z: 442.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.06(d,J=8.8Hz,1H),7.81(d,J=8.8Hz,1H),7.06(d,J =8.8Hz,2H),6.65(d,J=8.8Hz,2H),5.80(d,J=9.2Hz,1H),4.33-4.14(m,2H),3. 62-3.54(m,1H),3.52(s,3H),3.30-3.23(m,1H),3.16(dd,J=10.8,12.8Hz,1H), 2.18-2.08(m,1H),2.07-1.92(m,1H),1.55-1.44(m,1H),0.97(d,J=6.4Hz,3H).

[0841] Synthesis of Compound 30

[0842] 6-Chloro-4-[(3S,4S)-4-(4-chloro-2-fluoro-aniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo- Preparation of 1,5-naphthidine-3-carboxynitrile (compound 30)

[0843]

[0844] The title compound was prepared from (3S,4S)-4-(4-chloro-2-fluoro-anilino)-3-methyl-piperidin-1-carboxylate tert-butyl ester in a manner similar to that of 6-chloro-4-[(3S,4R)-4-(4-chloro-2-fluoro-anilino)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile (yellow solid). LC / MS (ESI) m / z: 460.0 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ8.04(d,J=9.2Hz,1H),7.80(d,J=9.2Hz,1H),7.16(dd,J=2.4,11 .6Hz,1H),7.00(dd,J=2.0,8.8Hz,1H),6.92-6.84(m,1H),5.56(dd,J=2.0,9.2Hz,1H),4. 32-4.16(m,2H),3.60-3.56(m,1H),3.52(s,3H),3.44-3.36(m,1H),3.20-3.12(m,1H),2 .24-2.12(m,1H),2.08-2.00(m,1H),1.64(dq,J=4.0,12.0Hz,1H),0.96(d,J=6.8Hz,3H).

[0845] Synthesis of Compound 31

[0846]

[0847] Step 1: Preparation of tert-butyl 3,4,4-trimethoxypiperidine-1-carboxylate

[0848]

[0849] Sodium hydride (115 mg, 2.87 mmol, 60% purity, 1.5 equivalents) was added to tetrahydrofuran (6 mL) containing tert-butyl 3-hydroxy-4,4-dimethoxy-piperidine-1-carboxylate (500 mg, 1.91 mmol, 1 equivalent) at 0 °C, and the resulting mixture was stirred at 0 °C for 0.5 h. Iodomethane (543 mg, 3.83 mmol, 0.24 mL, 2 equivalents) was then added, and the reaction mixture was stirred at 0 °C for 1 h under nitrogen. The mixture was diluted with saturated ammonium chloride aqueous solution (20 mL) and extracted with ethyl acetate (3 × 20 mL). The combined organic extracts were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography (gradient: 100 / 1 to 3:1 petroleum ether / ethyl acetate) to give tert-butyl 3,4,4-trimethoxypiperidine-1-carboxylate (480 mg, 1.74 mmol, 91% yield) as a colorless oil. 1 H NMR(400MHz,DMSO-d6)δ4.11(d,J=14.0Hz,1H),3.88-3.66(m,1H),3.31(s,3H),3.29-3.19(m,2H ),3.10–3.08(m,6H),2.90-2.69(m,1H),1.68(d,J=14.0Hz,1H),1.57-1.45(m,1H),1.39(s,9H).

[0850] Step 2: Preparation of tert-butyl 3-methoxy-4-oxo-piperidine-1-carboxylate

[0851]

[0852] A mixture of tert-butyl 3,4,4-trimethoxypiperidine-1-carboxylate (330 mg, 1.20 mmol, 1 equivalent) and 4-methylbenzenesulfonic acid (41 mg, 0.24 mmol, 0.2 equivalent) in acetone (10 mL) and water (1 mL) was stirred at 80 °C for 1 h. The mixture was concentrated under vacuum to give tert-butyl 3-methoxy-4-oxo-piperidine-1-carboxylate (280 mg, crude product) as a grayish-white oil.

[0853] Step 3: Preparation of tert-butyl (3S,4R)-4-(4-fluoroaniline)-3-methoxy-piperidine-1-carboxylate

[0854]

[0855] A mixture of tert-butyl 3-methoxy-4-oxo-piperidine-1-carboxylate (280 mg, 1.22 mmol, 1 equivalent), 4-fluoroaniline (135.70 mg, 1.22 mmol, 0.12 mL, 1 equivalent), and borane-2-methylpyridine (261 mg, 2.44 mmol, 2 equivalents) in methanol (1.5 mL) and acetic acid (1.5 mL) was stirred at 25 °C for 12 h. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL x 2). The combined organic extracts were washed with brine (20 mL), dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by preparative HPLC (column: Phenomenex luna C18150*25mm*10μm; mobile phase: [39-69% CH3CN / water (0.225% formic acid)]) to give (3S,4R)-4-(4-fluoroaniline)-3-methoxy-piperidine-1-carboxylic acid tert-butyl ester (95 mg, 0.29 mmol, 24% yield) as a gray solid. LC / MS (ESI) m / z: 268.9 (M-55) + . 1 HNMR (400MHz, DMSO-d6) δ6.96-6.84(m,2H),6.72-6.64(m,2H),5.12(d,J=9.2Hz,1H),4.16(d,J=13.2Hz,1H),3.96- 3.76(m,1H),3.56-3.44(m,1H),3.40-3.36(m,1H),3.28(s,3H),3.00-2.72(m,2H),1.60-1.48(m,2H),1.40(s,9H).

[0856] Step 4: Preparation of tert-butyl (3S,4R)-4-(4-fluoro-N-methyl-aniline)-3-methoxy-piperidine-1-carboxylic acid

[0857]

[0858] A mixture of (3S,4R)-4-(4-fluoroaniline)-3-methoxy-piperidine-1-carboxylic acid tert-butyl ester (90 mg, 0.28 mmol, 1 equivalent), formaldehyde (68 mg, 0.83 mmol, 0.06 mL, 37% purity, 3 equivalents) and sodium cyanoborohydride (52 mg, 0.83 mmol, 3 equivalents) in methanol (1 mL) was stirred at 25 °C for 12 h. The mixture was diluted with water (5 mL) and extracted with ethyl acetate (5 mL x 2). The combined organic extracts were washed with brine (10 mL), dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (gradient: 100 / 1 to 1:1 petroleum ether / ethyl acetate) to give a colorless oil, (3S,4R)-4-(4-fluoro-N-methylaniline)-3-methoxy-piperidine-1-carboxylic acid tert-butyl ester (89 mg, 0.26 mmol, 95% yield). LC / MS (ESI) m / z: 339.0 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ7.04-6.96(m,2H),6.84-6.76(m,2H),4.32-4.04(m,2H),3.80(d,J=12.0Hz,1H),3 .52-3.36(m,1H),3.20(s,3H),2.92(q,J=13.6Hz,1H),2.80(s,3H),2.04(d,J=12.0Hz,1H),1.40(s,11H).

[0859] Step 5: Preparation of (3S,4R)-N-(4-fluorophenyl)-3-methoxy-N-methyl-piperidine-4-amine

[0860]

[0861] A mixture of (3S,4R)-4-(4-fluoro-N-methylaniline)-3-methoxy-piperidine-1-carboxylic acid tert-butyl ester (89 mg, 0.26 mmol, 1 equivalent) and trifluoroacetic acid (2 g, 13.51 mmol, 1 mL, 51.36 equivalent) in dichloromethane (1 mL) was stirred at 25 °C for 15 min. The mixture was concentrated under vacuum to give (3S,4R)-N-(4-fluorophenyl)-3-methoxy-N-methyl-piperidine-4-amine (100 mg, crude, TFA salt) as a red oil. LC / MS (ESI) m / z: 239.1 [M+H] + .

[0862] Step 6: 6-Chloro-4-[(3S,4R)-4-(4-fluoro-N-methylaniline)-3-methoxy-1-piperidinyl]-1-methyl Preparation of 2-oxo-1,5-naphthidium-3-carboxynitrile (compound 31)

[0863]

[0864] A mixture of (3S,4R)-N-(4-fluorophenyl)-3-methoxy-N-methyl-piperidin-4-amine (100 mg, 0.28 mmol, 1 equivalent, TFA salt), 4,6-dichloro-1-methyl-2-oxo-1,5-naphthyl-3-carboxynitrile (50 mg, 196.79 μmol, 6.93 e-1 equivalent), and diisopropylethylamine (371.00 mg, 2.87 mmol, 0.5 mL, 10.11 equivalent) in acetonitrile (1 mL) was stirred at 25 °C for 12 h. The mixture was concentrated under vacuum, and the crude product was prepared in DMF (0.5 mL), washed with acetonitrile (1.5 mL), and collected by filtration to give 6-chloro-4-[(3S,4R)-4-(4-fluoro-N-methylaniline)-3-methoxy-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile (60.8 mg, 0.13 mmol, 46% yield) as a yellow solid. LC / MS (ESI) m / z: 456.0 [M+H] + . 1 HNMR(400MHz,DMSO-d6)δ8.08(d,J=9.2Hz,1H),7.84(d,J=8.8Hz,1H),7.08-7.00(m ,2H),6.88(dd,J=4.4,9.2Hz,2H),4.48(dd,J=2.4,13.2Hz,1H),4.36(d,J=13.6Hz,1 H),4.12(d,J=11.6Hz,1H),3.80(d,J=13.6Hz,1H),3.64(s,1H),3.52(s,3H),3.48(t ,J=11.6Hz,1H),3.04(s,3H),2.88(s,3H),2.84-2.80(m,1H),1.68(d,J=9.6Hz,1H).

[0865] Synthesis of Compound 32

[0866]

[0867] Step 1: Preparation of (3S,4R)-3-methyl-4-[4-(trifluoromethoxy)anilino]piperidine-1-carboxylic acid tert-butyl ester.

[0868]

[0869] A mixture of tert-butyl 3-methyl-4-oxo-piperidine-1-carboxylate (2 g, 9.38 mmol, 1 equivalent), 4-(trifluoromethoxy)aniline (1.66 g, 9.38 mmol, 1 mL, 1 equivalent), sodium cyanoborohydride (884 mg, 14.07 mmol, 1.5 equivalent), and acetic acid (56 mg, 0.938 mmol, 0.05 mL, 0.1 equivalent) in methanol (20 mL) was stirred at 25 °C for 12 h. The mixture was concentrated under vacuum, and the crude product was diluted with water (10 mL) and extracted with ethyl acetate (10 mL x 2). The combined organic extracts were washed with brine (20 mL), dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by preparative HPLC (column: Welch Xtimate C18 250*50mm*10μm; mobile phase: [35-70% CH3CN / water (TFA)]) to give (3S,4R)-3-methyl-4-[4-(trifluoromethoxy)anilino]piperidine-1-carboxylic acid tert-butyl ester (140 mg, 0.374 mmol, 4% yield) as a yellow solid. LC / MS (ESI) m / z: 319.2 (M-55) + . 1 H NMR (400MHz, DMSO-d6) δ7.04(d,J=8.4Hz,2H),6.68(d,J=9.2Hz,2H),5.72(d,J=8.4Hz,1H),3.52(dt,J=4.4,8.4Hz,2H),3.32( s,1H),3.2(dd,J=3.2,13.2Hz,1H),2.04-1.96(m,1H),1.6-1.48(m,2H),1.40(s,9H),1.32-1.16(m,1H),0.8(d,J=6.8Hz,3H).

[0870] Step 2: (3S,4R)-3-methyl-4-[N-methyl-4-(trifluoromethoxy)anilino]piperidine-1-carboxylic acid tert-butyl ester Preparation of .

[0871]

[0872] A mixture of (3S,4R)-3-methyl-4-[4-(trifluoromethoxy)anilino]piperidine-1-carboxylic acid tert-butyl ester (140 mg, 0.37 mmol, 1 equivalent), formaldehyde (91 mg, 1.12 mmol, 0.084 mL, 37% purity, 3 equivalents) and sodium cyanoborohydride (71 mg, 1.12 mmol, 3 equivalents) in methanol (1.5 mL) was stirred at 25 °C for 12 h. The mixture was concentrated under vacuum, and the residue was purified by silica gel chromatography (gradient: 100 / 1 to 1:1 petroleum ether / ethyl acetate) to give (3S,4R)-3-methyl-4-[N-methyl-4-(trifluoromethoxy)anilino]piperidine-1-carboxylic acid tert-butyl ester (99 mg, 255 mmol, 68% yield) as a white solid. LC / MS (ESI) m / z: 333.1 (M-55) + . 1 H NMR (400MHz, DMSO-d6) δ7.12(d,J=8.4Hz,2H),6.8(d,J=7.6Hz,2H),4.16-3.96(m,1H),3.92-3.68(m,2H),3.16-3.0 0(m,1H),2.80(s,3H),2.16-1.96(m,2H),1.52-1.48(m,1H),1.40(s,9H),1.28-1.12(m,1H),0.80(d,J=6.0Hz,3H).

[0873] Step 3: Preparation of (3S,4R)-N,3-dimethyl-N-[4-(trifluoromethoxy)phenyl]piperidine-4-amine.

[0874]

[0875] A mixture of (3S,4R)-3-methyl-4-[N-methyl-4-(trifluoromethoxy)anilino]piperidine-1-carboxylic acid tert-butyl ester (99 mg, 0.26 mmol, 1 equivalent) and trifluoroacetic acid (1.54 g, 13.51 mmol, 1 mL, 52.99 equivalent) in dichloromethane (1 mL) was stirred at 25 °C for 15 min. The mixture was concentrated under vacuum to give (3S,4R)-N,3-dimethyl-N-[4-(trifluoromethoxy)phenyl]piperidine-4-amine (110 mg, crude substance, TFA salt) as a red oil. LC / MS (ESI) m / z: 289.1 [M+H] + .

[0876] Step 4: 6-Chloro-1-methyl-4-[(3S,4R)-3-methyl-4-[N-methyl-4-(trifluoromethoxy)anilino]- Preparation of [1-piperidinyl]-2-oxo-1,5-naphthyl-3-carboxynitrile (compound 32)

[0877]

[0878] The title compound was prepared from (3S,4R)-N,3-dimethyl-N-[4-(trifluoromethoxy)phenyl]piperidin-4-amine in a manner similar to that of 6-chloro-4-[4-(4-chloroanilino)-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile. (Yellow solid). LC / MS (ESI) m / z: 506.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.08(d,J=9.2Hz,1H),7.8(d,J=8.8Hz,1H),7.2(d,J=8. 8Hz,2H),6.88(d,J=9.2Hz,2H),4.4-4.28(m,1H),4.16(td,J=3.6,12.0Hz,1H),4 .04-3.96(m,1H),3.92-3.84(m,1H),3.52(s,3H),3.48-3.44(m,1H),2.88(s,3H ),2.76-2.64(m,1H),2.4-2.28(m,1H),1.80-1.72(m,1H),0.88(d,J=7.2Hz,3H).

[0879] Synthesis of Compounds 33 and 34

[0880]

[0881]

[0882] Step 1: (3S,4R)-4-(4-chloroaniline)-3-methyl-piperidine-1-carboxylic acid tert-butyl ester and (3R,4R)-4-(4- Preparation of tert-butyl chloroaniline (3-methyl-piperidine-1-carboxylate)

[0883]

[0884] Sodium cyanoborohydride (1.47 g, 23.44 mmol, 2.5 equivalents) was added to a mixture of tert-butyl 3-methyl-4-oxo-piperidine-1-carboxylate (2 g, 9.38 mmol, 1 equivalent) and 4-chloroaniline (1.20 g, 9.38 mmol, 1 equivalent) in methanol (20 mL), and the reaction mixture was stirred at 40 °C for 12 h. The mixture was concentrated under reduced pressure, and the resulting residue was purified by preparative HPLC (column: Welch Xtimate C18 250*50 mm*10 μm; mobile phase: [40-75% CH3CN / water (0.225% formic acid)]) to obtain the desired product.

[0885] (3S,4R)-4-(4-chloroanilino)-3-methyl-piperidine-1-carboxylic acid tert-butyl ester was obtained as a white solid (223 mg, 0.69 mmol, 7.3% yield).1 H NMR (400MHz, DMSO-d6) δ7.08-7.03(m,2H),6.66-6.61(m,2H),5.63(d,J=8.4Hz,1H),3.79-3.60(m,1H),3.57-3.47(m,2H), 3.30-3.27(m,1H),3.16(dd,J=3.6,13.6Hz,1H),2.05-1.97(m,1H),1.57-1.47(m,2H),1.39(s,9H),0.77(d,J=6.8Hz,3H).

[0886] (3R,4R)-4-(4-chloroanilino)-3-methyl-piperidine-1-carboxylic acid tert-butyl ester was obtained as a colorless oil (153 mg, 0.48 mmol, 5.0% yield). 1 H NMR (400MHz, DMSO-d6) δ7.09-7.00(m,2H),6.61-6.53(m,2H),5.80-5.45(m,1H),3.87(d,J=13.2Hz,2H),3.08-2.96(m,1H), 2.86(s,1H),2.63-2.52(m,1H),1.93-1.84(m,1H),1.51-1.43(m,1H),1.40(s,9H),1.15-1.02(m,1H),0.89(d,J=6.4Hz,3H).

[0887] Step 2: Preparation of (3S,4R)-N-(4-chlorophenyl)-3-methyl-piperidin-4-amine

[0888]

[0889] Trifluoroacetic acid (1.54 g, 13.51 mmol, 1 mL, 43.87 equivalents) was added dropwise to a solution of (3S,4R)-4-(4-chloroanilino)-3-methyl-piperidin-1-carboxylic acid tert-butyl ester (100 mg, 0.31 mmol, 1 equivalent) in dichloromethane (1 mL), and the resulting mixture was stirred at 25 °C for 30 min. The reaction mixture was concentrated under reduced pressure to give (3S,4R)-N-(4-chlorophenyl)-3-methyl-piperidin-4-amine (100 mg, crude substance, TFA salt) as a brown oil.

[0890] Step 3: 6-Chloro-4-[(3S,4R)-4-(4-chloroanilino)-3-methyl-1-piperidinyl]-1-methyl-2-oxo- Preparation of 1,5-naphthyl-3-carboxynitrile

[0891]

[0892] The title compound was prepared in a manner similar to that of 6-chloro-4-[4-(4-chloroanilino)-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidium-3-carboxynitrile (yellow solid). 1 H NMR(400MHz,DMSO-d6)δ8.06(d,J=8.8Hz,1H),7.81(d,J=8.8Hz,1H),7.10- 7.05(m,2H),6.75-6.70(m,2H),5.90(d,J=8.4Hz,1H),4.08-3.97(m,1H),3. 85(d,J=4.4Hz,2H),3.81-3.72(m,1H),3.70-3.61(m,1H),3.52(s,3H),2.3 3-2.26(m,1H),2.14-2.01(m,1H),1.87-1.82(m,1H),0.86(d,J=7.2Hz,3H).

[0893] Step 4: 6-Chloro-4-[(3S,4R)-4-(4-chloroanilino)-3-methyl-1-piperidinyl]-1-methyl-2-oxo- 1,5-Naphthoidin-3-carboxynitrile (compound 33) and 6-chloro-4-[(3R,4S)-4-(4-chloroanilino)-3-methyl-1-piperidinyl]-1- Preparation of methyl-2-oxo-1,5-naphthyl-3-carboxynitrile (compound 34)

[0894]

[0895] Enantiomers were separated by SFC (column: DAICL CHIRALCEL OJ (250 mm * 30 mm, 10 μm); mobile phase: 40% methanol (0.1% NH4OH) / CO2) followed by preparative HPLC (column: Phenomenex luna C18 150 * 25 mm * 10 μm; mobile phase: [50-80% CH3CN / water (0.225% formic acid)]).

[0896] The absolute configuration is arbitrarily specified.

[0897] 6-Chloro-4-[(3S,4R)-4-(4-chloroanilino)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxylonitrile (33.8 mg, 0.076 mmol, 39% yield) (Compound 33). (Yellow solid). LC / MS (ESI) m / z: 442.1 [M+1] + . 1H NMR(400MHz,DMSO-d6)δ8.07(d,J=8.8Hz,1H),7.84-7.78(m,1H),7.07(d, J=8.8Hz,2H),6.80-6.63(m,2H),5.94-5.86(m,1H),4.06-3.96(m,1H),3.8 5(d,J=4.8Hz,2H),3.80-3.74(m,1H),3.70-3.63(m,1H),3.52(s,3H),2.32 -2.26(m,1H),2.14-2.00(m,1H),1.90-1.79(m,1H),0.86(d,J=7.2Hz,3H).

[0898] 6-Chloro-4-[(3R,4S)-4-(4-chloroanilino)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile (31.1 mg, 68.37 μmol, 35% yield) (Compound 34). (Yellow solid). LC / MS (ESI) m / z: 442.1 [M+1] + . 1 H NMR(400MHz,DMSO-d6)δ8.07(d,J=8.8Hz,1H),7.81(d,J=8.8Hz,1H),7.11- 7.03(m,2H),6.72(d,J=8.8Hz,2H),5.94-5.86(m,1H),4.11-3.96(m,1H),3. 85(d,J=4.8Hz,2H),3.79-3.74(m,1H),3.69-3.63(m,1H),3.52(s,3H),2.3 1-2.26(m,1H),2.14-2.01(m,1H),1.89-1.79(m,1H),0.86(d,J=7.2Hz,3H).

[0899] Synthesis of Compound 35

[0900] 6-Chloro-4-[(3R,4R)-4-(4-chloro-2-fluoro-aniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo- Preparation of 1,5-naphthidine-3-carboxynitrile (compound 35)

[0901]

[0902] The title compound was prepared from (3R,4R)-4-(4-chloro-2-fluoro-aniline)-3-methyl-piperidin-1-carboxylic acid tert-butyl ester in a manner similar to that of 6-chloro-4-[(3S,4R)-4-(4-chloro-2-fluoro-aniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile (yellow solid). LC / MS (ESI) m / z: 460.0 [M+H] +. 1 H NMR (400MHz, DMSO-d6) δ8.04(d,J=9.2Hz,1H),7.80(d,J=9.2Hz,1H),7.2(dd,J=2.4,12. 0Hz,1H),7.00(dd,J=2.0,8.8Hz,1H),6.92-6.84(m,1H),5.56(dd,J=2.0,9.2Hz,1H),4. 32-4.20(m,2H),3.60-3.56(m,1H),3.52(s,3H),3.44-3.36(m,1H),3.16-3.08(m,1H),2 .20-2.12(m,1H),2.04(dd,J=3.2,13.2Hz,1H),1.72-1.60(m,1H),0.96(d,J=6.8Hz,3H).

[0903] Synthesis of Compound 36

[0904]

[0905] Step 1: Preparation of tert-butyl 4-(4-chloro-N-methyl-aniline)piperidine-1-carboxylate

[0906]

[0907] A mixture of tert-butyl 4-(4-chloroanilino)piperidine-1-carboxylate (200 mg, 0.64 mmol, 1 equivalent), sodium cyanoborohydride (61 mg, 0.97 mmol, 1.5 equivalent), and formaldehyde (57 mg, 0.71 mmol, 0.05 mL, 37% purity, 1.1 equivalent) in methanol (2 mL) was stirred at 25 °C for 12 h. The mixture was concentrated under vacuum, and the resulting residue was purified by preparative HPLC (column: Waters xbridge 150*25 mm 10 μm; mobile phase: [56-86% CH3CN / water (NH4HCO3)]) to give tert-butyl 4-(4-chloro-N-methylanilino)piperidine-1-carboxylate (114 mg, 0.351 mmol, 55% yield) as a white solid. LC / MS (ESI) m / z: 268.9 [M-55] + .

[0908] Step 2: Preparation of (3R,4R)-N-(4-fluorophenyl)-3-methoxy-piperidine-4-amine

[0909]

[0910] A mixture of tert-butyl 4-(4-chloro-N-methylaniline)piperidine-1-carboxylate (114 mg, 0.35 mmol, 1 equivalent) and trifluoroacetic acid (80 mg, 0.7 mmol, 0.05 mL, 2 equivalents) in dichloromethane (1 mL) was stirred at 25 °C for 15 min. The mixture was concentrated under vacuum to give N-(4-chlorophenyl)-N-methylpiperidine-4-amine (190 mg, crude substance, trifluoroacetic acid) as a red oil. LC / MS (ESI) m / z: 225.2 [M+H] + .

[0911] Step 3: 6-Chloro-4-[4-(4-chloro-N-methyl-aniline)-1-piperidinyl]-2-oxo-1H-1,5-naphthidine-3- Preparation of formonitrile

[0912]

[0913] The title compound was prepared from N-(4-chlorophenyl)-N-methylpiperidin-4-amine in a manner similar to that of 6-chloro-4-[4-(4-chloroanilino)-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile. (Yellow solid). LC / MS (ESI) m / z: 442.0 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.08(d,J=9.2Hz,1H),7.84(d,J=9.2Hz,1H),7.20(d,J=9.2Hz,2H),6.8(d,J=9.2Hz,2H),4.28(d ,J=12.4Hz,2H),4.16-4.04(m,1H),3.6-3.52(m,2H),3.53(s,3H),2.72(s,3H),2.04–2.0(m,2H),1.76(d,J=12.4Hz,2H).

[0914] Synthesis of Compound 37

[0915]

[0916] Step 1: Preparation of tert-butyl (3S,4R)-4-(4-fluoro-2-methyl-aniline)-3-methyl-piperidine-1-carboxylate

[0917]

[0918] To a solution of tert-butyl 3-methyl-4-oxo-piperidin-1-carboxylate (2 g, 9.38 mmol, 1 equivalent) and 4-fluoro-2-methylaniline (1.17 g, 9.38 mmol, 1.0 equivalent) in methanol (20 mL), sodium cyanoborohydride (1.47 g, 23.44 mmol, 2.5 equivalent) was added, and the reaction mixture was stirred at 40 °C for 12 h. The mixture was concentrated under reduced pressure, and the resulting residue was purified by preparative HPLC (column: Phenomenex luna C18 (250*70 mm, 10 μm); mobile phase: [30-95% CH3CN / water (0.225% formic acid)]) to give (3S,4R)-4-(4-fluoro-2-methylaniline)-3-methyl-piperidin-1-carboxylate (250 mg, 0.78 mmol, 8% yield) as a brown solid. LC / MS (ESI) m / z: 267.0 [M-55] + . 1 H NMR (400MHz, DMSO-d6) δ6.90-6.74(m,2H),6.64-6.52(m,1H),4.13-4.02(m,1H),3.93-3.77(m,1H),3.70-3.62(m,1H),3.57(td,J=4.4,8.4Hz,1H ),3.29(s,1H),3.13-3.05(m,1H),2.98-2.84(m,1H),2.11-2.07(m,3H), 1.70-1.62(m,1H),1.58-1.51(m,1H),1.40(s,9H),0.77(d,J=6.8Hz,3H).

[0919] Step 2: Preparation of tert-butyl (3S,4R)-4-(4-fluoro-N,2-dimethylaniline)-3-methylpiperidine-1-carboxylate Preparation

[0920]

[0921] Acetic acid (105 mg, 1.75 mmol, 0.1 mL, 3.76 equivalents) was added to a mixture of (3S,4R)-4-(4-fluoro-2-methyl-aniline)-3-methyl-piperidin-1-carboxylic acid tert-butyl ester (150 mg, 0.47 mmol, 1 equivalent), sodium cyanoborohydride (88 mg, 1.40 mmol, 3 equivalents), and formaldehyde (189 mg, 2.33 mmol, 0.17 mL, 37% purity, 5 equivalents) in methanol (1 mL) and tetrahydrofuran (1 mL), and the reaction mixture was stirred at 40 °C for 12 h. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel chromatography (gradient: 100:1 to 1:1 petroleum ether / ethyl acetate) to give tert-butyl (3S,4R)-4-(4-fluoro-N,2-dimethylaniline)-3-methylpiperidine-1-carboxylic acid (87 mg, 0.26 mmol, 56% yield) as a colorless oil. LC / MS (ESI) m / z: 337.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ7.23(dd,J=5.6,8.4Hz,1H),7.08-6.92(m,2H),4.17-3.67(m,2H),3.56-3.39(m,1H),2.98(td,J=4.0,11.6Hz,1H ),2.93-2.74(m,1H),2.41(s,3H),2.23(s,3H),2.14-2.00(m,1H),1.37(s,9H),1.31-1.23(m,1H),1.21-1.11(m,1H),0.83-0.74(m,3H).

[0922] Step 3: Preparation of (3S,4R)-N-(4-fluoro-2-methyl-phenyl)-N,3-dimethyl-piperidin-4-amine

[0923]

[0924] Under a nitrogen atmosphere, a mixture of (3S,4R)-4-(4-fluoro-N,2-dimethylaniline)-3-methylpiperidin-1-carboxylic acid tert-butyl ester (90 mg, 0.27 mmol, 1 equivalent) and trifluoroacetic acid (1.54 g, 13.51 mmol, 1.00 mL, 50.49 equivalent) in dichloromethane (1 mL) was stirred at 25 °C for 30 min. The reaction mixture was concentrated under reduced pressure to give (3S,4R)-N-(4-fluoro-2-methyl-phenyl)-N,3-dimethylpiperidin-4-amine (90 mg, crude product, TFA salt) as a colorless oil. LC / MS (ESI) m / z: 237.0 [M+H] + .

[0925] Step 4: 6-Chloro-4-[(3S,4R)-4-(4-fluoro-N,2-dimethylaniline)-3-methyl-1-piperidinyl]-1- Preparation of methyl-2-oxo-1,5-naphthyl-3-carboxynitrile (compound 37)

[0926]

[0927] The title compound was prepared from (3S,4R)-N-(4-fluoro-2-methyl-phenyl)-N,3-dimethyl-piperidin-4-amine in a manner similar to that of 6-chloro-4-[4-(4-chloroanilino)-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile. (Yellow solid). LC / MS (ESI) m / z: 454.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.06(d,J=8.8Hz,1H),7.79(d,J=8.8Hz,1H),7.32(dd,J=5.6,8.8Hz,1H),7.10-6.97(m,2H),4.27-4.01(m,2H),3 .70-3.59(m,1H),3.51(s,3H),3.28-3.19(m,2H),2.47(s,3H),2.27(s,4H),1.99-1.85(m,1H),1.56-1.46(m,1H),0.87(d,J=6.8Hz,3H).

[0928] Synthesis of Compound 38

[0929]

[0930] Step 1: (3aR,6aR)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-2,5-dicarboxylic acid O2-benzyl ester Preparation of O5-butyl ester

[0931]

[0932] Benzyl chloroformate (482 mg, 2.83 mmol, 0.4 mL, 1.2 equivalents) was added to a mixture of (3aR,6aR)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrolo-5-carboxylic acid tert-butyl ester (500 mg, 2.36 mmol, 1 equivalent) and triethylamine (715 mg, 7.07 mmol, 0.98 mL, 3 equivalents) in dichloromethane (10 mL), and the reaction mixture was stirred at 25 °C under N2 for 12 h. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL x 2). The combined organic extracts were washed with brine (20 mL), dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by preparative HPLC (column: Phenomenex C18 250*50mm*10um; mobile phase: [40-70% CH3CN / water (NH4HCO3)]) to obtain a colorless oily (3aR,6aR)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-2,5-dicarboxylic acid O2-benzyl ester O5-tert-butyl ester (95 mg, 0.27 mmol, 12% yield). LC / MS (ESI) m / z: 291.1 [M-55] + .

[0933] Step 2: (3aS,6aS)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrolo-5-carboxylic acid benzyl ester preparation

[0934]

[0935] A solution of (3aR,6aR)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-2,5-dicarboxylic acid O2-benzyl ester O5-tert-butyl ester (95 mg, 0.27 mol, 1 equivalent) in dichloromethane (1 mL) was mixed with trifluoroacetic acid (770 mg, 6.75 mmol, 0.5 mL, 24.6 equivalents), and the reaction mixture was stirred at 25 °C for 0.25 h. The mixture was concentrated under reduced pressure to give (3aS,6aS)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrolo-5-carboxylic acid benzyl ester (90 mg, crude substance, TFA salt) as a brown oil. LC / MS (ESI) m / z: 247.0 [M+H] + .

[0936] Step 3: (3aR,6aR)-2-(4-fluoro-2-methyl-phenyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c] Preparation of benzyl pyrrole-5-carboxylate

[0937]

[0938] The solution of (3aS,6aS)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole-5-carboxylic acid benzyl ester (250 mg, 0.69 mmol, 1 equivalent, trifluoroacetic acid), 4-fluoro-1-iodo-2-methylbenzene (245 mg, 1.04 mmol, 1.5 equivalent), Cs2CO3 (1.13 g, 3.47 mmol, 5 equivalent) and 1,3-bis[2,6-bis(1-propylbutyl)phenyl]-4,5-dichloro-2H-imidazol-1-onthium-2-ylidene; 3-chloropyridine; palladium dichloro(34 mg, 0.03 mmol, 0.05 equivalent) in dioxane (3 mL) was degassed and purged with nitrogen (3X), and the reaction mixture was stirred at 100 °C for 4 hours under a nitrogen atmosphere. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL x 2). The combined organic extracts were washed with brine (25 mL), dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (gradient: 100 / 1 to 1:1 petroleum ether / ethyl acetate) to give (3aR,6aR)-2-(4-fluoro-2-methyl-phenyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylic acid benzyl ester (200 mg, crude) as a yellow oil. LC / MS (ESI) m / z: 355.0 [M+H] + . 1 HNMR(400MHz, CDCl3)δ7.42-7.30(m,5H),6.87-6.76(m,3H),5.21-5.13(m,2H),3.82 -3.73(m,2H),3.39-3.31(m,2H),3.21-3.13(m,4H),2.42-2.31(m,2H),2.28(s,3H).

[0939] Step 4: (3aS,6aS)-5-(4-fluoro-2-methyl-phenyl)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3, Preparation of 4-c]pyrrole

[0940]

[0941] Under nitrogen atmosphere, a palladium / activated carbon catalyst (50 mg, 10% purity) was added to a solution of (3aR,6aR)-2-(4-fluoro-2-methyl-phenyl)-1,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole-5-carboxylic acid benzyl ester (200 mg, 564.31 μmol, 1 equivalent) in CH3OH (5 mL), and the resulting suspension was degassed under vacuum and purged several times with hydrogen. The mixture was then stirred at 30 °C for 12 hours under hydrogen (15 psi). The mixture was concentrated to give (3aS,6aS)-5-(4-fluoro-2-methyl-phenyl)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole (120 mg, crude substance) as a colorless oil. LC / MS(ESI) m / z: 221.1 [M+H] + .

[0942] Step 5: 4-[(3aR,6aR)-2-(4-fluoro-2-methyl-phenyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4- Preparation of [c]pyrrolo-5-yl]-6-chloro-1-methyl-2-oxo-1,5-naphthyl-3-carboxylonitrile (compound 38)

[0943]

[0944] The title compound was prepared from (3aS,6aS)-5-(4-fluoro-2-methyl-phenyl)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole in a manner similar to that of 6-chloro-4-[4-(4-chloroanilino)-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile. (Yellow solid). LC / MS (ESI) m / z: 438.0 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.01(d,J=9.2Hz,1H),7.80(d,J=9.2Hz,1H),6.94(d,J=9.6Hz,1H),6.88-6.82(m,2H ),4.26-4.14(m,4H),3.50(s,3H),3.46(d,J=10.0Hz,2H),3.23-3.17(m,2H),2.46-2.39(m,2H),2.27(s,3H).

[0945] Synthesis of Compound 39

[0946]

[0947] Step 1: Preparation of tert-butyl 4-[(4-chloro-2-hydroxy-phenyl)methyl]piperazine-1-carboxylate

[0948]

[0949] A mixture of piperazine-1-carboxylate tert-butyl ester (357 mg, 1.92 mmol, 1 equivalent), 4-chloro-2-hydroxybenzaldehyde (300 mg, 1.92 mmol, 1 equivalent), and sodium cyanoborohydride (241 mg, 3.83 mmol, 2 equivalent) in methanol (3 mL) was stirred at 25 °C for 12 h. The mixture was concentrated under vacuum, and the resulting crude product was diluted with water (10 mL) and extracted with ethyl acetate (10 mL x 2). The combined organic extracts were washed with brine (20 mL), dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by preparative HPLC (column: Phenomenex C18 250*50mm*10μm; mobile phase: [49-79% CH3CN / water (NH4HCO3)]) to give a yellow oily tert-butyl 4-[(4-chloro-2-hydroxy-phenyl)methyl]piperazine-1-carboxylate (530 mg, 1.62 mmol, 85% yield). LC / MS (ESI) m / z: 327.2 [M+H] + . 1 H NMR (400MHz, CDCl3) δ6.88(d,J=8.0Hz,1H),6.84(d,J=2.0Hz,1H),6.8-6.8(m,1H),3.68(s,2H),3.6-3.2(m,4H),2.52(s,4H),1.48(s,9H).

[0950] Step 2: Preparation of 5-chloro-2-(piperazin-1-ylmethyl)phenol

[0951]

[0952] A mixture of tert-butyl 4-[(4-chloro-2-hydroxy-phenyl)methyl]piperazine-1-carboxylate (20 mg, 0.06 mmol, 1 equivalent) and trifluoroacetic acid (154 mg, 1.35 mmol, 0.1 mL, 22.07 equivalent) in dichloromethane (0.2 mL) was stirred at 20 °C for 0.5 h. The mixture was concentrated to give 5-chloro-2-(piperazine-1-ylmethyl)phenol (21 mg, crude product, TFSA salt) as a yellow oil. LC / MS (ESI) m / z: 227.2 [M+H] + .

[0953] Step 3: 7-{4-[(4-chloro-2-hydroxyphenyl)methyl]piperazin-1-yl}-2,4-dimethyl-5-oxo-4H,5H- Preparation of [1,3]thiazo[5,4-b]pyridine-6-carboxylonitrile (compound 39)

[0954]

[0955] The title compound was prepared from 5-chloro-2-(piperazin-1-ylmethyl)phenol in a manner similar to that of 2,4-dimethyl-5-oxo-7-spiro[3H-benzofuran-2,4'-piperidin]-1'-yl-thiazo[5,4-b]pyridin-6-carboxynitrile. (White solid). LC / MS (ESI) m / z: 430.0 [M+H] + . 1 HNMR (400MHz, DMSO-d6) δ7.21 (d, J = 8.8Hz, 1H), 6.87-6.79 (m, 2H), 3.93 (s, 4H), 3.61 (s, 2H), 3.48 (s, 3H), 2.68 (s, 3H), 2.61 (s, 4H).

[0956] Synthesis of Compound 40

[0957]

[0958] Step 1: (3aS,6aR)-2-(4-fluoro-2-methyl-phenyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c] Preparation of tert-butyl pyrrole-5-carboxylate

[0959]

[0960] Under a nitrogen atmosphere, tert-butyl pyrrolo[3,4-c]pyrrolo-5-carboxylate (400 mg, 1.88 mmol, 1 equivalent), 1-bromo-4-fluoro-2-methylbenzene (392 mg, 2.07 mmol, 1.1 equivalent), and potassium carbonate (781 mg, 5.65 mmol, 3 equivalent) in dioxane (4 mL) were added to a mixture of 1,3-bis[2,6-bis(1-propylbutyl)phenyl]-4,5-dichloro-2H-imidazol-1-onthium-2-ylidene; 3-chloropyridine; and palladium dichloro (91 mg, 0.94 mmol, 0.05 equivalent). The reaction mixture was degassed, purged with nitrogen (3X), and then stirred at 100 °C for 4 h. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL x 2). The combined organic extracts were washed with brine (20 mL), dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (gradient: 100 / 1 to 1:1 petroleum ether / ethyl acetate) to give (3aS,6aR)-2-(4-fluoro-2-methyl-phenyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylic acid tert-butyl ester (117 mg, 0.37 mmol, 19% yield) as a white solid. LC / MS (ESI) m / z: 265.0 [M-55] + . 1H NMR (400MHz, CDCl3) δ6.8-6.8(m,3H),3.68(s,2H),3.32(s,2H),3.12(s,2H),2.92(s,4H),2.28(s,3H),1.44(s,9H).

[0961] Step 2: (3aR,6aS)-5-(4-fluoro-2-methyl-phenyl)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3, Preparation of 4-c]pyrrole

[0962]

[0963] A mixture of (3aS,6aR)-2-(4-fluoro-2-methyl-phenyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylic acid tert-butyl ester (110 mg, 0.34 mmol, 1 equivalent) and trifluoroacetic acid (1.54 g, 13.51 mmol, 1 mL, 1 equivalent) in dichloromethane (1 mL) was stirred at 25 °C for 15 min. The mixture was concentrated under vacuum to give a red oily (3aR,6aS)-5-(4-fluoro-2-methyl-phenyl)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole (190 mg, crude substance, TFA salt). LC / MS (ESI) m / z: 221.0 (M+H) + .

[0964] Step 3: 6-Chloro-4-((3aR,6aS)-5-(4-fluoro-2-methylphenyl)hexahydropyrrolo[3,4-c]pyrrole-2 Preparation of (1H)-yl)-1-methyl-2-oxo-1,2-dihydro-1,5-naphthidine-3-carboxynitrile (compound 40)

[0965]

[0966] The title compound was prepared from (3aR,6aS)-5-(4-fluoro-2-methyl-phenyl)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole in a manner similar to that of 6-chloro-4-[4-(4-chloroanilino)-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile. (Yellow solid). LC / MS (ESI) m / z: 438.1 [M+H] + .

[0967] 1 H NMR(400MHz, DMSO-d6)δ8.0(d,J=8.4Hz,1H),7.8(d,J=8.8Hz,1H),7.2-6.8(m,3H),4.48-4.36(m,2 H), 4.28 (d, J = 12.0Hz, 2H), 3.52 (s, 3H), 3.16 (d, J = 6.0Hz, 2H), 3.08 (d, J = 9.2Hz, 4H), 2.16 (s, 3H).

[0968] Synthesis of Compound 41

[0969]

[0970] Step 1: 3,3a,4,6,7,7a-hexahydro-2H-pyrrolo[3,2-c]pyridine-1,5-dicarboxylic acid O5-benzyl ester O1-tert- Preparation of butyl ester

[0971]

[0972] Benzyl chloroformate (226 mg, 1.33 mmol, 0.19 mL, 1.2 equivalent) was added dropwise to a mixture of 2,3,3a,4,5,6,7,7a-octahydropyrrolo[3,2-c]pyridine-1-carboxylic acid tert-butyl ester (250 mg, 1.10 mmol, 1 equivalent) and triethylamine (223 mg, 2.21 mmol, 0.31 mL, 2 equivalent) in dichloromethane (5 mL), and the reaction mixture was stirred at 20 °C under N2 for 12 h. The mixture was concentrated, and the resulting residue was purified by preparative HPLC (column: Waters xbridge 150*25mm 10um; mobile phase: [42-72% CH3CN / water (NaHCO3)]) to give 3,3a,4,6,7,7a-hexahydro-2H-pyrrolo[3,2-c]pyridine-1,5-dicarboxylic acid O5-benzyl ester O1-tert-butyl ester (170 mg, 0.47 mmol, 43% yield) as a yellow solid. LC / MS (ESI) m / z: 383.0 [M+H] + . 1 H NMR (400MHz, CDCl3) δ7.38-7.29(m,5H),5.14(d,J=3.2Hz,2H),3.93(s,3H),3.47-3.27(m,3H),3.02- 2.75(m,1H),2.40-2.19(m,1H),2.05-1.92(m,1H),1.91-1.75(m,2H),1.66-1.58(m,1H),1.46(s,9H).

[0973] Step 2: Preparation of 1,2,3,3a,4,6,7,7a-octahydropyrrolo[3,2-c]pyridine-5-carboxylic acid benzyl ester

[0974]

[0975] A mixture of 3,3a,4,6,7,7a-hexahydro-2H-pyrrolo[3,2-c]pyridine-1,5-dicarboxylic acid O5-benzyl ester O1-tert-butyl ester (170 mg, 0.47 mmol, 1 equivalent) and trifluoroacetic acid (3.08 g, 27.01 mmol, 2 mL, 57.27 equivalent) in dichloromethane (2 mL) was stirred at 25 °C for 15 min. The mixture was concentrated under vacuum to give a red oily 1,2,3,3a,4,6,7,7a-octahydropyrrolo[3,2-c]pyridine-5-carboxylic acid benzyl ester (200 mg, crude substance, TFA salt). LC / MS (ESI) m / z: 261.0 [M+H] + .

[0976] Step 3: 1-(4-fluorophenyl)-3,3a,4,6,7,7a-hexahydro-2H-pyrrolo[3,2-c]pyridine-5-carboxylic acid benzyl ester Preparation

[0977]

[0978] Under a nitrogen atmosphere, 1,3-bis[2,6-bis(1-propylbutyl)phenyl]-4,5-dichloro-2H-imidazol-1-onthium-2-ylidene; 3-chloropyridine; and palladium dichloroisocyanurate (26 mg, 0.027 mmol, 0.05 equivalent) were added to a mixture of 1,2,3,3a,4,6,7,7a-octahydropyrrolo[3,2-c]pyridine-5-carboxylic acid benzyl ester (200 mg, 0.53 mmol, 1 equivalent, trifluoroacetic acid), 1-fluoro-4-iodobenzene (296 mg, 1.34 mmol, 0.15 mL, 2.5 equivalent) and Cs₂CO₃ (522 mg, 1.60 mmol, 3 equivalent) in DMF (2 mL), and the reaction mixture was stirred at 80 °C for 3 h. The mixture was diluted with water (8 mL) and extracted with ethyl acetate (8 mL x 2). The combined organic extracts were washed with brine (16 mL), dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (gradient: 100 / 1 to 1:1 petroleum ether / ethyl acetate) to give 1-(4-fluorophenyl)-3,3a,4,6,7,7a-hexahydro-2H-pyrrolo[3,2-c]pyridine-5-carboxylic acid benzyl ester (110 mg, 0.31 mmol, 58% yield) as a white solid. LC / MS (ESI) m / z: 355.2 [M+H] + .

[0979] Step 4: Preparation of 1-(4-fluorophenyl)-2,3,3a,4,5,6,7,7a-octahydropyrrolo[3,2-c]pyridine

[0980]

[0981] Under nitrogen atmosphere, a palladium / activated carbon catalyst (30 mg, 10% purity) was added to a solution of 1-(4-fluorophenyl)-3,3a,4,6,7,7a-hexahydro-2H-pyrrolo[3,2-c]pyridine-5-carboxylic acid benzyl ester (108 mg, 0.31 mmol, 1 equivalent) in CH3OH (3 mL), and the resulting suspension was degassed under vacuum and purged several times with hydrogen. The mixture was stirred at 25 °C for 12 hours under hydrogen (15 psi). The mixture was filtered and the filtrate was concentrated to give 1-(4-fluorophenyl)-2,3,3a,4,5,6,7,7a-octahydropyrrolo[3,2-c]pyridine (70 mg, crude) as a colorless oil. LC / MS (ESI) m / z: 221.0 [M+H] + .

[0982] Step 5: 4-[(3aR,7aS)-1-(4-fluorophenyl)-3,3a,4,6,7,7a-hexahydro-2H-pyrrolo[3,2-c]pyridine Preparation of [5-pyridyl]-6-chloro-1-methyl-2-oxo-1,5-naphthidium-3-carboxynitrile (compound 41)

[0983]

[0984] The title compound was prepared from 1-(4-fluorophenyl)-2,3,3a,4,5,6,7,7a-octahydropyrrolo[3,2-c]pyridine in a manner similar to that of 6-chloro-4-[4-(4-chloroanilino)-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile. (Yellow solid). LC / MS (ESI) m / z: 438.1 [M+H] + . 1 H NMR (400MHz, DMSO) δ8.08(d,J=9.2Hz,1H),7.8(d,J=9.2Hz,1H),7.00(t,J=8.8Hz,2H),6.56(dd,J=4.4,8.8Hz,2H),4.24-4.08(m,2H),4.04- 3.88(m,2H),3.52(s,3H),3.49-3.4(m,1H),3.24-3.16(m,1H),2.6(d, J=6.8Hz,2H),2.24-2.12(m,1H),2.12-2.04(m,2H),1.84-1.72(m,1H).

[0985] Synthesis of Compound 43

[0986]

[0987] Step 1: Preparation of tert-butyl 4-(4-chloroaniline)piperidine-1-carboxylate

[0988]

[0989] A mixture of tert-butyl 4-oxopiperidin-1-carboxylate (600 mg, 3.01 mmol, 1 equivalent), 4-chloroaniline (384 mg, 3.01 mmol, 1 equivalent), sodium cyanoborohydride (473.10 mg, 7.53 mmol, 2.5 equivalent), and acetic acid (18 mg, 0.30 mmol, 0.017 mL, 0.1 equivalent) in methanol (6 mL) was stirred at 25 °C for 12 h. The mixture was concentrated under vacuum, and the crude product was diluted with water (5 mL) and extracted with ethyl acetate (5 mL x 2). The combined organic extracts were washed with brine (10 mL), dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (gradient: 100:1 to 1:1 petroleum ether / ethyl acetate) to give tert-butyl 4-(4-chloroanilino)piperidine-1-carboxylate (250 mg, 0.80 mmol, 27% yield) as a white solid. LC / MS (ESI) m / z: 255.1 [M-55] + . 1 H NMR (400MHz, CDCl3) δ7.18-7.05(m,2H),6.58-6.50(m,2H),4.05(d,J=8.0Hz,2H) ,2.92(t,J=12.0Hz,2H),2.05-1.98(m,2H),1.47(s,11H),1.32(d,J=10.8Hz,2H).

[0990] Step 2: Preparation of N-(4-chlorophenyl)piperidine-4-amine

[0991]

[0992] A mixture of tert-butyl 4-(4-chloroaniline)piperidine-1-carboxylate (62 mg, 0.20 mmol, 1 equivalent) and trifluoroacetic acid (924 mg, 8.10 mmol, 0.6 mL, 83.96 equivalent) in dichloromethane (0.6 mL) was stirred at 25 °C for 15 min. The mixture was concentrated under vacuum to give N-(4-chlorophenyl)piperidine-4-amine (100 mg, crude substance, trifluoroacetic acid) as a red oil. LC / MS (ESI) m / z: 211.0 [M+H] + .

[0993] Step 3: 6-Chloro-4-[4-(4-chloroanilino)-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthyl-3-carboxynitrile Preparation

[0994]

[0995] A mixture of N-(4-chlorophenyl)piperidin-4-amine (41 mg, 0.13 mmol, 6.49 e⁻¹ equivalent, trifluoroacetic acid), 4,6-dichloro-1-methyl-2-oxo-1,5-naphthyl-3-carboxynitrile (50 mg, 0.2 mmol, 1 equivalent), and diisopropylethylamine (76 mg, 0.59 mmol, 0.10 mL, 3 equivalent) in acetonitrile (0.6 mL) was stirred at 40 °C for 12 hours. The mixture was concentrated under vacuum, and the resulting precipitate was prepared in dimethylformamide (1.5 mL), washed with acetonitrile (1.5 mL), and collected by filtration to give 6-chloro-4-[4-(4-chloroanilino)-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthyl-3-carboxynitrile (30.4 mg, 0.07 mmol, 35% yield) as a yellow solid. LC / MS (ESI) m / z: 428.0 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.07(d,J=9.2Hz,1H),7.81(d,J=9.2Hz,1H),7.09(d,J=8.8Hz,2H),6.66(d,J=8.8Hz,2H),5.88(d,J=8.0Hz,1H),4.20(br d,J=12.8Hz,2H),3.64-3.56(m,2H),3.53(s,3H),3.30(s,1H),2.10(d,J=10.8Hz,2H),1.77-1.55(m,2H).

[0996] Synthesis of Compound 44

[0997]

[0998]

[0999] Step 1: Preparation of ethyl 3-acetamido-6-chloropyridine-2-carboxylate

[1000]

[1001] A mixture of ethyl 3-amino-6-chloro-pyridine-2-carboxylate (4 g, 19.94 mmol, 1 equivalent) and acetic anhydride (2.04 g, 19.94 mmol, 1.87 mL, 1 equivalent) in dioxane (40 mL) was stirred at 110 °C for 12 h. The mixture was concentrated under vacuum, and the residue was purified by silica gel rapid chromatography (gradient: 100 / 1 to 1:1 petroleum ether / ethyl acetate) to give ethyl 3-acetamido-6-chloro-pyridine-2-carboxylate (5 g, crude product) as a yellow solid. LC / MS (ESI) m / z: 243.1 [M+H] + . 1H NMR (400MHz, CDCl3) δ11.00(s,1H),9.12(d,J=9.2Hz,1H),7.48(d,J=8.8Hz,1H),4.51(q,J=7.2Hz,2H),2.28(s,3H),1.47(t,J=7.2Hz,3H).

[1002] Step 2: Preparation of ethyl 3-[acetyl(methyl)amino]-6-chloro-pyridine-2-carboxylate

[1003]

[1004] A mixture of ethyl 3-acetamido-6-chloro-pyridine-2-carboxylate (200 mg, 0.82 mmol, 1 equivalent), iodomethane (234 mg, 1.65 mmol, 0.1 mL, 2 equivalents), and Cs₂CO₃ (671 mg, 2.06 mmol, 2.5 equivalents) in DMF (2 mL) was stirred at 25 °C for 12 h. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL x 2). The combined organic layers were washed with brine (20 mL), dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (gradient: 0 to 1:1 petroleum ether / ethyl acetate) followed by preparative HPLC (column: Waters xbridge 150*25mm 10μm; mobile phase: [10-40% CH3CN / water (NH4HCO3)]) to give ethyl 3-[acetyl(methyl)amino]-6-chloro-pyridine-2-carboxylate (110 mg, 0.43 mmol, 52% yield) as a white solid. LC / MS (ESI) m / z: 257.1 [M+H] + . 1 H NMR (400MHz, CDCl3) δ8.12(s,1H),7.6(s,1H),4.48-4.4(m,2H),3.08(s,3H),1.92-1.84(m,3H),1.40(t,J=7.2Hz,3H).

[1005] Step 3: Preparation of 6-chloro-4-hydroxy-1-methyl-1,5-naphthidium-2-one

[1006]

[1007] At 0 °C, potassium bis(trimethylsilyl)amide (1 M, 0.64 mL, 1.5 equivalent) was added dropwise to a solution of ethyl 3-[acetyl(methyl)amino]-6-chloro-pyridine-2-carboxylate (110 mg, 0.43 mmol, 1 equivalent) in tetrahydrofuran (1 mL), and the reaction mixture was stirred at 0 °C for 2 hours. The pH of the mixture was adjusted to 5 by adding 1 M hydrochloric acid. The mixture was filtered and the residue was washed with acetonitrile (2 mL) to give 6-chloro-4-hydroxy-1-methyl-1,5-naphthidium-2-one (32 mg, 0.15 mmol, 35% yield) as a white solid. LC / MS (ESI) m / z: 210.9 [M+H] + . 1 HNMR(400MHz,DMSO-d6)δ8.01(d,J=8.8Hz,1H),7.72(d,J=8.8Hz,1H),6.10(s,1H),3.52(s,3H)

[1008] Step 4: Preparation of trifluoromethanesulfonic acid (6-chloro-1-methyl-2-oxo-1,5-naphthid-4-yl) ester

[1009]

[1010] A mixture of 6-chloro-4-hydroxy-1-methyl-1,5-naphthid-2-one (32 mg, 0.15 mmol, 1 equivalent), trifluoromethanesulfonic anhydride (107 mg, 0.38 mmol, 0.062 mL, 2.5 equivalent), triethylamine (77 mg, 0.76 mmol, 0.11 mL, 5 equivalent), and 4-dimethylaminopyridine (2 mg, 0.015 mmol, 0.1 equivalent) in dichloromethane (1 mL) was stirred at 0 °C for 2 hours under a nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel chromatography (gradient: 100 / 1 to 1:1 petroleum ether / ethyl acetate) to give trifluoromethanesulfonic acid (6-chloro-1-methyl-2-oxo-1,5-naphthid-4-yl) ester (33 mg, 0.095 mmol, 63% yield) as a yellow solid. LC / MS (ESI) m / z: 342.9 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.23(d,J=8.8Hz,1H),7.91(d,J=8.8Hz,1H),7.31(s,1H),3.63(s,3H).

[1011] Step 5: 2-(4-fluorophenyl)-4-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-5-carboxylic acid Preparation of tert-butyl ester

[1012]

[1013] A mixture of tert-butyl 4-methyl-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole-5-carboxylate (200 mg, 0.88 mmol, 1 equivalent), 1-bromo-4-fluorobenzene (185 mg, 1.06 mmol, 0.12 mL, 1.2 equivalent), Cs₂CO₃ (864 mg, 2.65 mmol, 3 equivalent) and 1,3-bis[2,6-bis(1-propylbutyl)phenyl]-4,5-dichloro-2H-imidazol-1-onthium-2-ylidene; 3-chloropyridine; palladium dichloroisocyanurate (43 mg, 0.044 mmol, 0.05 equivalent) in dioxane (5 mL) was stirred at 100 °C for 3 h under N₂. The mixture was diluted with water (30 mL) and extracted with ethyl acetate (30 mL x 2). The combined organic extracts were washed with brine (50 mL), dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (gradient: 100 / 1 to 5:1 petroleum ether / ethyl acetate) to give tert-butyl 2-(4-fluorophenyl)-4-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylic acid (150 mg, 0.47 mmol, 53% yield) as a yellow solid. LC / MS (ESI) m / z: 321.0 [M+H] + . 1 H NMR (400MHz, CDCl3) δ6.99-6.90(m,2H),6.50-6.42(m,2H),3.82(s,1H),3.66(dd,J=8.0,11.6Hz,1H),3.56-3.42(m ,2H),3.37(d,J=14.8Hz,1H),3.19-3.11(m,2H),3.04(s,1H),2.67-2.57(m,1H),1.46(s,9H),1.27(d,J=6.4Hz,3H).

[1014] Step 6: (3S,3aS,6aS)-5-(4-fluorophenyl)-3-methyl-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo Preparation of [3,4-c]pyrrole

[1015]

[1016] A mixture of (3aS,4S,6aR)-2-(4-fluorophenyl)-4-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylic acid tert-butyl ester (80 mg, 0.25 mmol, 1 equivalent) and trifluoroacetic acid (770 mg, 6.75 mmol, 0.5 mL, 27.05 equivalent) in dichloromethane (1 mL) was stirred at 20 °C for 0.5 h. The mixture was concentrated to give a brown oily (3S,3aS,6aS)-5-(4-fluorophenyl)-3-methyl-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole (85 mg, crude substance, TFA salt). LC / MS (ESI) m / z: 221.0 [M+H] + .

[1017] Step 7: 4-[(3aS,4S,6aR)-2-(4-fluorophenyl)-4-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3, Preparation of 4-c]pyrrolo-5-yl]-6-chloro-1-methyl-1,5-naphthid-2-one

[1018]

[1019] The title compound was prepared from (3S,3aS,6aS)-5-(4-fluorophenyl)-3-methyl-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole and trifluoromethanesulfonic acid (6-chloro-1-methyl-2-oxo-1,5-naphthid-4-yl) ester in a manner similar to that of 6-chloro-4-[4-(4-chloroanilino)-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthid-3-carboxynitrile. (Yellow solid). LC / MS (ESI) m / z: 413.2 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ7.94(d,J=8.8Hz,1H),7.67(d,J=8.8Hz,1H),6.99(t, J=8.8Hz,2H),6.56-6.47(m,2H),5.63(s,1H),5.00(s,1H),3.97(dd,J=8.4,1 1.6Hz,1H),3.54-3.49(m,1H),3.48(s,3H),3.46-3.39(m,2H),3.20(d,J=7.6 Hz,2H),3.10(dd,J=6.0,9.6Hz,1H),2.88-2.79(m,1H),1.20(d,J=6.4Hz,3H).

[1020] Synthesis of Compound 45

[1021]

[1022] Step 1: (3aR,6aS)-5-(4-fluorophenyl)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole Preparation

[1023]

[1024] To a solution of (3aS,6aR)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrolo-5-carboxylic acid tert-butyl ester (200 mg, 0.94 mmol, 1 equivalent) and 1-bromo-4-fluorobenzene (247 mg, 1.41 mmol, 0.15 mL, 1.5 equivalent) in dioxane (4 mL), Cs₂CO₃ (921 mg, 2.83 mmol, 3 equivalent) and 1,3-bis[2,6-bis(1-propylbutyl)phenyl]-4,5-dichloro-2H-imidazol-1-onthium-2-ylidene; 3-chloropyridine; palladium dichloroisocyanurate (46 mg, 0.047 mmol, 0.05 equivalent) were added, and the reaction mixture was stirred at 100 °C for 4 hours. The mixture was diluted with water (40 mL) and extracted with ethyl acetate (40 mL x 2). The combined organic extracts were washed with brine (100 mL), dried over sodium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel chromatography (gradient: 100 / 1 to 1:1 petroleum ether / ethyl acetate). Trifluoroacetic acid (2 mL) was added to the product, and the mixture was stirred at 20 °C for 1 h. The mixture was concentrated to give (3aR,6aS)-5-(4-fluorophenyl)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole (200 mg, crude, TFA salt) as a red oil. LC / MS (ESI) m / z: 207.2 [M+H] + .

[1025] Step 2: 6-Chloro-4-((3aR,6aS)-5-(4-fluorophenyl)hexahydropyrrolo[3,4-c]pyrrolo-2(1H)-yl)- Preparation of 1-methyl-2-oxo-1,2-dihydro-1,5-naphthidine-3-carboxynitrile (compound 45)

[1026]

[1027] The title compound was prepared from (3aR,6aS)-5-(4-fluorophenyl)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole in a manner similar to that of 6-chloro-4-[4-(4-chloroanilino)-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile. (Yellow solid). LC / MS (ESI) m / z: 424.1 [M+H] + . 1H NMR(400MHz, DMSO-d6)δ8.00(d,J=9.2Hz,1H),7.82-7.74(m,1H),7.01(t,J=8.4Hz,2H),6.53(dd,J=2.4,4.8Hz,2 H), 4.50 (dd, J = 6.4, 12.4Hz, 2H), 4.14 (d, J = 12.4Hz, 2H), 3.50-3.43 (m, 5H), 3.25 (d, J = 10.4Hz, 2H), 3.15 (s, 2H).

[1028] Synthesis of Compound 46

[1029]

[1030] Step 1: Preparation of tert-butyl 4-(4-fluoro-N-(4-fluorophenyl)aniline)piperidine-1-carboxylate

[1031]

[1032] A mixture of tert-butyl 4-(4-fluoroaniline)piperidin-1-carboxylate (200 mg, 0.68 mmol, 1 equivalent), 1-fluoro-4-iodobenzene (151 mg, 0.68 mmol, 0.078 mL, 1 equivalent), tert-butylphosphine (6 mg, 0.03 mmol, 0.007 mL, 4.42e-2 equivalent), palladium diacetoxy (7 mg, 0.03 mmol, 4.42e-2 equivalent), and potassium 2-methylprop-2-ol (229 mg, 2.04 mmol, 3 equivalent) in toluene (10 mL) was stirred at 100 °C for 6 hours. The reaction mixture was filtered and then concentrated under reduced pressure. The residue was purified by silica gel chromatography (gradient: 100 / 1 to 10:1 petroleum ether / ethyl acetate) to give tert-butyl 4-(4-fluoro-N-(4-fluorophenyl)aniline)piperidine-1-carboxylate (188 mg, 0.48 mmol, 71% yield) as a white solid. LC / MS (ESI) m / z: 333.0 [M-55] + . 1 H NMR (400MHz, DMSO-d6) δ7.11 (t, J=8.8Hz, 4H), 6.82 (dd, J=4.8, 8.8Hz, 4H), 3.99-3.89 (m, 2H), 2.99-2.77(m,2H),1.88(d,J=12.0Hz,2H),1.33(s,9H),1.10-0.99(m,2H),0.89-0.77(m,1H).

[1033] Step 2: Preparation of N,N-bis(4-fluorophenyl)piperidine-4-amine

[1034]

[1035] Trifluoroacetic acid (1.20 g, 10.50 mmol, 0.78 mL, 58.29 equivalents) was added dropwise to a solution of tert-butyl piperidine-1-carboxylate (70 mg, 0.18 mmol, 1 equivalent) in dichloromethane (1 mL), and the resulting mixture was stirred at 25 °C for 30 min. The reaction mixture was concentrated under reduced pressure to give N,N-bis(4-fluorophenyl)piperidine-4-amine (60 mg, crude substance, TFA salt) as a green oil. LC / MS (ESI) m / z: 289.1 [M+H] + .

[1036] Step 3: Preparation of 6-chloro-4-[4-(4-fluoro-N-(4-fluorophenyl)anilino)-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile

[1037]

[1038] The title compound was prepared from N,N-bis(4-fluorophenyl)piperidin-4-amine in a manner similar to that of 6-chloro-4-[4-(4-chloroanilino)-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidium-3-carboxynitrile. (Yellow solid). LC / MS (ESI) m / z: 506.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.02(d,J=9.2Hz,1H),7.75(d,J=8.8Hz,1H),7.13(t,J=8.8Hz,4H),6.88(dd,J=4.8,8.8Hz ,4H),4.37-4.26(m,1H),4.25-4.17(m,2H),3.64-3.54(m,2H),3.49(s,3H),2.11-2.02(m,2H),1.67-1.51(m,2H).

[1039] Synthesis of Compound 48

[1040]

[1041] Step 1: (3aR,6aR)-2-[4-(trifluoromethoxy)phenyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4- c] Preparation of tert-butyl pyrrole-5-carboxylate

[1042]

[1043] To a mixture of 1-bromo-4-(trifluoromethoxy)benzene (50 mg, 0.21 mmol, 0.030 mL, 1 equivalent), (3aR,6aR)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole-5-carboxylic acid tert-butyl ester (48 mg, 0.23 mmol, 1.1 equivalent) and Cs2CO3 (203 mg, 0.62 mmol, 3 equivalent) in dioxane (1 mL), 1,3-bis[2,6-bis(1-propylbutyl)phenyl]-4,5-dichloro-2H-imidazol-1-onthium-2-ylidene; 3-chloropyridine; and palladium dichloro (10 mg, 0.01 mmol, 0.05 equivalent) were added, and the reaction mixture was stirred at 100 °C for 3 hours. The mixture was filtered, and the filtrate was diluted with water (2 mL) and extracted with ethyl acetate (2 mL x 2). The combined organic extracts were concentrated under reduced pressure, and the resulting residue was purified by silica gel chromatography (gradient: 100 / 1 to 10:1 petroleum ether / ethyl acetate) to give (3aR,6aR)-2-[4-(trifluoromethoxy)phenyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylic acid tert-butyl ester (20 mg, 0.054 mmol, 26% yield) as a yellow solid. LC / MS (ESI) m / z: 373.0 [M+H] + . 1 H NMR (400MHz, CDCl3) δ7.09 (d, J = 8.4Hz, 2H), 6.50-6.40 (m, 2H), 3.81-3.63 (m ,2H),3.55-3.39(m,2H),3.17-3.03(m,4H),2.42-2.26(m,2H),1.49(s,9H).

[1044] Step 2: (3aS,6aS)-5-[4-(trifluoromethoxy)phenyl]-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo Preparation of [3,4-c]pyrrole

[1045]

[1046] To a solution of (3aR,6aR)-2-[4-(trifluoromethoxy)phenyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-5-carboxylic acid tert-butyl ester (110 mg, 0.30 mmol, 1 equivalent) in dichloromethane (1 mL), trifluoroacetic acid (1.69 g, 14.86 mmol, 1.1 mL, 50.29 equivalent) was added dropwise, and the resulting mixture was stirred at 25 °C for 30 min. The reaction mixture was concentrated under reduced pressure to give a yellow oil of (3aS,6aS)-5-[4-(trifluoromethoxy)phenyl]-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole (120 mg, crude substance, TFA). LC / MS (ESI) m / z: 272.9 [M+H] + .

[1047] Step 3: 4-[(3aR,6aR)-2-[4-(trifluoromethoxy)phenyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3, Preparation of 4-c]pyrrolo-5-yl]-6-chloro-1-methyl-2-oxo-1,5-naphthyl-3-carboxylonitrile

[1048]

[1049] The title compound was prepared from (3aS,6aS)-5-[4-(trifluoromethoxy)phenyl]-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole in a manner similar to that of 6-chloro-4-[4-(4-chloroanilino)-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile. (Yellow solid). LC / MS (ESI) m / z: 490.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.05-7.99(m,1H),7.81(d,J=9.2Hz,1H),7.16(d,J=8.8Hz,2H),6.57(d, J=8.8Hz,2H),4.27-4.14(m,4H),3.58-3.51(m,2H),3.50(s,3H),3.25-3.16(m,2H),2.52(s,2H).

[1050] Synthesis of Compound 49

[1051]

[1052] Step 1: (3aR,6aS)-2-(4-fluoro-2-methyl-phenyl)-3a,6a-dimethyl-1,3,4,6-tetrahydropyrrolo Preparation of [3,4-c]pyrrole-5-carboxylic acid tert-butyl ester

[1053]

[1054] To a solution of 1-bromo-4-fluoro-2-methylbenzene (300 mg, 1.59 mmol, 1 equivalent) and (3aR,6aS)-3a,6a-dimethyl-2,3,4,6-tetrahydro-1H-pyrrolo[3,4-c]pyrrole-5-carboxylic acid tert-butyl ester (343 mg, 1.43 mmol, 0.9 equivalent) in dioxane (6 mL), K₂CO₃ (658 mg, 4.76 mmol, 3 equivalent) and 1,3-bis[2,6-bis(1-propylbutyl)phenyl]-4,5-dichloro-2H-imidazol-1-onthium-2-ylidene; 3-chloropyridine; palladium dichloroisocyanurate (77 mg, 0.079 mmol, 0.05 equivalent) were added, and the reaction mixture was stirred at 100 °C for 4 hours. The mixture was diluted with water (40 mL) and extracted with ethyl acetate (40 mL x 2). The combined organic extracts were washed with brine (100 mL), dried over sodium sulfate, and concentrated. The resulting residue was purified by silica gel chromatography (gradient: 100 / 1 to 1:1 petroleum ether / ethyl acetate) to give (3aR,6aS)-2-(4-fluoro-2-methyl-phenyl)-3a,6a-dimethyl-1,3,4,6-tetrahydropyrrolo[3,4-c]pyrrole-5-carboxylic acid tert-butyl ester (50 mg, crude) as a white solid. LC / MS (ESI) m / z: 349.1 [M+H] + .

[1055] Step 2: (3aS,6aR)-5-(4-fluoro-2-methyl-phenyl)-3a,6a-dimethyl-2,3,4,6-tetrahydro-1H-pyridine Preparation of pyrrolo[3,4-c]pyrrole

[1056]

[1057] A solution of (3aR,6aS)-2-(4-fluoro-2-methyl-phenyl)-3a,6a-dimethyl-1,3,4,6-tetrahydropyrrolo[3,4-c]pyrrole-5-carboxylic acid tert-butyl ester (60 mg, 0.17 mmol, 1 equivalent) in dichloromethane (0.6 mL) was mixed with trifluoroacetic acid (19 mg, 0.17 mmol, 0.013 mL, 1 equivalent), and the reaction mixture was stirred at 25 °C for 0.25 h. The mixture was concentrated under reduced pressure to give (3aS,6aR)-5-(4-fluoro-2-methyl-phenyl)-3a,6a-dimethyl-2,3,4,6-tetrahydro-1H-pyrrolo[3,4-c]pyrrole (65 mg, crude substance, trifluoroacetate) as a green solid. LC / MS (ESI) m / z: 249.0 [M+H] + .

[1058] Step 3: 4-[(3aS,6aR)-2-(4-fluoro-2-methyl-phenyl)-3a,6a-dimethyl-1,3,4,6-tetrahydropyrrole] Preparation of [3,4-c]pyrrolo-5-yl]-6-chloro-1-methyl-2-oxo-1,5-naphthidine-3-carboxylonitrile (compound 49)

[1059]

[1060] The title compound was prepared from (3aS,6aR)-5-(4-fluoro-2-methyl-phenyl)-3a,6a-dimethyl-2,3,4,6-tetrahydro-1H-pyrrolo[3,4-c]pyrrole in a manner similar to that of 6-chloro-4-[4-(4-chloroanilino)-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile. (White solid). LC / MS (ESI) m / z: 466.1 [M+H] + . 1 H NMR (400MHz, CDCl3) δ7.64-7.57(m,1H),7.49(d,J=8.8Hz,1H),6.87-6.75(m,3H),4.62(d,J=12.8Hz,2H),4 .24(d,J=12.8Hz,2H),3.61(s,3H),3.39(d,J=9.2Hz,2H),3.10(d,J=9.2Hz,2H),2.23(s,3H),1.24(s,6H).

[1061] Synthesis of Compound 50

[1062]

[1063] Step 1: Preparation of tert-butyl (3R,4R)-4-(4-fluoroaniline)-3-hydroxypiperidine-1-carboxylate

[1064]

[1065] Scandium (3 g, 15.06 mmol, 1 equivalent) was added to a mixture of 7-oxa-3-azabicyclo[4.1.0]heptane-3-carboxylic acid tert-butyl ester (3 g, 15.06 mmol, 1 equivalent) and 4-fluoroaniline (1.67 g, 15.06 mmol, 1.44 mL, 1 equivalent) in dichloroethane (30 mL). + The reaction mixture was prepared by stirring the trifluoromethanesulfonate (1.48 g, 3.01 mmol, 0.2 equivalents) at 80 °C under N2 for 8 h. The mixture was partitioned between ethyl acetate (100 mL) and water (100 mL). The layers were separated, and the aqueous phase was further extracted with ethyl acetate (100 mL × 2). The combined organic extracts were dried over sodium sulfate and concentrated. The crude product was purified by preparative HPLC (column: Phenomenex luna C18 250*50 mm*10 μm; mobile phase: [20-50% CH3CN / water (0.225% formic acid)]) to give tert-butyl (3R,4R)-4-(4-fluoroaniline)-3-hydroxy-piperidine-1-carboxylate (1.7 g, 5.48 mmol, 36% yield) as a yellow solid. LC / MS (ESI) m / z: 255.2 (M-55) + . 1H NMR (400MHz, CDCl3) δ6.92-6.68(m,2H),6.64-6.52(m,2H),4.32-4.16(m,1H),4.12-3.92(m,1H),3.36(d ,J=4.0Hz,1H),3.16-3.08(m,1H),2.80-2.48(m,3H),2.04-1.96(m,1H),1.40(s,9H),1.24-1.16(m,1H).

[1066] Step 2: Preparation of tert-butyl (3R,4R)-4-(4-fluoroaniline)-3-methoxy-piperidine-1-carboxylate

[1067]

[1068] Sodium hydride (129 mg, 3.22 mmol, 60% purity, 2.5 equivalents) was added to a mixture of (3R,4R)-4-(4-fluoroaniline)-3-hydroxypiperidine-1-carboxylic acid tert-butyl ester (400 mg, 1.29 mmol, 1 equivalent) in tetrahydrofuran (5 mL) at 0 °C, and the resulting mixture was stirred at 0 °C for 0.5 h. Iodimethane (549 mg, 3.87 mmol, 0.024 mL, 3 equivalents) was then added, and the reaction mixture was stirred at 20 °C under N2 for 1 h. The mixture was diluted with a saturated aqueous solution of ammonium chloride (20 mL) and then extracted with ethyl acetate (3 × 20 mL). The combined organic extracts were washed with brine (3 × 20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography (gradient: 30 / 1 to 3:1 petroleum ether / ethyl acetate) to give a yellow oil, (3R,4R)-4-(4-fluoroaniline)-3-methoxy-piperidine-1-carboxylic acid tert-butyl ester (390 mg, 1.20 mmol, 93% yield). LC / MS (ESI) m / z: 347.0 (M+Na) + .

[1069] 1 H NMR (400MHz, CDCl3) δ6.94-6.83(m,2H),6.68-6.56(m,2H),4.25-4.04(m,1H),3.89-3.75(m,1H),3.4 5(s,3H),3.26(d,J=4.4Hz,1H),3.17-2.75(m,3H),2.20-2.08(m,1H),1.48(s,9H),1.43-1.32(m,1H).

[1070] Step 3: Preparation of (3R,4R)-N-(4-fluorophenyl)-3-methoxy-piperidine-4-amine

[1071]

[1072] A mixture of (3R,4R)-4-(4-fluoroaniline)-3-methoxy-piperidine-1-carboxylic acid tert-butyl ester (150 mg, 0.46 mmol, 1 equivalent) and trifluoroacetic acid (1.54 g, 13.51 mmol, 1 mL, 29.21 equivalent) in dichloromethane (1 mL) was stirred at 25 °C for 0.5 h. The reaction mixture was concentrated under vacuum to give (3R,4R)-N-(4-fluorophenyl)-3-methoxy-piperidine-4-amine (1.1 g, crude substance, trifluoroacetic acid) as a white solid. LC / MS (ESI) m / z: 225.2 [M+H] + .

[1073] Step 4: 6-Chloro-4-[(3R,4R)-4-(4-fluoroaniline)-3-methoxy-1-piperidinyl]-1-methyl-2-oxo Preparation of 1,5-naphthyl-3-carboxynitrile (compound 50)

[1074]

[1075] The title compound was prepared from (3R,4R)-N-(4-fluorophenyl)-3-methoxy-piperidin-4-amine in a manner similar to that of 6-chloro-4-[4-(4-chloroanilino)-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile. (Yellow solid). LC / MS (ESI) m / z: 442.2 [M+H] + . 1 HNMR(400MHz,DMSO-d6)δ8.08-9.2(m,1H),7.84-9.2(m,1H),6.92-8.8(m,2H),6.68-4.4,8.8(m,2H),5.6-7.6(m,1H),4.52-12.0(m,1H),4 .04-3.88(m,1H),3.76-3.56(m,2H),3.52(s,3H),3.4(s,3H),3.24-3 .16(m,1H),2.24-2.16(m,1H),1.56-1.44(m,1H),1.35-1.12(m,1H).

[1076] Synthesis of Compound 51

[1077]

[1078] Step 1: Preparation of tert-butyl (3R,4R)-4-(4-fluoro-N-methyl-aniline)-3-methoxy-piperidine-1-carboxylic acid

[1079]

[1080] To (3R,4R)-4-(4-fluoroaniline)-3-methoxy-piperidine-1-carboxylic acid tert-butyl ester (140 mg, 0.43 mmol, 1 equivalent) and formaldehydeSodium cyanoborohydride (81 mg, 1.29 mmol, 3 equivalents) was added to a solution of methanol (1 mL) and tetrahydrofuran (1 mL), and the reaction mixture was stirred at 40 °C for 12 h. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL x 2). The combined organic extracts were concentrated under reduced pressure, and the resulting residue was purified by silica gel chromatography (gradient: 100 / 1 to 10:1 petroleum ether / ethyl acetate) to give tert-butyl (3R,4R)-4-(4-fluoro-N-methyl-aniline)-3-methoxy-piperidine-1-carboxylic acid (50 mg, 147.75 mol, 34% yield) as a yellow oil. LC / MS (ESI) m / z: 339.0 [M+H] + . 1 H NMR (400MHz, CDCl3) δ7.00-6.87(m,2H),6.81(dd,J=4.4,8.8Hz,2H),4.71-4.29(m,1H),4.23-3.91(m,1H),3.56-3.46(m,1H) ,3.41(s,3H),3.29(dt,J=4.8,9.6Hz,1H),2.78(s,3H),2.74-2.63(m,1H),2.58-2.46(m,1H),1.73-1.61(m,2H),1.49(s,9H).

[1081] Step 2: Preparation of (3R,4R)-N-(4-fluorophenyl)-3-methoxy-N-methyl-piperidine-4-amine

[1082]

[1083] A solution of (3R,4R)-4-(4-fluoro-N-methylaniline)-3-methoxy-piperidine-1-carboxylic acid tert-butyl ester (120 mg, 0.35 mmol, 1 equivalent) in dichloromethane (1 mL) was mixed with trifluoroacetic acid (1.85 g, 16.21 mmol, 1.20 mL, 45.71 equivalents), and the resulting mixture was stirred at 25 °C for 30 min. The reaction mixture was concentrated under reduced pressure to give (3R,4R)-N-(4-fluorophenyl)-3-methoxy-N-methyl-piperidine-4-amine (125 mg, crude, TFA salt) as a yellow oil. LC / MS (ESI) m / z: 239.1 [M+H] + .

[1084] Step 3: 6-Chloro-4-[(3R,4R)-4-(4-fluoro-N-methylaniline)-3-methoxy-1-piperidinyl]-1-methyl Preparation of 2-oxo-1,5-naphthidium-3-carboxynitrile (compound 51)

[1085]

[1086] The title compound was prepared from (3R,4R)-N-(4-fluorophenyl)-3-methoxy-N-methylpiperidin-4-amine in a manner similar to that of 6-chloro-4-[4-(4-chloroanilino)-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile. (Yellow solid). LC / MS (ESI) m / z: 456.2 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.10(d,J=8.8Hz,1H),7.84(d,J=8.8Hz,1H),7.04-6.95(m,2H),6.89-6.82(m,2H),4.66(d,J=12.0Hz,1H),4.06(d,J=12. 0Hz,1H),3.95-3.79(m,2H),3.62(dt,J=2.8,12.4Hz,1H),3.54(s,3H),3 .38(s,3H),3.07(dd,J=9.6,12.4Hz,1H),2.76(s,3H),1.95-1.76(m,2H).

[1087] Synthesis of Compounds 52 and 53

[1088]

[1089] Step 1: Preparation of tert-butyl 2,5-dimethyl-4-oxo-piperidine-1-carboxylate

[1090]

[1091] At -78 °C, tetrahydrofuran (2 M, 5.16 mL, 1.10 equivalent) containing lithium diisopropylaminocarbon was added dropwise to a solution of tert-butyl 2-methyl-4-oxo-piperidine-1-carboxylate (2.0 g, 9.38 mmol, 1.00 equivalent) in tetrahydrofuran (70 mL), and the reaction mixture was stirred at -78 °C for 2 h. Iodomethane (1.73 g, 12.19 mmol, 1.30 equivalent) was then added, and the mixture was stirred at 25 °C for 12 h. The reaction mixture was quenched by adding a saturated ammonium chloride solution (100 mL), and the resulting aqueous mixture was extracted with ethyl acetate (100 mL × 2). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give tert-butyl 2,5-dimethyl-4-oxo-piperidine-1-carboxylate (2.1 g, crude product) as a colorless oil. LC / MS (ESI) m / z: 172.2 [M-C4H9+H] + .

[1092] Step 2: Preparation of (2S,5R)-2,5-dimethyl-4-oxo-piperidine-1-carboxylic acid benzyl ester

[1093]

[1094] A solution of tert-butyl 2,5-dimethyl-4-oxo-piperidine-1-carboxylate (2.1 g, 9.24 mmol, 1.00 equivalent) in dichloromethane (10 mL) was added with dioxane containing hydrogen chloride (4 M, 10 mL, 4.33 equivalent), and the resulting mixture was stirred at 25 °C for 0.5 h. The mixture was concentrated under reduced pressure. The resulting residue was dissolved in tetrahydrofuran (20 mL) and water (10 mL), and then treated with NaHCO3 (3.85 g, 45.83 mmol, 5.00 equivalent) and benzyl chloroformate (3.13 g, 18.33 mmol, 2.00 equivalent). The reaction mixture was stirred at 25 °C for 0.5 h. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (50 mL × 2). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (100 / 1 to 30 / 1 petroleum ether / ethyl acetate) followed by semi-preparative reversed-phase HPLC (32-62% acetonitrile + 0.1% formic acid / water, 11 min) to give benzyl 2,5-dimethyl-4-oxo-piperidine-1-carboxylate (600 mg, 2.30 mmol, 25% yield) as a colorless oil. 1 ¹H NMR (400MHz, CDCl₃) δ 7.44–7.29 (m, 5H), 5.28–5.07 (m, 2H), 4.64–4.60 and 3.46–3.31 (m, 1H), 4.43–4.22 (m, 1H), 3.86–3.65 (m, 1H), 2.88–2.60 (m, 1H), 2.57–2.36 (m, 1H), 2.32–2.22 (m, 1H), 1.26 (dd, J = 5.6, 6.8 Hz, 3H), 1.18 (dd, J = 7.2, 9.6 Hz, 3H). This material was analyzed by SFC method: (Column: DAICL CHIRALPAK AY-H (250 mm * 30 mm, 10 μm); Mobile phase: 15%) [CH3OH / CO2] was further purified to give (2S,5R)-2,5-dimethyl-4-oxo-piperidine-1-carboxylic acid benzyl ester (350 mg, 1.34 mmol, 58% yield), which was a yellow oil. 1H NMRδ7.45-7.31(m,5H),5.28-5.12(m,2H),4.65(dt,J=3.1,6.6Hz,1H),3.90-3.78(m,1H),3.75-3.65(m,1H),2.84(d d,J=6.8,15.4Hz,1H),2.60-2.47(m,1H),2.28(dd,J=3.3,15.4Hz,1H),1.26(d,J=6.8Hz,3H),1.18(d,J=7.1Hz,3H).

[1095] Step 3: Preparation of (2S,5R)-4-(4-fluoroaniline)-2,5-dimethyl-piperidine-1-carboxylic acid benzyl ester

[1096]

[1097] A solution of (2S,5R)-2,5-dimethyl-4-oxo-piperidine-1-carboxylic acid benzyl ester (100 mg, 0.38 mmol, 1.00 equivalent) and 4-fluoroaniline (63 mg, 0.57 mmol, 1.50 equivalent) in methanol (2 mL) was mixed with sodium cyanoborohydride (48 mg, 0.76 mmol, 2.00 equivalent) and acetic acid (2 mg, 38.27 mmol, 0.10 equivalent), and the reaction mixture was stirred at 25 °C for 12 h. The reaction mixture was diluted with 10 mL of water and extracted with ethyl acetate (10 mL × 2). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by semi-preparative reversed-phase HPLC (70-80% acetonitrile + 0.225% formic acid / water, 7 min) to obtain benzyl (2S,5R)-4-(4-fluoroaniline)-2,5-dimethyl-piperidine-1-carboxylate (60 mg, 0.16 mmol, 43% yield) as a colorless oil. 1 H NMR (400MHz, CDCl3) δ7.41-7.29(m,5H),6.96-6.83(m,2H),6.61-6.45(m,2H),5.24-5.07(m,2H),4.17(t,J=6.8Hz,1H),3.78-3.61(m,1H),3. 40(dd,J=4.8,14.0Hz,1H),3.21-3.04(m,1H),2.27-2.09(m,1H),1.81 -1.68(m,1H),1.44-1.32(m,1H),1.29-1.21(m,3H),1.18-0.96(m,2H).

[1098] Step 4: Preparation of (2S,5R)-4-(4-fluoro-N-methylaniline)-2,5-dimethylpiperidine-1-carboxylic acid benzyl ester

[1099]

[1100] A solution of (2S,5R)-4-(4-fluoro-N-methyl-aniline)-2,5-dimethyl-piperidine-1-carboxylate (60 mg, 0.16 mmol, 1.00 equivalent) in methanol (2 mL) was mixed with sodium cyanoborohydride (15 mg, 0.25 mmol, 1.50 equivalent) and formaldehyde (136 mg, 1.68 mmol, 37% purity, 10.00 equivalent), and the reaction mixture was stirred at 25 °C for 12 h. The reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL × 2). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give (2S,5R)-4-(4-fluoro-N-methyl-aniline)-2,5-dimethyl-piperidine-1-carboxylate (62 mg, crude) as a white solid. LC / MS (ESI) m / z: 370.9 [M+H] + .

[1101] Step 5: Preparation of (2S,5R)-N-(4-fluorophenyl)-N,2,5-trimethyl-piperidin-4-amine

[1102]

[1103] Under a nitrogen atmosphere, a palladium / activated carbon catalyst (20 mg, 10% purity) was added to a solution of (2S,5R)-4-(4-fluoro-N-methylaniline)-2,5-dimethyl-piperidin-1-carboxylate (62 mg, 0.16 mmol, 1.00 equivalent) in methanol (4 mL). The suspension was degassed and purged with hydrogen (3X), and the reaction mixture was stirred at 25 °C for 2 h under hydrogen (15 Psi). The reaction mixture was filtered and concentrated under reduced pressure to give (2S,5R)-N-(4-fluorophenyl)-N,2,5-trimethyl-piperidin-4-amine (40 mg, crude substance) as a white solid.

[1104] Step 6: 8-[(2S,4R,5R)-4-(4-fluoro-N-methylaniline)-2,5-dimethyl-1-piperidinyl]-5-methyl 8-[(2S,4S,5R)-4-(4-fluoro-N-methylaniline)-2, Preparation of [5-dimethyl-1-piperidinyl]-5-methyl-6-oxo-1,5-naphthyl-2-carboxynitrile (compound 53)

[1105]

[1106] N,N-diisopropylethylamine (43 mg, 0.33 mmol, 2.00 equivalent) was added to a solution of (2S,5R)-N-(4-fluorophenyl)-N,2,5-trimethyl-piperidin-4-amine (40 mg, 0.16 mmol, 1.00 equivalent) and trifluoromethanesulfonic acid (6-cyano-1-methyl-2-oxo-1,5-naphthidin-4-yl) ester (62 mg, 0.18 mmol, 1.10 equivalent) in propan-2-ol (2 mL), and the reaction mixture was stirred at 100 °C for 12 h. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by semi-preparative reversed-phase HPLC (48-78% CH3CN / water (0.225% formic acid)) to give the desired product.

[1107] 8-[(2S,4R,5R)-4-(4-fluoro-N-methylaniline)-2,5-dimethyl-1-piperidinyl]-5-methyl-6-oxo-1,5-naphthidine-2-carboxynitrile (Compound 52) (8.4 mg, 0.02 mol, 11% yield, yellow solid). LC / MS (ESI) m / z: 420.2 [M+H] + . 1 H NMR (400MHz, CDCl3) δ7.86-7.79(m,1H),7.77-7.70(m,1H),6.98(t,J=8.4Hz,2H),6.83(s,2H),6.38(s,1H),3.97(dd,J=3.6,12.0Hz,1H),3.68( s,3H),3.52-3.26(m,2H),2.84(s,3H),2.63-2.46(m,1H),2.43-2.29(m, 1H), 1.89 (d, J = 6.8Hz, 2H), 1.20 (d, J = 5.6Hz, 3H), 0.89 (d, J = 6.4Hz, 3H).

[1108] 8-[(2S,4S,5R)-4-(4-fluoro-N-methylaniline)-2,5-dimethyl-1-piperidinyl]-5-methyl-6-oxo-1,5-naphthidine-2-carboxynitrile (compound 53) (5.4 mg, 0.01 mmol, 7% yield, yellow solid). LC / MS (ESI) m / z: 420.2 [M+H] + . 1H NMR(400MHz, CDCl3)δ7.80(d,J=8.8Hz,1H),7.73-7.66(m,1H),7.00(t,J=8.8Hz,2H ),6.81(dd,J=4.4,9.2Hz,2H),6.16(s,1H),5.02(d,J=6.0Hz,1H),4.04-3.92(m,1H) ,3.76-3.61(m,4H),3.50(dd,J=2.4,12.8Hz,1H),2.87(s,3H),2.57(m,1H),2.42(d ,J=2.4Hz,1H),1.57(d,J=12.4Hz,1H),1.24(d,J=6.8Hz,3H),1.12(d,J=7.2Hz,3H).

[1109] Synthesis of Compound 54

[1110]

[1111] Step 1: (3aR,6aR)-5-benzyl-3-methyl-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole Preparation

[1112]

[1113] A mixture of (3aR,6aS)-2-benzyl-4-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylic acid tert-butyl ester (200 mg, 0.63 mmol, 1 equivalent) and HCl / dioxane (4 M, 1 mL, 6.33 equivalent) in dichloromethane (1 mL) was stirred at 20 °C for 1 h. The mixture was concentrated to give (3aR,6aR)-5-benzyl-3-methyl-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole (200 mg, crude substance, HCl) as a white solid. LC / MS (ESI) m / z: 217.3 [M+H] + .

[1114] Step 2: (3aR,6aS)-2-benzyl-5-(4-fluorophenyl)-4-methyl-1,3,3a,4,6,6a-hexahydropyrrolo Preparation of [3,4-c]pyrrole

[1115]

[1116] To a mixture of (3aR,6aR)-5-benzyl-3-methyl-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole (160.00 mg, 0.63 mmol, 1 equivalent, HCl), 1-bromo-4-fluorobenzene (122 mg, 0.69 mmol, 0.076 mL, 1.1 equivalent), and Cs₂CO₃ (619 mg, 1.90 mmol, 3 equivalent) in dioxane (3 mL), 1,3-bis[2,6-bis(1-propylbutyl)phenyl]-4,5-dichloro-2H-imidazol-1-onthium-2-ylidene; 3-chloropyridine; and palladium dichloro (30.79 mg, 31.65 μmol, 0.05 equivalent) were added, and the reaction mixture was stirred at 100 °C for 3 h under N₂. The mixture was filtered and the filtrate was concentrated. The residue was purified by silica gel chromatography (gradient: 40 / 1 to 5:1 petroleum ether / ethyl acetate) to give (3aR,6aS)-2-benzyl-5-(4-fluorophenyl)-4-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole (140 mg, 451.02 mol, 71% yield) as a yellow oil. LC / MS (ESI) m / z: 311.2 [M+H] + .

[1117] Step 3: (3aR,6aS)-5-(4-fluorophenyl)-4-methyl-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4- c] Preparation of pyrrole

[1118]

[1119] Under N2, palladium / activated carbon catalyst (30 mg, 10% purity) was added to a solution of (3aR,6aS)-2-benzyl-5-(4-fluorophenyl)-4-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole (140.00 mg, 0.45 mmol, 1 equivalent) in ethanol (3 mL). The suspension was degassed under vacuum and purged several times with H2. The mixture was stirred at 50 °C for 12 h under H2 (50 psi). The mixture was filtered and the filtrate was concentrated to give a yellow oily (3aR,6aS)-5-(4-fluorophenyl)-4-methyl-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole (70 mg, crude). LC / MS (ESI) m / z: 220.8 [M+H] + .

[1120] Step 4: 4-[(3aR,6aS)-5-(4-fluorophenyl)-4-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4- Preparation of c]pyrrolo-2-yl]-6-chloro-1-methyl-2-oxo-1,5-naphthyl-3-carboxylon

[1121]

[1122] The title compound was prepared from (3aR,6aS)-5-(4-fluorophenyl)-4-methyl-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole in a manner similar to that of 6-chloro-4-[4-(4-chloroanilino)-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile. (Off-white solid). LC / MS (ESI) m / z: 438.0 [M+H] + . 1 H NMR(400MHz, DMSO-d6)δ7.99(d,J=9.2Hz,1H),7.77(d,J=9.2Hz,1H),7.24(s, 1H),7.11(s,1H),7.03-6.98(m,2H),6.53(dd,J=4.0,8.8Hz,2H),4.53-4.44( m,2H),4.20(d,J=12.8Hz,1H),3.97-3.86(m,2H),3.61-3.55(m,1H),3.47(s, 3H),3.10-3.04(m,1H),2.81-2.74(m,1H),2.52(s,1H),1.16(d,J=6.4Hz,3H).

[1123] Synthesis of Compounds 55 and 56

[1124]

[1125] Step 1: (1R,3aS,6aR)-5-(6-chloro-3-cyano-1-methyl-2-oxo-1,2-dihydro-1,5-naphthidine-4-) Preparation of tert-butyl 1-methylhexahydropyrrolo[3,4-c]pyrrolo-2(1H)-carboxylate

[1126]

[1127] Diisopropylethylamine (171 mg, 1.33 mmol, 3 equivalents) was added to a mixture of (3aR,6aS)-4-methyl-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrolo-5-carboxylic acid tert-butyl ester (0.10 g, 0.44 mmol, 1 equivalent) and 4,6-dichloro-1-methyl-2-oxo-1,5-naphthyl-3-carboxylonitrile (112 mg, 0.44 mmol, 1 equivalent) in acetonitrile (3 mL), and the reaction mixture was stirred at 40 °C for 12 h. The mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (5:1 to 1:0 petroleum ether:ethyl acetate) to give (1R,3aS,6aR)-5-(6-chloro-3-cyano-1-methyl-2-oxo-1,2-dihydro-1,5-naphthidin-4-yl)-1-methylhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid tert-butyl ester (50 mg, 0.11 mmol, 25% yield) as a yellow oil. LC / MS (ESI) m / z: 388.3 [M-56+H] + . 1 H NMR (400MHz, CDCl3) δ7.54(d,J=8.8Hz,1H),7.43(d,J=8.8Hz,1H),4.57-4.45(m,2H),4.16-4.07(m,2H),3.87-3.78(m,1H) ,3.68-3.58(m,1H),3.51(s,3H),3.27-3.19(m,1H),3.06-2.95(m,1H),2.60-2.50(m,1H),1.39(s,9H),1.26-1.21(m,3H).

[1128] Step 2: 6-Chloro-1-methyl-4-((3aR,4R,6aR)-4-methylhexahydropyrrolo[3,4-c]pyrrole-2(1H)- Preparation of 2-oxo-1,2-dihydro-1,5-naphthyl-3-carboxynitrile

[1129]

[1130] Trifluoroacetic acid (1 mL) was added to a mixture of (1R,3aS,6aR)-5-(6-chloro-3-cyano-1-methyl-2-oxo-1,2-dihydro-1,5-naphthid-4-yl)-1-methylhexahydropyrrolo[3,4-c]pyrrolo-2(1H)-carboxylate (50 mg, 0.11 mmol, 1 equivalent) in dichloromethane (2 mL), and the reaction mixture was stirred at 25 °C for 0.5 h. The mixture was concentrated under reduced pressure to give a yellow oil of 6-chloro-1-methyl-4-((3aR,4R,6aR)-4-methylhexahydropyrrolo[3,4-c]pyrrolo-2(1H)-yl)-2-oxo-1,2-dihydro-1,5-naphthid-3-carboxynitrile (50 mg, 0.11 mmol, 96% yield, trifluoroacetate). LC / MS (ESI) m / z: 344.2 [M+H] + .

[1131] Step 3: 4-[(3aR,4R,6aR)-5-[(4-chloro-2-hydroxy-phenyl)methyl]-4-methyl-1,3,3a,4,6, Preparation of 6a-hexahydropyrrolo[3,4-c]pyrrolo-2-yl]-6-chloro-1-methyl-2-oxo-1,5-naphthidine-3-carboxylonitrile

[1132]

[1133] To a mixture of 6-chloro-1-methyl-4-((3aR,4R,6aR)-4-methylhexahydropyrrolo[3,4-c]pyrrolo-2(1H)-yl)-2-oxo-1,2-dihydro-1,5-naphthidium-3-carboxynitrile (50 mg, 0.11 mmol, 1 equivalent, trifluoroacetate) and 4-chloro-2-hydroxybenzaldehyde (34 mg, 0.22 mmol, 2 equivalents) in 1,2-dichloroethane (3 mL), sodium triacetoxyborohydride (69 mg, 0.32 mmol, 3 equivalents) and triethylamine (33 mg, 0.32 mmol, 3 equivalents) were added, and the reaction mixture was stirred at 60 °C for 12 h. The mixture was concentrated under reduced pressure, and the resulting residue was purified by a semi-preparative reversed-phase chromatography (column: Phenomenex Synergi Polar-RP 100*25mm*4um; mobile phase: [32-52% CH3CN / water (TFA)]) to give 4-[(3aR,4R,6aR)-5-[(4-chloro-2-hydroxy-phenyl)methyl]-4-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-2-yl]-6-chloro-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile. LC / MS (ESI) m / z: 484.2 [M+H] + .

[1134] Step 4: 4-[(3aR,4R,6aR)-5-[(4-chloro-2-hydroxy-phenyl)methyl]-4-methyl-1,3,3a,4,6, 6a-Hexahydropyrrolo[3,4-c]pyrrolo-2-yl]-6-chloro-1-methyl-2-oxo-1,5-naphthidine-3-carboxylonitrile (compound 55) and 4-[(3aS,4S,6aS)-5-[(4-chloro-2-hydroxy-phenyl)methyl]-4-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3, Preparation of [4-c]pyrrolo-2-yl]-6-chloro-1-methyl-2-oxo-1,5-naphthidine-3-carboxylonitrile (compound 56)

[1135]

[1136] The mixture of enantiomers (40 mg, 0.08 mmol, 1 equivalent) was separated by supercritical fluid chromatography (column: DAICL CHIRALCEL OD (250 mm * 30 mm, 10 μm); mobile phase: [0.1% NH3OH / CH3OH]; B%: 60%-60%, 3.4 min; 40 min).

[1137] A grayish-white solid, 4-[(3aR,4R,6aR)-5-[(4-chloro-2-hydroxy-phenyl)methyl]-4-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-2-yl]-6-chloro-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile (14.6 mg, 0.03 mmol, 36% yield) (compound 55) was obtained. LC / MS (ESI) m / z: 484.1 [M+H] + . 1 H NMR (400MHz, CDCl3) δ7.60-7.52(m,1H),7.48-7.41(m,1H),6.79(d,J=8.0Hz,1H), 6.75-6.70(m,1H),6.69-6.63(m,1H),4.60(d,J=12.4Hz,1H),4.40(dd,J=2.0,12. 4Hz,1H),4.10(d,J=13.6Hz,1H),4.01-3.89(m,2H),3.54(s,3H),3.35-3.25(m,2H ),2.96-2.85(m,1H),2.61-2.48(m,2H),2.30-2.19(m,1H),1.27(d,J=5.6Hz,3H).

[1138] The second peak was purified by a semi-preparative reversed-phase chromatography (column: Unisil 3-100C18 Ultra 150*50mm*3um; mobile phase: [5-35% CH3CN / water (0.225% formic acid)]) to give a white solid 4-[(3aS,4S,6aS)-5-[(4-chloro-2-hydroxy-phenyl)methyl]-4-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-2-yl]-6-chloro-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile (9.6 mg, 0.02 mmol, 23% yield) (compound 56). LC / MS (ESI) m / z: 484.1 [M+H] + . 1H NMR (400MHz, CDCl3) δ7.69-7.62(m,1H),7.57-7.51(m,1H),6.89(d,J=8.0Hz,1H ),6.84-6.80(m,1H),6.79-6.74(m,1H),4.75-4.59(m,1H),4.55-4.41(m,1H),4 .19(d,J=13.6Hz,1H),4.11-3.99(m,2H),3.68-3.61(m,3H),3.44-3.33(m,2H), 3.06-2.95(m,1H),2.69-2.58(m,2H),2.37-2.28(m,1H),1.37(d,J=5.6Hz,3H).

[1139] Synthesis of Compounds 57 and 58

[1140]

[1141] Step 1: (1S,3aR,6aS)-5-(4-chloro-2-hydroxybenzyl)-1-methylhexahydropyrrolo[3,4-c]pyrrole-2 Preparation of (1H)-tert-butyl formate

[1142]

[1143] To a mixture of (1R,3aS,6aR)-1-methylhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid tert-butyl ester (0.50 g, 2.21 mmol, 1 equivalent) and 4-chloro-2-hydroxybenzaldehyde (371 mg, 2.37 mmol, 1.07 equivalent) in 1,2-dichloroethane (10 mL), sodium triacetoxyborohydride (1.40 g, 6.63 mmol, 3 equivalent) and triethylamine (447 mg, 4.42 mmol, 2 equivalent) were added, and the reaction mixture was stirred at 60 °C for 12 h. The mixture was diluted with water (5 mL) and then extracted with ethyl acetate (20 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether:ethyl acetate = 5:1 to 0:1) to give (1S,3aR,6aS)-5-(4-chloro-2-hydroxybenzyl)-1-methylhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid tert-butyl ester (0.70 g, 1.91 mmol, 86% yield) as a yellow solid. LC / MS (ESI) m / z: 367.3 [M+H] + .

[1144] Step 2: 5-Chloro-2-(((3aS,4S,6aS)-4-methylhexahydropyrrolo[3,4-c]pyrrolo-2(1H)-yl)methyl Preparation of hydroxyphenol

[1145]

[1146] Trifluoroacetic acid (3 mL) was added to a mixture of (1S,3aR,6aS)-5-(4-chloro-2-hydroxybenzyl)-1-methylhexahydropyrrolo[3,4-c]pyrrolo-2(1H)-carboxylic acid tert-butyl ester (0.30 g, 0.81 mmol, 1 equivalent) in dichloromethane (6 mL), and the reaction mixture was stirred at 25 °C for 0.5 h. The mixture was concentrated under reduced pressure to give 5-chloro-2-(((3aS,4S,6aS)-4-methylhexahydropyrrolo[3,4-c]pyrrolo-2(1H)-yl)methyl)phenol (0.30 g, 0.78 mmol, 96% yield, TFA salt) as a yellow oil.

[1147] Step 3: 4-[(3aS,4S,6aR)-2-[(4-chloro-2-hydroxy-phenyl)methyl]-4-methyl-1,3,3a,4,6, Preparation of 6a-hexahydropyrrolo[3,4-c]pyrrolo-5-yl]-6-chloro-1-methyl-2-oxo-1,5-naphthidine-3-carboxylonitrile

[1148]

[1149] Diisopropylethylamine (152 mg, 1.18 mmol, 3 equivalents) was added to a mixture of 4,6-dichloro-1-methyl-2-oxo-1,5-naphthidium-3-carboxylonitrile (0.10 g, 0.39 mmol, 1 equivalent) and 5-chloro-2-(((3aS,4S,6aS)-4-methylhexahydropyrrolo[3,4-c]pyrrolo-2(1H)-yl)methyl)phenol (0.30 g, 0.78 mmol, 2.00 equivalents, trifluoroacetate) in tetrahydrofuran (5 mL), and the reaction mixture was stirred at 60 °C for 12 h. The mixture was concentrated under reduced pressure, and the resulting residue was purified by a semi-preparative reversed-phase chromatography (column: Phenomenex Synergi Polar-RP 100*25mm*4μm; mobile phase: [32-52% CH3CN / water (TFA)]) to give 4-[(3aS,4S,6aR)-2-[(4-chloro-2-hydroxy-phenyl)methyl]-4-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-5-yl]-6-chloro-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile (0.15 g, 0.30 mmol, 78% yield) as a grayish-white solid. LC / MS (ESI) m / z: 484.2 [M+H] + .

[1150] Step 4: 4-[(3aS,4S,6aR)-2-[(4-chloro-2-hydroxy-phenyl)methyl]-4-methyl-1,3,3a,4,6, 6a-Hexahydropyrrolo[3,4-c]pyrrolo-5-yl]-6-chloro-1-methyl-2-oxo-1,5-naphthidine-3-carboxylonitrile (compound 57) and 4-[(3aR,4R,6aS)-2-[(4-chloro-2-hydroxy-phenyl)methyl]-4-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3, Preparation of [4-c]pyrrolo-5-yl]-6-chloro-1-methyl-2-oxo-1,5-naphthidine-3-carboxylonitrile (compound 58)

[1151]

[1152] The mixture of enantiomers (0.15 g, 0.30 mmol, 1 equivalent) was separated by supercritical fluid chromatography (column: DAICL CHIRALPAK AD (250 mm * 30 mm, 10 μm); mobile phase: [0.1% NH4OH / isopropanol]; B%: 40%-40%, 3.2 min; 60 min).

[1153] The absolute configuration is arbitrarily specified.

[1154] The first peak was further purified by a semi-preparative reversed-phase chromatography (column: Waters Xbridge 150*25mm*5um; mobile phase: [45-75% CH3CN / water (NH4OH)]) to give a yellow solid, 4-[(3aS,4S,6aR)-2-[(4-chloro-2-hydroxy-phenyl)methyl]-4-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-5-yl]-6-chloro-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile (22.6 mg, 0.04 mmol, 14% yield) (compound 57). LC / MS (ESI) m / z: 484.1 [M+H] + . 1 H NMR(400MHz, DMSO-d6)δ8.06(d,J=9.2Hz,1H),7.85-7.78(m,1H),7.02(d,J=8.0Hz,1H),6. 64(dd,J=2.0,8.0Hz,1H),6.60-6.55(m,1H),6.00-5.86(m,1H),4.44-4.34(m,1H),3.79(br d,J=12.4Hz,1H),3.65-3.47(m,7H),3.11-3.00(m,1H),2.78-2.59(m,4H),1.21(d,J=6.4Hz,3H).

[1155] The second peak was further purified by a semi-preparative reversed-phase chromatography (column: Phenomenex C18 75*30mm*3μm; mobile phase: [12-42% CH3CN / water (formic acid)]) to give a grayish-white solid, 4-[(3aR,4R,6aS)-2-[(4-chloro-2-hydroxy-phenyl)methyl]-4-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-5-yl]-6-chloro-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile (30.9 mg, 0.06 mmol, 77% yield) (compound 58). LC / MS (ESI) m / z: 484.1 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ8.06(d,J=8.8Hz,1H),7.81(d,J=8.8Hz,1H),7.07(brd,J=8.0Hz,1H),6.77-6.56(m,2H),5.97-5.81(m,1H) ,4.43-4.30(m,1H),3.86-3.54(m,4H),3.52(s,3H),3.13-3.03(m,1H),2.94-2.70(m,3H),2.69-2.57(m,2H),1.20(d,J=6.8Hz,3H).

[1156] Synthesis of Compound 61

[1157] 8-[(3aR,6aR)-2-[(4-chloro-2-hydroxy-phenyl)methyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4- Preparation of [c]pyrrolo-5-yl]-5-methyl-6-oxo-1,5-naphthyl-2-carboxynitrile (compound 61)

[1158]

[1159] A solution of 2-(2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrolo-5-ylmethyl)-5-chlorophenol (65 mg, 0.22 mmol, 1 equivalent, hydrochloride), triethylamine (113 mg, 1.12 mmol, 0.15 mL, 5.0 equivalent), and trifluoromethanesulfonic acid (6-cyano-1-methyl-2-oxo-1,5-naphthid-4-yl) ester (74 mg, 0.22 mmol, 1 equivalent) in dichloromethane (5 mL) and DMF (1 mL) was stirred at 20 °C for 15 h. The reaction mixture was concentrated under reduced pressure. The product was purified by preparative HPLC (column: Waters Xbridge 150*25mm*5μm; mobile phase: [35-65% CH3CN / water (NH4HCO3)]), followed by lyophilization to give 8-[(3aR,6aR)-2-[(4-chloro-2-hydroxy-phenyl)methyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-5-yl]-5-methyl-6-oxo-1,5-naphthidine-2-carboxynitrile (36.1 mg, 82.82 mol, 37% yield) as a white solid. LC / MS (ESI) m / z: 436.1 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ8.17-8.10(m,1H),8.05-7.98(m,1H),7.16-7.08(m,1H),6.82-6.73(m,2H),5.65-5.59(m,1H),3.98-3.93(m,2H),3.50(br s,5H),2.97-2.90(m,2H),2.71-2.64(m,4H),2.40-2.35(m,2H).

[1160] Synthesis of Compound 62

[1161]

[1162] Step 1: Preparation of 1-benzyl-4-(2-bromoanilino)piperidine-4-carboxynitrile

[1163]

[1164] TMSCN (5.5 g, 56.0 mmol, 7.0 mL, 1 equivalent) was added to a stirred solution of 1-benzylpiperidin-4-one (10.0 g, 52.8 mmol, 9.8 mL, 1 equivalent) and 2-bromoaniline (9.10 g, 52.8 mmol, 1 equivalent) in AcOH (40 mL), and the reaction mixture was stirred at 25 °C for 16 h. The reaction mixture was neutralized at 0 °C by adding 8N NaOH aqueous solution (120 mL), and the resulting mixture was extracted with ethyl acetate (100 mL × 3). The organic extract was dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by rapid silica gel chromatography (gradient: 0–10% ethyl acetate / petroleum ether) to give 1-benzyl-4-(2-bromoanilino)piperidin-4-carboxynitrile (10.0 g, 27.0 mmol, 51% yield) as a white solid. LC / MS (ESI) m / z: 370.2 [M+H] + .

[1165] Step 2: Preparation of 1'-benzylspiro[indoline-2,4'-piperidine]-3-imine

[1166]

[1167] AIBN (328 mg, 2.00 mmol, 0.1 equivalence) and Bu3SnH (6.4 g, 21.98 mmol, 1 equivalent) were added to a solution of 1-benzyl-4-(2-bromoanilino)piperidine-4-carboxynitrile (7.4 g, 19.98 mmol, 1 equivalent) in toluene (200 mL) with stirring, and the reaction mixture was stirred at 110 °C under N2 for 16 h. After cooling to 25 °C, the reaction mixture was quenched by adding saturated KF (200 mL) and extracted with ethyl acetate (200 mL × 2). The combined organic extracts were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a yellow gel-like 1'-benzylspiro[dihydroindole-2,4'-piperidine]-3-imine (7.7 g, crude). LC / MS (ESI) m / z: 292.3 [M+H] + .

[1168] Step 3: Preparation of 1'-benzylspiro[indoline-2,4'-piperidine]-3-one

[1169]

[1170] A mixture of 1'-benzylspiro[dihydroindole-2,4'-piperidine]-3-imine (7.70 g, 26.4 mmol, 1 equivalent) in aqueous HCl (1 M, 232 mL, 8.8 equivalent) was stirred at 100 °C for 1 h. After cooling to 25 °C, the mixture was alkalized to pH 8 with saturated NaHCO3 aqueous solution, and then extracted with CH2Cl2 (200 mL × 3). The combined organic layers were washed with brine (100 mL × 2), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by rapid silica gel chromatography (gradient: 0–1% CH3OH / CH2Cl2) to give 1'-benzylspiro[dihydroindole-2,4'-piperidine]-3-one (3.00 g, 10.3 mmol, 38.83% yield) as a yellow solid. LC / MS (ESI) m / z: 293.3 [M+H] + .

[1171] Step 4: Preparation of 1'-benzylspiro[indoline-2,4'-piperidine]-3-ol

[1172]

[1173] At 0 °C, LiAlH4 (1 M, 1.8 mL, 1.1 equivalent) was added to a solution of 1'-benzylspiro[dihydroindole-2,4'-piperidine]-3-one (500 mg, 1.71 mmol, 1 equivalent) in THF (5 mL), and the reaction mixture was stirred at 25 °C for 1 hour. The reaction was terminated by the continuous addition of water (0.3 mL), 15% NaOH aqueous solution (0.3 mL), and water (0.6 mL). The resulting suspension was dried over anhydrous Na2SO4 and then filtered. The filtrate was concentrated under vacuum to give 1'-benzylspiro[dihydroindole-2,4'-piperidine]-3-ol (500 mg, crude substance) as a white solid. LC / MS (ESI) m / z: 295.3 [M+H] + .

[1174] Step 5: Preparation of 1'-benzylspiro[dihydroindole-2,4'-piperidine]

[1175]

[1176] A solution of 1'-benzylspiro[dihydroindole-2,4'-piperidine]-3-ol (500 mg, 1.70 mmol, 1 equivalent) and Et3SiH (987 mg, 8.49 mmol, 1.3 mL, 5 equivalent) in CH2Cl2 (10 mL) was treated with TFA (1.9 g, 16.9 mmol, 1.3 mL, 10 equivalent) at 25 °C for 1 h. The mixture was alkalized to pH 8 with saturated NaHCO3 aqueous solution, and the suspension was extracted with CH2Cl2 (20 mL × 3). The combined organic extracts were washed with brine (15 mL × 3), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by rapid silica gel chromatography (gradient: 0-50% ethyl acetate / petroleum ether) to give 1'-benzylspiro[dihydroindole-2,4'-piperidine] as a white solid (370 mg, 1.33 mmol, 86.95% yield). LC / MS (ESI) m / z: 279.3 [M+H] + .

[1177] Step 6: Preparation of 1'-benzyl-1-methyl-spiro[indoline-2,4'-piperidine]

[1178]

[1179] AcOH (970 mg, 16.1 mmol, 924 μL, 10 equivalents) and borane-2-methylpyridine (864 mg, 8.08 mmol, 5 equivalents) were added to a mixture of 1'-benzylspiro[dihydroindole-2,4'-piperidine] (450 mg, 1.62 mmol, 1 equivalent) and formaldehyde (655 mg, 8.08 mmol, 601 μL, 37% purity, 5 equivalents) in CH3OH (10 mL), and the reaction mixture was stirred at 25 °C for 10 h. The mixture was basified to pH 8 with triethylamine and then concentrated. The crude product was purified by rapid silica gel chromatography (gradient: 0-50% ethyl acetate / petroleum ether) to give 1'-benzyl-1-methyl-spiro[dihydroindole-2,4'-piperidine] (300 mg, 1.03 mmol, 63% yield) as a yellow oil. LC / MS (ESI) m / z: 293.1 [M+H] + .

[1180] Step 7: Preparation of spiro[dihydroindole-2,4'-piperidine]

[1181]

[1182] Under N2, Pd(OH)2 (62 mg, 0.442 mmol, 20% purity, 0.8 equivalent) and AcOH (61 mg, 1.03 mmol, 58 μL, 2 equivalent) were added to a solution of 1'-benzyl-1-methyl-spiro[dihydroindole-2,4'-piperidine] (150 mg, 0.513 mmol, 1 equivalent) in CH3OH (5 mL), and the resulting mixture was degassed and purged with H2 (3X), then stirred at 50 °C for 2 hours under H2 (50 Psi). The reaction mixture was filtered, the filter cake was washed with CH3OH (200 mL), and the filtrate was concentrated under reduced pressure to give 1-methylspiro[dihydroindole-2,4'-piperidine] (100 mg, crude substance) as a white solid. LC / MS (ESI) m / z: 203.1 [M+H] + .

[1183] Step 8: 6-Chloro-1-methyl-4-(1-methylspiro[indoline-2,4-) ' -piperidine]-1 ' -2-oxo-1,5-naphthalene Preparation of pyridine-3-carboxynitrile (compound 62)

[1184]

[1185] To a solution of 4,6-dichloro-1-methyl-2-oxo-1,5-naphthyl-3-carboxynitrile (87 mg, 0.346 mol, 1 equivalent) in CH3CN (3 mL), 1-methylspiro[dihydroindole-2,4'-piperidine] (70 mg, 0.346 mmol, 1 equivalent) and diisopropylethylamine (223 mg, 1.73 mmol, 305 μL, 5 equivalent) were added, and the reaction mixture was stirred at 25 °C for 1 h. The reaction mixture was concentrated, and the crude product was purified by preparative HPLC (column: DAICL CHIRALPAK AD (250 mm * 30 mm, 10 μm); mobile phase: [0.1% NH4OH / EtOH]; B%: 45%-45%, 5 min). The pure fraction was concentrated and lyophilized to give 6-chloro-1-methyl-4-(1-methylspiro[dihydroindol-2,4'-piperidin]-1'-yl)-2-oxo-1,5-naphthyl-3-carboxynitrile (21.6 mg, 0.0506 mmol, 15% yield) as a yellow solid. LC / MS (ESI) m / z: 419.8 [M+H] + . 1 H NMR (400 MHz, DMSO-d6)

[1186] δ8.08(d,J=9.2Hz,1H),7.82(d,J=8.8Hz,1H),7.10-6.94

[1187]

[1188] 2.63(s,3H),2.18-2.15(m,2H),1.60(d,J=12.8Hz,2H).

[1189] Synthesis of Compound 63

[1190] 6-Chloro-1-methyl-2-oxo-4-spiro[3H-benzofuran-2,4- ' -piperidine]-1 ' -1,5-Naphthoid-3-carboxynitrile Preparation of (Compound 63)

[1191]

[1192] A mixture of spiro[3H-benzofuran-2,4'-piperidine] (250 mg, 1.32 mmol, 1 equivalent), 4,6-dichloro-1-methyl-2-oxo-1,5-naphthid-3-carboxynitrile (336 mg, 1.32 mmol, 1 equivalent), and diisopropylethylamine (371.00 mg, 2.87 mmol, 0.5 mL, 2.17 equivalent) in acetonitrile (3 mL) was stirred at 25 °C for 12 h. The mixture was concentrated under vacuum, and the crude product was prepared in dimethylformamide (1 mL), washed with acetonitrile, and collected by filtration to give 6-chloro-1-methyl-2-oxo-4-spiro[3H-benzofuran-2,4'-piperidine]-1'-yl-1,5-naphthid-3-carboxynitrile (475 mg, 1.15 mmol, 87% yield) as a white solid. LC / MS (ESI) m / z: 407.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.08(d,J=9.2Hz,1H),7.82(d,J=9.2Hz,1H),7.2(d,J=7.2Hz,1H),7.12-7 .08(m,1H),6.88-6.8(m,2H),4.00-3.84(m,4H),3.52(s,3H),3.12(s,2H),2.08(t,J=5.6Hz,4H).

[1193] Synthesis of Compound 64

[1194]

[1195] Step 1: 2-(4-fluorophenyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylic acid tert-butyl ester preparation

[1196]

[1197] 4-fluoroaniline (1.72 g, 15.49 mmol, 1.48 mL, 3.0 equivalent) was added to a solution of tert-butyl 3,4-bis(methanesulfonyloxymethyl)pyrrolidine-1-carboxylate (2.0 g, 5.16 mmol, 1.0 equivalent) and potassium carbonate (7.13 g, 51.62 mmol, 10.0 equivalent) in acetonitrile (50 mL), and the reaction mixture was stirred at 90 °C for 15 h. The reaction mixture was cooled to room temperature and partitioned between ethyl acetate (200 mL) and water (30 mL). The organic layer was washed with brine (30 mL), dried over sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography (gradient: 10 / 1 to 2 / 1 petroleum ether / ethyl acetate) followed by preparative TLC (SiO2, petroleum ether / ethyl acetate = 2 / 1) to give tert-butyl 2-(4-fluorophenyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylate (0.3 g, 979.19 μmol, 19% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ6.98-6.92(m,2H),6.45-6.38(m,2H),3.78-3.66(m, 2H),3.46-3.40(m,2H),3.15-3.03(m,4H),2.41-2.24(m,2H),1.49(s,9H).

[1198] Step 2: Preparation of 5-(4-fluorophenyl)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole

[1199]

[1200] A solution of tert-butyl 2-(4-fluorophenyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylate (0.3 g, 0.98 mmol, 1 equivalent) in methanol (3 mL) and dichloromethane (5 mL) was mixed with hydrochloric acid / dioxane (4 M, 10 mL), and the reaction mixture was stirred at 20 °C for 0.5 h. The reaction mixture was concentrated to give 5-(4-fluorophenyl)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole (0.23 g, 947.60 μmol, 97% yield, HCl salt) as a yellow solid. LC / MS (ESI) m / z: 207.5 [M+H] + .

[1201] Step 3: 4-[(3aR,6aR)-2-(4-fluorophenyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole- Preparation of [5-yl]-6-chloro-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile (compound 64)

[1202]

[1203] To a solution of 5-(4-fluorophenyl)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole (71 mg, 0.29 mmol, 1.5 equivalents, hydrochloride) and N,N-diisopropylethylamine (152 mg, 1.18 mmol, 0.2 mL, 6.00 equivalents) in dichloromethane (10 mL) and DMF (1 mL), 4,6-dichloro-1-methyl-2-oxo-1,5-naphthyl-3-carboxynitrile (50 mg, 0.2 mmol, 1.0 equivalents) was added, and the reaction mixture was stirred at 20 °C for 15 h. Water (20 mL) and ethyl acetate (20 mL) were added, and the resulting mixture was stirred at 20 °C for 10 min. The precipitate was filtered, and the product was washed with water (5 mL) and ethyl acetate (5 mL × 2), then concentrated at 40 °C to give 4-[(3aR,6aR)-2-(4-fluorophenyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-5-yl]-6-chloro-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile (48.9 mg, 115.37 μmol, 59% yield) as a yellow solid. LC / MS (ESI) m / z: 424.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ8.07-7.97(m,1H),7.85-7.75(m,1H),7.08-6.93(m,2H),6.55-6 .44(m,2H),4.28-4.15(m,4H),3.54-3.45(m,5H),3.31-3.28(m,2H),3.21-3.15(m,2H).

[1204] Synthesis of compounds 65, 66, 67 and 60

[1205]

[1206] Step 1: Preparation of 5-chloro-2-[(3-methyl-4-piperidinyl)amino]phenol

[1207]

[1208] Trifluoroacetic acid (33 mg, 0.29 mmol, 1.00 equivalent) was added to a solution of tert-butyl 4-(4-chloro-2-hydroxy-aniline)-3-methyl-piperidin-1-carboxylate (100 mg, 0.29 mmol, 1.00 equivalent) in dichloromethane (5 mL), and the reaction mixture was stirred at 25 °C for 1 h. The reaction mixture was concentrated under reduced pressure to give 5-chloro-2-[(3-methyl-4-piperidinyl)amino]phenol (100 mg, 0.28 mmol, 96% yield, trifluoroacetate) as a brown oil.

[1209] Step 2: 6-Chloro-4-[4-(4-chloro-2-hydroxyaniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo- Preparation of 1,5-naphthyl-3-carboxynitrile

[1210]

[1211] Add 4,6-dichloro-1-methyl-2-oxo-1,5-naphthyl-3-carboxynitrile (71 mg, 0.28 mmol, 1.00 equivalent) and N,N-diisopropylethylamine (36 mg, 0.28 mmol, 1.00 equivalent) to a solution of 5-chloro-2-[(3-methyl-4-piperidinyl)amino]phenol (100 mg, 0.28 mmol, 1.00 equivalent) in acetonitrile (5 mL) and stir the reaction mixture at 60 °C for 12 h. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by preparative HPLC (column: Unisil 3-100C18 Ultra 150*50mm*3μm; mobile phase [45-75% CH3CN / water (0.225% formic acid)]) to give 6-chloro-4-[4-(4-chloro-2-hydroxy-aniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile (100 mg, 0.21 mmol, 77% yield) as a yellow solid. LC / MS (ESI) m / z: 458.1 [M+H] + .

[1212] Step 3: 6-Chloro-4-[(3S,4R)-4-(4-chloro-2-hydroxy-aniline)-3-methyl-1-piperidinyl]-1-methyl- 2-Oxo-1,5-Naphthidium-3-carboxynitrile (Compound 65), 6-Chloro-4-[(3R,4S)-4-(4-chloro-2-hydroxy-aniline)-3-methyl [1-piperidinyl]-1-methyl-2-oxo-1,5-naphthyl-3-carboxylonitrile (compound 66), 6-chloro-4-[(3R,4R)-4-(4-chloro- [2-hydroxy-aniline]-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthyl-3-carboxynitrile (compound 67) and 6- Chloro-4-[(3S,4S)-4-(4-chloro-2-hydroxy-aniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthyl- Preparation of 3-formonitrile (compound 60)

[1213]

[1214] Isomers were separated by SFC (100 mg, 0.21 mmol). The first SFC method (column: DAICEL CHIRALPAKAD (250 mm * 30 mm, 10 μm); mobile phase: 60% ethanol (0.1% NH4OH) / CO2) yielded 6-chloro-4-[(3S,4R)-4-(4-chloro-2-hydroxy-aniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidium-3-carboxynitrile and 6-chloro-4-[(3R,4R)-4-(4-chloro-2-hydroxy-aniline)-3-methyl-1-piperidinyl] A mixture of 1-methyl-2-oxo-1,5-naphthyl-3-carboxylonitrile and a mixture of 6-chloro-4-[(3R,4S)-4-(4-chloro-2-hydroxy-aniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthyl-3-carboxylonitrile and 6-chloro-4-[(3S,4S)-4-(4-chloro-2-hydroxy-aniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthyl-3-carboxylonitrile. Each mixture was further purified as shown below to obtain individual isomers.

[1215] The SFC method (column: Daicel ChiralPak IG (250*30mm, 10um); mobile phase: 45% ethanol (0.1% NH4OH) / CO2) yielded 6-chloro-4-[(3S,4R)-4-(4-chloro-2-hydroxy-aniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphtho-3-carboxylonitrile (4.4 mg, 0.009 mmol, 14% yield) and 6-chloro-4-[(3R,4R)-4-(4-chloro-2-hydroxy-aniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphtho-3-carboxylonitrile (5.1 mg, 0.01 mmol, 16% yield) as yellow solids.

[1216] The SFC method (column: DAICL CHIRALPAK IC (250 mm * 30 mm, 10 μm); mobile phase: 50% methanol (0.1% NH4OH) / CO2) yielded 6-chloro-4-[(3R,4S)-4-(4-chloro-2-hydroxy-aniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphtho-3-carboxylonitrile (7.4 mg, 0.01 mmol, 23% yield) and 6-chloro-4-[(3S,4S)-4-(4-chloro-2-hydroxy-aniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphtho-3-carboxylonitrile (9.3 mg, 0.02 mmol, 29% yield) as yellow solids.

[1217] The absolute configuration is arbitrarily specified.

[1218] 6-Chloro-4-[(3S,4R)-4-(4-chloro-2-hydroxy-aniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile (Compound 65). LC / MS (ESI) m / z: 458.1 [M+H] + . 1 HNMR (400MHz, CD3OD) δ8.01(d,J=8.8Hz,1H),7.68(d,J=8.8Hz,1H),6.72-6.66(m,3H),4.18-3.93(m,1H),3.85-3.82(m,2H),3. 80-3.73(m,1H),3.72-3.70(m,1H),3.63(s,3H),2.46-2.45(m,1H),2.25-2.22(m,1H),2.05-2.01(m,1H),0.96(d,J=6.8Hz,3H).

[1219] 6-Chloro-4-[(3R,4S)-4-(4-chloro-2-hydroxyaniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile (Compound 66). LC / MS (ESI) m / z: 458.1 [M+H] + . 1 HNMR (400MHz, CD3OD) δ8.02(d,J=8.8Hz,1H),7.69(d,J=8.8Hz,1H),6.72-6.66(m,3H),4.18-4.17(m,1H),3.96-3.93(m,2H),3. 84-3.82(m,1H),3.81-3.73(m,1H),3.63(s,3H),2.45-2.43(m,1H),2.24-2.21(m,1H),2.01-2.00(m,1H),0.97(d,J=7.2Hz,3H)

[1220] 6-Chloro-4-[(3R,4R)-4-(4-chloro-2-hydroxyaniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile (Compound 67). LC / MS (ESI) m / z: 458.1 [M+H] + . 1HNMR(400MHz,DMSO-d6)δ8.01(d,J=8.8Hz,1H),7.68(d,J=8.8Hz,1H),6.70-6.63(m,3H),4.44 -4.36(m,2H),3.67-3.61(m,4H),3.31-3.19(m,1H),2.29-2.15(m,1H),2.14-2.11(m,1H),1.66 -1.63(m,1H),1.32-1.29(m,1H),1.10(d,J=6.4Hz,3H).

[1221] 6-Chloro-4-[(3S,4S)-4-(4-chloro-2-hydroxyaniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile (Compound 60). LC / MS (ESI) m / z: 458.0 [M+H] + . 1 HNMR(400MHz, DMSO-d6)δ8.01(d,J=8.8Hz,1H),7.69(d,J=8.8Hz,1H),6.74-6.58(m,3H),4.48-4.33(m,2H),3.69-3.61 (m,4H),3.27-3.19(m,1H),2.66(s,1H),2.33-2.23(m,1H),2.20-2.07(m,1H),1.73-1.56(m,1H),1.10(d,J=6.4Hz,3H).

[1222] Synthesis of Compound 68

[1223]

[1224] Step 1: Preparation of spiro[indoline-2,4'-piperidine]-3-one

[1225]

[1226] A solution of 1'-benzylspiro[dihydroindole-2,4'-piperidine]-3-one (150 mg, 0.513 mmol, 1 equivalent) in CH2Cl2 (3 mL) was added with 1-chloroethyl carbamate (733 mg, 5.13 mmol, 10 equivalents), and the reaction mixture was stirred at 45 °C for 10 h. The reaction mixture was concentrated to give a residue. The residue was then mixed with CH3OH (5 mL) and stirred at 60 °C for 1 h. The mixture was concentrated to give spiro[dihydroindole-2,4'-piperidine]-3-one (100 mg, crude substance) as a yellow solid. LC / MS (ESI) m / z: 203.3 [M+H] + .

[1227] Step 2: 6-Chloro-1-methyl-2-oxo-4-(3-oxospiro[indoline-2,4-) ' -piperidine]-1 '- 1,5-Naphthalene (-1,5-naphthalene) Preparation of pyridine-3-carboxynitrile

[1228]

[1229] The title compound was prepared starting from spiro[dihydroindole-2,4'-piperidin]-3-one in a manner similar to that of 6-chloro-4-[4-(4-fluoro-N-methylaniline)-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidium-3-carboxynitrile]. LC / MS (ESI) m / z: 419.9 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.09(d,J=8.8Hz,2H),7.83(d,J=9.2Hz,1H),7.57-7.38(m,2H),6.92(d,J=8.4Hz,1H),6.74 (t,J=7.2Hz,1H),4.27(d,J=13.6Hz,2H),3.79(t,J=11.6Hz,2H),3.55(s,3H),2.10-2.09(m,2H),1.51-1.50(m,2H).

[1230] Synthesis of Compounds 69 and 43

[1231]

[1232] Step 1: (3aR,6aR)-2-(4-fluorophenyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-methyl tert-butyl ester and (3aS,6aS)-2-(4-fluorophenyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-5-carboxylic acid Preparation of butyl ester

[1233]

[1234] Enantiomers were separated by SFC (column: DAICEL CHIRALCEL OJ (250mm*30mm, 10µm); mobile phase: 10% CH3OH (0.1% NH4OH) / CO2). Absolute configurations were arbitrarily specified.

[1235] (3aR,6aR)-2-(4-fluorophenyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-5-carboxylic acid tert-butyl ester (43 mg, 0.14 mmol, 43% yield, white solid) (Rt = 1.14 min).

[1236] (3aS,6aS)-2-(4-fluorophenyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylic acid tert-butyl ester (42 mg, 0.14 mmol, 42% yield, white solid) (Rt = 1.23 min).

[1237] Step 2: 4-[(3aR,6aR)-2-(4-fluorophenyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole- [5-yl]-6-chloro-1-methyl-2-oxo-1,5-naphthyl-3-carboxynitrile (compound 69) and 4-[(3aS,6aS)-2-(4-fluorobenzene) (yl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-5-yl]-6-chloro-1-methyl-2-oxo-1,5-naphthidine-3- Preparation of formonitrile (compound 43)

[1238]

[1239] The title compound was prepared in a manner similar to that of 4-[(3aR,6aR)-2-(4-fluorophenyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-5-yl]-6-chloro-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile.

[1240] 4-[(3aR,6aR)-2-(4-fluorophenyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-5-yl]-6-chloro-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile (yellow solid) (Compound 69). LC / MS (ESI) m / z: 424.0 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.02(d,J=9.2Hz,1H),7.80(d,J=9.2Hz,1H),7.01(t,J=8.8Hz,2H),6.60-6. 43(m,2H),4.28-4.17(m,4H),3.52-3.46(m,5H),3.39(dd,J=2.4,3.6Hz,2H),3.18(t,J=9.2Hz,2H).

[1241] 4-[(3aS,6aS)-2-(4-fluorophenyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-5-yl]-6-chloro-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile (yellow solid) (Compound 43). LC / MS (ESI) m / z: 424.0 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ8.08-7.98(m,1H),7.85-7.74(m,1H),7.08-6.94(m,2H),6.66-

[1242] MS(ESI) m / z: 424.0 [M+1] +

[1243] 1 H NMR: (400MHz, DMSO-d6) δ = 8.02 (d, J = 9.2Hz, 1H), 7.80 (d, J = 9.2Hz, 1H), 7.01 (t, J = 8.8Hz, 2H), 6.60-6.43 (m,

[1244] Synthesis of Compound 71

[1245]

[1246] Step 1: Preparation of ethyl 3-amino-6-chloropyridine-2-carboxylate

[1247]

[1248] A solution of 3-amino-6-chloro-pyridine-2-carboxylic acid (10.0 g, 58.0 mmol, 1 equivalent) in EtOH (100 mL) was added with SOCl2 (8.96 g, 75.3 mmol, 1.3 equivalents), and the reaction mixture was stirred at 85 °C for 16 h. The reaction mixture was concentrated under reduced pressure to give ethyl 3-amino-6-chloro-pyridine-2-carboxylate (13.5 g, 56.9 mmol, 98% yield, HCl) as a yellow solid. LC / MS (ESI) m / z: 201.2 [M+H] + .

[1249] Step 2: Preparation of ethyl 6-chloro-3-[(2-cyanoacetyl)amino]pyridine-2-carboxylate

[1250]

[1251] Triethylamine (17.1 g, 169 mmol, 5 equivalents), 2-cyanoacetic acid (8.61 g, 101 mmol, 3 equivalents), and 1-propionic acid anhydride (34.4 g, 54.0 mmol, 50% purity, 1.6 equivalents) were added to a solution of ethyl 3-amino-6-chloro-pyridine-2-carboxylate (8.00 g, 33.7 mmol, 1 equivalents) in DMF (50 mL), and the reaction mixture was stirred at 25 °C for 1 hour. The reaction mixture was diluted with water (80 mL) and extracted with EtOAc (80 mL × 3). The combined organic extracts were washed with brine (80 mL × 3), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give ethyl 6-chloro-3-[(2-cyanoacetyl)amino]pyridine-2-carboxylate (8.71 g, 24.1 mmol, 71% yield) as a yellow solid. LC / MS (ESI) m / z: 268.1 [M+H] + .

[1252] Step 3: Preparation of 6-chloro-4-hydroxy-2-oxo-1H-1,5-naphthyl-3-carboxynitrile

[1253]

[1254] At -78 °C, potassium bis(trimethylsilyl)amide (1 M, 39.05 mL, 1.2 equivalent) was added to a solution of ethyl 6-chloro-3-[(2-cyanoacetyl)amino]pyridine-2-carboxylate (8.71 g, 32.5 mmol, 1 equivalent) in THF (90 mL), and the reaction mixture was stirred at -78 °C under N2 for 1 h. The reaction mixture was quenched by adding 1 M HCl aqueous solution to adjust the pH to 3, and then concentrated under reduced pressure. The resulting residue was suspended in water (150 mL), and the suspension was cooled in an ice bath and then filtered. The solid was dried under vacuum to give 6-chloro-4-hydroxy-2-oxo-1H-1,5-naphthyl-3-carboxynitrile (5.33 g, 20.9 mmol, 64% yield) as a yellow solid. LC / MS (ESI) m / z: 221.9 [M+H] + .

[1255] Step 4: Preparation of 6-chloro-4-hydroxy-1-methyl-2-oxo-1,5-naphthyl-3-carboxynitrile

[1256]

[1257] At 0 °C, NaH (4.81 g, 120 mmol, 60% purity, 5.74 equivalents) was added to a solution of 6-chloro-4-hydroxy-2-oxo-1H-1,5-naphthyl-3-carboxynitrile (5.33 g, 20.9 mmol, 87% purity, 1 equivalent) in DMF (80 mL), and the reaction mixture was stirred at 0 °C under N2 for 0.5 h. Iodomethane (10.2 g, 72.2 mmol, 3.45 equivalents) was then added, and the reaction mixture was stirred at 25 °C under N2 for 16 h. The mixture was slowly poured into water (100 mL), and the pH of the resulting mixture was adjusted to pH 3 with a 1 N HCl aqueous solution. The resulting suspension was filtered, the filter cake was collected and dried under vacuum to give 6-chloro-4-hydroxy-1-methyl-2-oxo-1,5-naphthyl-3-carboxynitrile (5.14 g, 21.8 mmol, 91% yield) as a yellow solid. LC / MS (ESI) m / z: 235.9 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.12(d,J=8.8Hz,1H),7.87(d,J=9.2Hz,1H),3.54(s,3H).

[1258] Step 5: Preparation of 4,6-dichloro-1-methyl-2-oxo-1,5-naphthyl-3-carboxynitrile

[1259]

[1260] At 0 °C, benzyl(triethyl)ammonium chloride (9.94 g, 43.6 mmol, 2 equivalents) and POCl3 (16.7 g, 109 mmol, 5 equivalents) were added to a solution of 6-chloro-4-hydroxy-1-methyl-2-oxo-1,5-naphthyl-3-carboxynitrile (5.14 g, 21.8 mmol, 1 equivalent) and N,N-diisopropylethylamine (16.9 g, 131 mmol, 6 equivalents) in CH3CN (100 mL), and the reaction mixture was stirred at 25 °C under N2 for 16 hours. The mixture was concentrated under reduced pressure. The resulting residue was poured into ice and a saturated NaHCO3 solution (30 mL), and the mixture was extracted with CH2Cl2 (30 mL × 3). The combined organic extracts were washed with brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by rapid silica gel chromatography (gradient: 0-3% THF / CH2Cl2) to give 4,6-dichloro-1-methyl-2-oxo-1,5-naphthyl-3-carboxynitrile (3.03 g, 11.9 mmol, 55% yield) as a yellow solid. LC / MS (ESI) m / z: 253.8 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.29 (d, J = 9.2Hz, 1H), 8.00 (d, J = 8.8Hz, 1H), 3.65 (s, 3H).

[1261] Step 6: 6-Chloro-1-methyl-2-oxo-4-spiro[indan-2,4'-piperidine]-1'-yl-1,5-naphthidine-3-carboxynitrile preparation

[1262]

[1263] A mixture of spiro[indan-2,4'-piperidine] (300 mg, 1.34 mmol, 1 equivalent, hydrochloric acid), 4,6-dichloro-1-methyl-2-oxo-1,5-naphthyl-3-carboxynitrile (341 mg, 1.34 mmol, 1 equivalent), and diisopropylethylamine (693 mg, 5.36 mmol, 0.934 mL, 4 equivalent) in acetonitrile (3 mL) was stirred at 40 °C for 3 h. The mixture was concentrated under vacuum, and the resulting precipitate was prepared in dimethylformamide (1 mL), washed with acetonitrile (5 mL), and collected by filtration to give 6-chloro-1-methyl-2-oxo-4-spiro[indan-2,4'-piperidine]-1'-yl-1,5-naphthyl-3-carboxynitrile (471 mg, 1.15 mmol, 86% yield) as a yellow solid. LC / MS (ESI) m / z: 405.1 [M+H] + . 1H NMR(400MHz, DMSO-d6)δ8.04(d,J=9.2Hz,1H),7.60(d,J=9.2Hz,1H),7.24-7.2(m,2H),7.12 (dd,J=3.2,5.6Hz,2H),3.84(d,J=4.8Hz,4H),3.52(s,3H),2.92(s,4H),1.88-1.76(m,4H).

[1264] Synthesis of Compound 72

[1265]

[1266] Step 1: 2-[(4-chlorophenyl)methyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-5-carboxylic acid tert- Preparation of butyl ester

[1267]

[1268] Potassium carbonate (7.13 g, 51.62 mmol, 1 equivalent) was added to a solution of tert-butyl 3,4-bis(methanesulfonyloxymethyl)pyrrolidine-1-carboxylate (2.0 g, 5.16 mmol, 1 equivalent) and (4-chlorophenyl)methylamine (2.19 g, 15.49 mmol, 1.89 mL, 3.0 equivalent) in acetonitrile (50 mL), and the reaction mixture was stirred at 90 °C for 15 h. The reaction mixture was cooled to room temperature and partitioned between ethyl acetate (50 mL) and water (10 mL). The organic layer was washed with brine (10 mL), dried over sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography (petroleum ether / ethyl acetate = 10 / 1, 1 / 1, 0 / 1) to give crude product (2.0 g). The crude product was purified by preparative TLC (dichloromethane / ethyl acetate / methanol = 2 / 10 / 1) to give tert-butyl 2-[(4-chlorophenyl)methyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylic acid (0.77 g, 2.29 mmol, 44% yield) as a yellow solid. 1 H NMR(400MHz, CDCl3)δ7.34(m,4H),3.90-3.77(m,2H),3.64-3.45(m,2H),3 .00-2.77(m,4H),2.65-2.51(m,2H),2.35-2.14(m,2H),1.47-1.45(m,9H).

[1269] Step 2: Preparation of 5-[(4-chlorophenyl)methyl]-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole Preparation

[1270]

[1271] A solution of 0.1 g, 0.3 mol, 1 equivalent of 2-[(4-chlorophenyl)methyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-5-carboxylic acid tert-butyl ester in methanol (5 mL) was added to hydrochloric acid / dioxane (4 M, 10 mL), and the reaction mixture was stirred at 20 °C for 1 h. The reaction mixture was concentrated to give 5-[(4-chlorophenyl)methyl]-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole (81 mg, 296.49 μmol, hydrochloride) as a yellow solid. LC / MS (ESI) m / z: 237.1 [M+H] + .

[1272] Step 3: 6-Chloro-4-[2-[(4-chlorophenyl)methyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole- Preparation of [5-yl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile (compound 72)

[1273]

[1274] To a solution of 5-[(4-chlorophenyl)methyl]-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole (81 mg, 0.3 mmol, 1.51 equivalents, hydrochloride) and N,N-diisopropylethylamine (152 mg, 1.18 mmol, 0.2 mL, 6.00 equivalents) in dichloromethane (10 mL) and DMF (1 mL), 4,6-dichloro-1-methyl-2-oxo-1,5-naphthyl-3-carboxynitrile (50 mg, 0.2 mmol, 1.0 equivalents) was added, and the reaction mixture was stirred at 20 °C for 15 h. The reaction mixture was partitioned between water (20 mL) and ethyl acetate (20 mL). The mixture was stirred at 20 °C for 10 min. The precipitate was filtered, and the product was washed with water (5 mL) and ethyl acetate (5 mL × 2), then concentrated at 40 °C to give 6-chloro-4-[2-[(4-chlorophenyl)methyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-5-yl]-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile (34.1 mg, 72.91 mol, 37% yield) as a grayish-white solid. LC / MS (ESI) m / z: 470.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ8.03-7.96(m,1H),7.81-7.74(m,1H),7.41-7.31(m,4H),4.11-4.01(m,4H ),3.91-3.78(m,2H),3.51-3.47(m,3H),2.94-2.84(m,2H),2.69-2.64(m,2H),2.38-2.31(m,2H).

[1275] Synthesis of Compound 73

[1276] 8-[(3aR,6aR)-2-(4-fluorophenyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-5-yl]- Preparation of 5-methyl-6-oxo-1,5-naphthidine-2-carboxynitrile (compound 73)

[1277]

[1278] To a solution of 5-(4-fluorophenyl)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole (87.40 mg, 0.36 mmol, 1.5 equivalents, hydrochloride) and N,N-diisopropylethylamine (186 mg, 1.44 mmol, 0.25 mL, 6.00 equivalents) in dichloromethane (10 mL) and DMF (1 mL), trifluoromethanesulfonic acid (6-cyano-1-methyl-2-oxo-1,5-naphthid-4-yl) ester (80 mg, 0.24 mmol, 1.0 equivalents) was added, and the reaction mixture was stirred at 20 °C for 15 h. Water (20 mL) and ethyl acetate (20 mL) were added, and the mixture was stirred at 20 °C for 10 min. The precipitate was filtered, and the product was washed with water (5 mL) and ethyl acetate (5 mL × 2), then concentrated at 40 °C to give 8-[(3aR,6aR)-2-(4-fluorophenyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-5-yl]-5-methyl-6-oxo-1,5-naphthidine-2-carboxynitrile (40.8 mg, 100.83 μmol, 42% yield) as a yellow solid. LC / MS (ESI) m / z: 390.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ8.20(s,1H),8.06-7.98(m,1H),7.07-6.95(m,2H),6.57-6.43(m,2H),5.70-5.63(m,1H),3.91(br s,2H),3.78-3.57(m,2H),3.54-3.50(m,3H),3.49-3.44(m,2H),3.24-3.11(m,4H).

[1279] Synthesis of Compounds 74 and 75

[1280]

[1281] Step 1: Preparation of tert-butyl 5-oxo-2H-pyrrole-1-carboxylate

[1282]

[1283] Under argon atmosphere, a solution of NaBO3·4H2O (72.91 g, 473.88 mmol, 2.5 equivalents) in water (300 mL) was added to a solution of (1-tert-butoxycarbonylpyrrole-2-yl)boronic acid (40.00 g, 189.55 mmol, 1 equivalent) in tetrahydrofuran (500 mL) at 0 °C, and the reaction mixture was stirred at 20 °C for 3 h. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (300 mL × 2). The combined organic extracts were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give tert-butyl 5-oxo-2H-pyrrole-1-carboxylate (25.00 g, 136.46 mmol, 72% yield) as a yellow oil. 1 HNMR (400MHz, CDCl3) δ7.21-7.14(m,1H),6.19-6.09(m,1H),4.37-4.31(m,2H),1.55(s,9H).

[1284] Step 2: Preparation of tert-butyl 2-[tert-butyl(dimethyl)silyl]oxypyrrole-1-carboxylate

[1285]

[1286] Under argon atmosphere and at 0 °C, triethylamine (41.42 g, 409.38 mmol, 56.98 mL, 3.0 equivalent) was added to a solution of tert-butyl 5-oxo-2H-pyrrole-1-carboxylate (25.00 g, 136.46 mmol, 1 equivalent) in dichloromethane (500 mL), followed by the addition of [tert-butyl(dimethyl)silyl]trifluoromethanesulfonate (43.29 g, 163.75 mmol, 1.2 equivalent), and the reaction mixture was stirred at 20 °C for 2 h. The mixture was concentrated at 30 °C, and the resulting residue was purified by silica gel column chromatography (gradient: 100 / 0 to 10 / 1 petroleum ether / ethyl acetate) to give tert-butyl 2-[tert-butyl(dimethyl)silyl]oxopyrrole-1-carboxylate (32.00 g, 107.58 mmol, 79% yield) as a yellow oil.

[1287] Step 3: Preparation of tert-butyl 2-methyl-5-oxo-2H-pyrrole-1-carboxylate

[1288]

[1289] Under nitrogen atmosphere, iodomethane (45.81 g, 322.73 mmol, 1 equivalent) was added to a solution of 2-[tert-butyl(dimethyl)silyl]oxypyrrole-1-carboxylate (32.00 g, 107.58 mmol, 1 equivalent) in dichloromethane (400 mL), and the mixture was cooled to 0 °C. Silver trifluoroacetate (71.29 g, 322.73 mmol, 3.0 equivalent) was added, and the reaction mixture was stirred at 20 °C for 15 h. The mixture was filtered, and the filter cake was washed with dichloromethane (30 mL × 2). The filtrate was concentrated at 30°C, and the residue was purified by silica gel column chromatography (gradient: 1 / 0 to 10 / 1 petroleum ether / ethyl acetate) to give tert-butyl 2-methyl-5-oxo-2H-pyrrole-1-carboxylate (5.30 g, 26.87 mmol, 25% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ7.14-7.07(m,1H),6.12-6.01(m,1H),4.68-4.57(m,1H),1.58-1.54(m,9H),1.44(d,J=6.8Hz,3H).

[1290] Step 4: (1R,3aS,6aR)-5-benzyl-1-methyl-3-oxohexahydropyrrolo[3,4-c]pyrrolo-2(1H)-methyl Preparation of tert-butyl ester

[1291]

[1292] Under nitrogen atmosphere and at 0 °C, a solution of N-(methoxymethyl)-1-phenyl-N-(trimethylsilylmethyl)methylamine (10.13 g, 36.28 mmol, 85% purity, 1.35 equivalent) in dichloromethane (20 mL) was added dropwise to a solution of tert-butyl 2-methyl-5-oxo-2H-pyrrole-1-carboxylate (5.30 g, 26.87 mmol, 1 equivalent) and trifluoroacetic acid (1.53 g, 13.44 mmol, 0.5 equivalent) in dichloromethane (100 mL), and the reaction mixture was stirred at 20 °C for 15 h. The mixture was concentrated at 30 °C, and the resulting residue was purified by silica gel column chromatography (gradient: 50 / 1 to 1 / 1 petroleum ether / ethyl acetate) to give (1R,3aS,6aR)-5-benzyl-1-methyl-3-oxohexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid tert-butyl ester (8.00 g, 24.21 mmol, 90% yield) as a yellow oil. LC / MS (ESI) m / z: 331.1 [M+H] + .

[1293] Step 5: (1R,3aS,6aR)-5-benzyl-1-methylhexahydropyrrolo[3,4-c]pyrrolo-2(1H)-formic acid tert-butyl Preparation of esters

[1294]

[1295] Under nitrogen atmosphere and at 0 °C, a solution of borane dimethyl sulfide complex (10 M, 6.0 mL, 2.48 equivalents) was added dropwise to a mixture of (1R,3aS,6aR)-5-benzyl-1-methyl-3-oxohexahydropyrrolo[3,4-c]pyrrolo-2(1H)-carboxylic acid tert-butyl ester (8.00 g, 24.21 mmol, 1 equivalent) in tetrahydrofuran (50 mL), and the reaction mixture was stirred at 90 °C for 0.5 h. The reaction was quenched by adding CH3OH (50 mL) and refluxed. The mixture was concentrated under vacuum, and the resulting residue was purified by semi-preparative reversed-phase separation (column: Phenomenex luna C18 250*80mm*10um; mobile phase: [20-45% CH3CN / water (TFA)]) to give tert-butyl (1R,3aS,6aR)-5-benzyl-1-methylhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid (3.60 g, 11.38 mmol, 47% yield) as a colorless oil. LC / MS (ESI) m / z: 317.1 [M+H] + . 1 H NMR (400MHz, CDCl3) δ7.28(s,5H),4.05(s,2H),3.69(s,3H),3.32(s,2H),3.03(d,J =8.0Hz,1H),2.67(s,1H),2.47(d,J=4.0Hz,2H),1.33(s,9H),1.01(d,J=6.4Hz,3H).

[1296] Step 6: Preparation of (1R,3aS,6aR)-1-methylhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid tert-butyl ester

[1297]

[1298] Under nitrogen atmosphere, palladium / activated carbon (0.20 g, 10% purity) was added to a solution of (1R,3aS,6aR)-5-benzyl-1-methylhexahydropyrrolo[3,4-c]pyrrolo-2(1H)-carboxylic acid tert-butyl ester (2.00 g, 6.32 mmol, 1 equivalent) in methanol (30 mL), and the suspension was degassed under vacuum and purged several times with hydrogen. The mixture was stirred at 60 °C for 12 h under hydrogen (20 psi). The reaction mixture was filtered and the filtrate was concentrated to give (1R,3aS,6aR)-1-methylhexahydropyrrolo[3,4-c]pyrrolo-2(1H)-carboxylic acid tert-butyl ester (1.20 g, 5.30 mmol, 84% yield) as a colorless oil.

[1299] Step 7: (1S,3aR,6aS)-5-(4-fluorobenzyl)-1-methylhexahydropyrrolo[3,4-c]pyrrolo-2(1H)-methyl Preparation of tert-butyl ester

[1300]

[1301] Under nitrogen atmosphere, sodium cyanoborohydride (111 mg, 2 equivalences) was added in a single step to a mixture of 4-fluorobenzaldehyde (219 mg, 1.77 mmol, 2 equivalences), (1R,3aS,6aR)-1-methylhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid tert-butyl ester (200 mg, 0.88 mmol, 1 equivalence) and triethylamine (268 mg, 2.65 mmol, 0.37 mL, 3 equivalences) in 1,2-dichloroethane (20 mL).

[1302] 1.77 mmol (2 equivalents) was added, and the reaction mixture was stirred at 60 °C for 10 h. The residue was poured into ice water (w / w = 1 / 1) (10 mL), and the aqueous phase was extracted with dichloromethane (20 mL × 2). The combined organic extracts were washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum to give (1S,3aR,6aS)-5-(4-fluorobenzyl)-1-methylhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid tert-butyl ester (130 mg, 0.39 mmol, 44% yield) as a yellow gel. LC / MS (ESI) m / z: 334.9 [M+H] + .

[1303] Step 8: Preparation of (1S,3aS,6aS)-5-(4-fluorobenzyl)-1-methyloctahydropyrrolo[3,4-c]pyrrole

[1304]

[1305] Under nitrogen atmosphere, trifluoroacetic acid (456 mg, 4.00 mmol, 2 mL, 11.15 equivalents) was added in a single step to a mixture of (1S,3aR,6aS)-5-(4-fluorobenzyl)-1-methylhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid tert-butyl ester (120 mg, 0.34 mmol, 1 equivalent) in dichloromethane (10 mL), and the reaction mixture was stirred at 25 °C for 0.5 h. The mixture was concentrated under reduced pressure to give a yellow gel-like (1S,3aS,6aS)-5-(4-fluorobenzyl)-1-methyloctahydropyrrolo[3,4-c]pyrrole (120 mg, 0.34 mmol, 96% yield, TFA salt).

[1306] Step 9: 8-[(3aS,4S,6aR)-2-[(4-fluorophenyl)methyl]-4-methyl-1,3,3a,4,6,6a-hexahydropyridine Preparation of pyrrolo[3,4-c]pyrrolo-5-yl]-5-methyl-6-oxo-1,5-naphthyl-2-carboxynitrile

[1307]

[1308] Under nitrogen atmosphere, diisopropylethylamine (134 mg, 1.03 mmol, 3 equivalents) was added in a single step to a mixture of trifluoromethanesulfonic acid (6-cyano-1-methyl-2-oxo-1,5-naphthid-4-yl) ester (115 mg, 0.34 mmol, 1 equivalent) and (1S,3aS,6aS)-5-(4-fluorobenzyl)-1-methyloctahydropyrrolo[3,4-c]pyrrole (120 mg, 0.34 mmol, 1 equivalent, trifluoroacetate) in isopropanol (10 mL), and the reaction mixture was stirred at 100 °C for 10 h. The mixture was concentrated under reduced pressure, and the resulting residue was purified by semi-preparative reversed-phase separation (column: Phenomenex Synergi Polar-RP 100*25mm*4um; mobile phase: [26-46% CH3CN / water (TFA)]) to give a yellow gel-like 8-[(3aS,4S,6aR)-2-[(4-fluorophenyl)methyl]-4-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-5-yl]-5-methyl-6-oxo-1,5-naphthidine-2-carboxynitrile (120 mg, 0.29 mmol, 83% yield). LC / MS (ESI) m / z: 418.2 [M+H] + .

[1309] Step 10: 8-[(3aS,4S,6aR)-2-[(4-fluorophenyl)methyl]-4-methyl-1,3,3a,4,6,6a-hexahydropyridine [3,4-c]pyrrolo-5-yl]-5-methyl-6-oxo-1,5-naphthyl-2-carboxynitrile (compound 74) and 8-[(3aR,4R, 6aS)-2-[(4-fluorophenyl)methyl]-4-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-5-yl]-5-methyl Preparation of 6-oxo-1,5-naphthidium-2-carboxynitrile (compound 75)

[1310]

[1311] The mixture of enantiomers (100 mg, 0.24 mmol, 1 equivalent) was separated by supercritical fluid chromatography (column: DAICL CHIRALPAK AS (250 mm * 30 mm, 10 μm); mobile phase [0.1% NH4OH / CH3OH]; B%: 65%-65%, 4.2 min; 50 min).

[1312] The absolute configuration is arbitrarily specified.

[1313] The first peak was further purified by a semi-preparative reversed-phase chromatography (column: Waters Xbridge 150*25mm*5um; mobile phase: [36-66% CH3CN / water (NH4OH)]) to give a grayish-white solid, 8-[(3aS,4S,6aR)-2-[(4-fluorophenyl)methyl]-4-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-5-yl]-5-methyl-6-oxo-1,5-naphthidine-2-carboxynitrile (14.6 mg, 0.03 mmol, 14% yield) (compound 74). LC / MS (ESI) m / z: 418.2 [M+H] + . 1 H NMR (400MHz, CDCl3) δ7.82(d,J=8.8Hz,1H),7.69(d,J=8.8Hz,1H),7.35-7.29(m,2H),7.02(t ,J=8.8Hz,2H),5.91(s,1H),5.33-5.18(m,1H),3.81-3.74(m,1H),3.68-3.54(m,6H),3.05(br s,3H),2.76-2.66(m,1H),2.53-2.43(m,1H),2.39-2.29(m,1H),1.10(d,J=6.4Hz,3H).

[1314] The second peak yielded a grayish-white solid, 8-[(3aR,4R,6aS)-2-[(4-fluorophenyl)methyl]-4-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-5-yl]-5-methyl-6-oxo-1,5-naphthyl-2-carboxynitrile (17.7 mg, 0.04 mmol, 17% yield) (compound 75). LC / MS (ESI) m / z: 418.2 [M+H] + . 1 H NMR (400MHz, CDCl3) δ7.72(d,J=8.8Hz,1H),7.60(d,J=8.8Hz,1H),7.26-7.20(m,2H),6.92(t,J=8.8H z,2H),5.82(s,1H),5.22-5.08(m,1H),3.71-3.65(m,1H),3.58-3.45(m,6H),2.96(brs,3H),2.63(br s,1H),2.46-2.35(m,1H),2.31-2.17(m,1H),1.00(d,J=6.4Hz,3H).

[1315] Synthesis of Compounds 76 and 70

[1316]

[1317] Step 1: Preparation of tert-butyl (1R,3aS,6aR)-5-(6-cyano-1-methyl-2-oxo-1,2-dihydro-1,5-naphthid-4-yl)-1-methylhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate

[1318]

[1319] Under nitrogen atmosphere, diisopropylethylamine (343 mg, 2.65 mmol, 3 equivalents) was added in a single step to a mixture of trifluoromethanesulfonic acid (6-cyano-1-methyl-2-oxo-1,5-naphthid-4-yl) ester (295 mg, 0.88 mmol, 1 equivalent) and (1R,3aS,6aR)-1-methylhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid tert-butyl ester (200 mg, 0.88 mmol, 1 equivalent) in n-butanol (20 mL), and the reaction mixture was stirred at 100 °C for 10 h. The mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel chromatography (gradient: 5 / 1 to 0 / 1 petroleum ether / ethyl acetate) to give (1R,3aS,6aR)-5-(6-cyano-1-methyl-2-oxo-1,2-dihydro-1,5-naphthid-4-yl)-1-methylhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid tert-butyl ester (210 mg, 0.51 mmol, 58% yield) as a yellow gel. LC / MS (ESI) m / z: 354.1 [M-56+H] + .

[1320] Step 2: 5-Methyl-8-((3aR,4R,6aR)-4-methylhexahydropyrrolo[3,4-c]pyrrolo-2(1H)-yl)-6- Preparation of oxo-5,6-dihydro-1,5-naphthyl-2-carboxynitrile

[1321]

[1322] Under nitrogen atmosphere, trifluoroacetic acid (3.08 g, 27.01 mmol, 2 mL, 55.30 equivalents) was added to a mixture of (1R,3aS,6aR)-5-(6-cyano-1-methyl-2-oxo-1,2-dihydro-1,5-naphthid-4-yl)-1-methylhexahydropyrrolo[3,4-c]pyrrolo-2(1H)-carboxylic acid tert-butyl ester (200 mg, 0.49 mmol, 1 equivalent) in dichloromethane (20 mL), and the reaction mixture was stirred at 25 °C for 0.5 h. The mixture was concentrated under vacuum to give a yellow, gel-like 5-methyl-8-((3aR,4R,6aR)-4-methylhexahydropyrrolo[3,4-c]pyrrolo-2(1H)-yl)-6-oxo-5,6-dihydro-1,5-naphthidium-2-carboxynitrile (180 mg, 0.43 mmol, 87% yield, TFA salt). LC / MS (ESI) m / z: 309.8 [M+H] + .

[1323] Step 3: 8-[(3aR,4R,6aR)-5-[(4-fluorophenyl)methyl]-4-methyl-1,3,3a,4,6,6a-hexahydropyridine Preparation of pyrrolo[3,4-c]pyrrolo-2-yl]-5-methyl-6-oxo-1,5-naphthyl-2-carboxylon

[1324]

[1325] Under nitrogen atmosphere, sodium triacetoxyborohydride (270 mg, 1.28 mmol, 3 equivalents) was added in a single batch to a mixture of 4-fluorobenzaldehyde (106 mg, 0.85 mmol, 2 equivalents), triethylamine (215 mg, 2.13 mmol, 5 equivalents), and 5-methyl-8-((3aR,4R,6aR)-4-methylhexahydropyrrolo[3,4-c]pyrrolo-2(1H)-yl)-6-oxo-5,6-dihydro-1,5-naphthidium-2-carboxynitrile (180 mg, 0.43 mmol, 1 equivalent, trifluoroacetate) in 1,2-dichloromethane (10 mL), and the reaction mixture was stirred at 60 °C for 10 h. The residue was poured into ice water (w / w = 1 / 1) (10 mL), and the aqueous phase was extracted with dichloromethane (20 mL × 2). The combined organic extracts were washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The resulting residue was purified by semi-preparative reversed-phase separation (column: Phenomenex Synergi Polar-RP 100*25mm*4μm; mobile phase: [26-46% CH3CN / water (TFA)]) to give a yellow gel-like 8-[(3aR,4R,6aR)-5-[(4-fluorophenyl)methyl]-4-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-2-yl]-5-methyl-6-oxo-1,5-naphthidine-2-carboxynitrile (150 mg, 0.36 mmol, 85% yield). LC / MS (ESI) m / z: 418.2 [M+H]+ .

[1326] Step 4: WC-ARV-JM-004-E, 8-[(3aR,4R,6aR)-5-[(4-fluorophenyl)methyl]-4-methyl-1,3, 3a,4,6,6a-Hexahydropyrrolo[3,4-c]pyrrolo-2-yl]-5-methyl-6-oxo-1,5-naphthyl-2-carboxynitrile (Compound 76) And 8-[(3aS,4S,6aS)-5-[(4-fluorophenyl)methyl]-4-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyridine Preparation of [-2-yl]-5-methyl-6-oxo-1,5-naphthyl-2-carboxynitrile (compound 70)

[1327]

[1328] The mixture of enantiomers (150 mg, 0.35 mmol, 1 equivalent) was separated by supercritical fluid chromatography (column: DAICL CHIRALCEL OJ (250 mm * 30 mm, 10 μm); mobile phase: [0.1% NH4OH / CH3OH]; B%: 40%-40%, 2.9 min; 25 min).

[1329] The absolute configuration is arbitrarily specified.

[1330] 8-[(3aR,4R,6aR)-5-[(4-fluorophenyl)methyl]-4-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-2-yl]-5-methyl-6-oxo-1,5-naphthidine-2-carboxynitrile (44.1 mg, 0.10 mmol, 28% yield, 98% purity) (Compound 76) was found as a grayish-white solid. LC / MS (ESI) m / z: 418.2 [M+H] + . 1 H NMR (400MHz, CDCl3) δ7.71(d,J=8.8Hz,1H),7.58(d,J=8.8Hz,1H),7.23(br t,J=6.4Hz,2H),6.93(t,J=8.8Hz,2H),5.80(s,1H),4.02-3.78(m,3H),3.63-3.51(m,5H),3.26-3.07( m,2H),2.92-2.76(m,1H),2.59-2.45(m,1H),2.43-2.28(m,1H),2.17-2.00(m,1H),1.31-1.14(m,3H).

[1331] 8-[(3aS,4S,6aS)-5-[(4-fluorophenyl)methyl]-4-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-2-yl]-5-methyl-6-oxo-1,5-naphthidine-2-carboxynitrile (95.2 mg, 0.22 mmol, 62% yield, 98% purity) (Compound 70) was a yellow solid. LC / MS (ESI) m / z: 418.2 [M+H] + . 1H NMR(400MHz, CDCl3)δ:7.76(d,J=8.8Hz,1H),7.65(d,J=8.8Hz,1H),7.46-7.38(m,2H),7.10-7.02(m,2H),5.95(s,1H),4.49(br d,J=12.8Hz,1H),4.11(br d,J=11.2Hz,1H),3.90-3.71(m,3H),3.57(s,3H),3.38-3.19(m,3H),3.10-2.93(m,2H),2.70-2.56(m,1H),1.70-1.56(m,3H).

[1332] Synthesis of Compound 78

[1333]

[1334] Step 1: Preparation of tert-butyl 2-benzyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylate

[1335]

[1336] Benzylamine (331 mg, 3.10 mmol, 0.33 mL, 3.0 equivalent) was added to a solution of tert-butyl 3,4-bis(methanesulfonyloxymethyl)pyrrolidine-1-carboxylate (0.4 g, 1.03 mmol, 1.0 equivalent) and potassium carbonate (1.43 g, 10.32 mmol, 0.64 mL, 10.0 equivalent) in acetonitrile (20 mL), and the reaction mixture was stirred at 90 °C for 15 h. The reaction mixture was cooled to room temperature and partitioned between ethyl acetate (50 mL) and water (10 mL). The organic layer was washed with brine (10 mL), dried over sodium sulfate, filtered, and concentrated. The residue was purified by preparative TLC (SiO2, petroleum ether / ethyl acetate = 2 / 3) to give tert-butyl 2-benzyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylic acid (0.15 g, 496.02 mol, 48% yield), which was a yellow oil. LC / MS (ESI) m / z: 303.5 [M+H] + . 1 H NMR (400MHz, CDCl3)

[1337] δ7.36-7.28(m,5H),3.99-3.81(m,2H),3.63-3.46(m,2H),3.02-2.83(m,4H),2.73-2.50(m,2H),2.33-2.15(m,2H),1.46(s,9H).

[1338] Step 2: Preparation of tert-butyl 2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole-5-carboxylate

[1339]

[1340] Under nitrogen atmosphere, palladium / activated carbon catalyst (0.05 g, 10% purity) was added to a stirred solution of 2-benzyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-5-carboxylic acid tert-butyl ester (150.00 mg, 0.5 mmol, 1 equivalent) in ethanol (10 mL), and the reaction mixture was degassed with hydrogen (3X) and stirred at 20 °C for 15 h under hydrogen (15 psi). The reaction mixture was filtered and the filter cake was washed with ethanol (10 mL × 2). The filtrate was concentrated under reduced pressure to give 2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrolo-5-carboxylic acid tert-butyl ester (90 mg, 423.95 mol, 85% yield) as a white solid. LC / MS (ESI) m / z: 156.9 [M-55] + . 1 H NMR (400MHz, CDCl3) δ4.43-4.16(m,1H),3.76-3.53(m,2H),2.91(br s,6H),2.45-2.19(m,2H),1.53-1.39(m,9H).

[1341] Step 3: Preparation of tert-butyl 2-[(4-chloro-2-hydroxy-phenyl)methyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylic acid

[1342]

[1343] A solution of tert-butyl 2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole-5-carboxylate (90 mg, 0.42 mmol, 1 equivalent) and 4-chloro-2-hydroxybenzaldehyde (79 mg, 0.51 mmol, 1.2 equivalent) in ethanol (10 mL) and dichloromethane (5 mL) was stirred at 20 °C for 2 h. Then sodium cyanoborohydride (79 mg, 1.27 mmol, 3.0 equivalent) was added, and the reaction mixture was stirred at 20 °C for 13 h under nitrogen. The product was purified by preparative TLC (petroleum ether / ethyl acetate = 1 / 2) followed by preparative TLC (dichloromethane / methanol = 10 / 1) to give tert-butyl 2-[(4-chloro-2-hydroxy-phenyl)methyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylic acid (40 mg, 113.36 mol, 27% yield) as a yellow solid. LC / MS (ESI) m / z: 353.0 [M+H]+ . 1 HNMR (400MHz, CDCl3) δ6.99-6.95(m,1H),6.94-6.90(m,1H),6.78(dd,J=1.8,7.8Hz,1H),4.12-3.96(m,2H),3. 67-3.57(m,2H),3.19-3.07(m,2H),3.02-2.93(m,2H),2.76-2.65(m,2H),2.34-2.25(m,2H),1.47-1.46(m,9H).

[1344] Step 4: 2-(2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrolo-5-ylmethyl)-5-chlorophenol Preparation

[1345]

[1346] Hydrochloric acid / methanol (4M, 10 mL) was added to a solution of 2-[(4-chloro-2-hydroxy-phenyl)methyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-5-carboxylic acid tert-butyl ester (40 mg, 0.11 mmol, 1 equivalent) in dichloromethane (5 mL), and the mixture was stirred at 20 °C for 1 h. The reaction mixture was concentrated under reduced pressure to give 2-(2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrolo-5-ylmethyl)-5-chlorophenol (33 mg, crude substance, hydrochloride) as a yellow solid. LC / MS (ESI) m / z: 253.0 [M+H] + .

[1347] Step 5: 4-[(3aR,6aR)-2-[(4-chloro-2-hydroxy-phenyl)methyl]-1,3,3a,4,6,6a-hexahydropyrrole Preparation of [3,4-c]pyrrolo-5-yl]-6-chloro-1-methyl-2-oxo-1,5-naphthidine-3-carboxylonitrile (compound 78)

[1348]

[1349] A solution of 2-(2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrolo-5-ylmethyl)-5-chlorophenol (33 mg, 0.11 mmol, 1 equivalent, hydrochloride), triethylamine (57 mg, 0.57 mmol, 0.08 mL, 5.0 equivalent), and 4,6-dichloro-1-methyl-2-oxo-1,5-naphthyl-3-carboxynitrile (29 mg, 0.11 mmol, 1 equivalent) in dichloromethane (5 mL) and DMF (1 mL) was stirred at 20 °C for 15 h. The reaction mixture was concentrated under reduced pressure, and the product was purified by preparative HPLC (column: Waters Xbridge 150*25 mm*5 μm; mobile phase: [45-75% CH3CN / water (NH4HCO3)]). The pure fraction was freeze-dried to give 4-[(3aR,6aR)-2-[(4-chloro-2-hydroxy-phenyl)methyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolo-5-yl]-6-chloro-1-methyl-2-oxo-1,5-naphthidine-3-carboxynitrile (13.3 mg, 28.28 mol, 25% yield) as a white solid. LC / MS (ESI) m / z: 470.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ8.02-7.96(m,1H),7.81-7.73(m,1H),7.15-7.10(m,1H),6.83-6.73(m,2H),4.1 5-4.05(m,4H),4.01-3.89(m,2H),3.49(s,3H),3.00-2.91(m,2H),2.71-2.67(m,2H),2.44-2.35(m,2H).

[1350] Synthesis of Compounds 79 and 80

[1351]

[1352] Step 1: Preparation of tert-butyl 4-(4-fluoro-N-methyl-aniline)-3-methyl-piperidine-1-carboxylate

[1353]

[1354] Paraformaldehyde (292 mg, 9.73 mmol, 0.26 mL, 10 equivalents) and sodium cyanoborohydride (61 mg, 0.97 mmol, 1 equivalent) were added to a solution of tert-butyl 4-(4-fluoro-N-methyl-aniline)-3-methylpiperidine-1-carboxylate (300 mg, 0.97 mmol, 1 equivalent) in methanol (5 mL), and the reaction mixture was stirred at 25 °C for 12 h. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (gradient: 1 / 0 to 20 / 1 petroleum ether / ethyl acetate) to give tert-butyl 4-(4-fluoro-N-methyl-aniline)-3-methylpiperidine-1-carboxylate (200 mg, 0.62 mmol, 64% yield) as a yellow oil. LC / MS (ESI) m / z: 323.2 [M+H] + .

[1355] Step 2: Preparation of N-(4-fluorophenyl)-N,3-dimethyl-piperidin-4-amine

[1356]

[1357] Trifluoroacetic acid (17 mg, 0.15 mmol, 1 equivalent) was added to a solution of tert-butyl 4-(4-fluoro-N-methylaniline)-3-methylpiperidin-1-carboxylate (50 mg, 0.15 mmol, 1 equivalent) in dichloromethane (5 mL), and the reaction mixture was stirred at 25 °C for 1 h. The reaction mixture was concentrated under reduced pressure to give N-(4-fluorophenyl)-N,3-dimethylpiperidin-4-amine (50 mg, 148.67 μmol, 96% yield, TFA salt) as a brown oil.

[1358] Step 3: 6-Chloro-4-[(3S,4R)-4-(4-fluoro-N-methyl-aniline)-3-methyl-1-piperidinyl]-1-methyl- 2-O-1,5-Naphtho-3-carboxynitrile and 6-chloro-4-[(3R,4R)-4-(4-fluoro-N-methyl-aniline)-3-methyl-1-piperidine] Preparation of 1-methyl-2-oxo-1,5-naphthyl-3-carboxynitrile

[1359]

[1360] Diisopropylethylamine (19.21 mg, 148.67 μmol, 1 equivalent, trifluoroacetic acid) and 4,6-dichloro-1-methyl-2-oxo-1,5-naphthyl-3-carboxynitrile (30.22 mg, 118.93 μmol, 0.8 equivalent) were added to a solution of N-(4-fluorophenyl)-N,3-dimethylpiperidin-4-amine (50 mg, 148.67 μmol, 1 equivalent) in acetonitrile (5 mL), and the reaction mixture was stirred at 60 °C for 12 h. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by preparative HPLC (column: Phenomenex luna C18 150*25 mm*10 μm; mobile phase: [33-63% CH3CN / water (formic acid)]) to obtain the desired product.

[1361] A yellow solid, 6-chloro-4-[(3S,4R)-4-(4-fluoro-N-methylaniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidium-3-carboxynitrile (19.8 mg, 42.85 mol, 29% yield) (compound 79) was obtained. LC / MS (ESI) m / z: 440.0 [M+H] + . 1 HNMR(400MHz,DMSO-d6)δ8.08(d,J=9.2Hz,1H),7.82(d,J=9.2Hz,1H),7.09-6.99(m ,2H),6.86(dd,J=4.4,9.2Hz,2H),4.33(d,J=12.0Hz,1H),4.06-3.96(m,1H),4.06- 3.95(m,1H),3.84(dd,J=2.4,12.8Hz,1H),3.53(s,3H),3.46-3.40(m,1H),2.82(s, 3H),2.68-2.62(m,1H),2.33(s,1H),1.74(d,J=11.2Hz,1H),0.87(d,J=6.4Hz,3H).

[1362] A yellow solid, 6-chloro-4-[(3R,4R)-4-(4-fluoro-N-methylaniline)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidium-3-carboxynitrile (5.8 mg, 12.37 mol, 8% yield) (compound 80) was obtained. LC / MS (ESI) m / z: 440.0 [M+H] + . 1 HNMR(400MHz,DMSO-d6)δ8.07(d,J=9.2Hz,1H),7.81(d,J=8.8Hz,1H),7.07-6. 96(m,2H),6.90-6.83(m,2H),4.28(d,J=12.4Hz,2H),3.73(dt,J=3.6,11.1Hz, 1H),3.66-3.55(m,1H),3.53(s,3H),3.17(s,1H),2.70-2.66(m,3H),2.28(dd, J=4.0,6.4Hz,1H),1.97-1.84(m,1H),1.77-1.65(m,1H),0.83(d,J=6.4Hz,3H).

[1363] Synthesis of Compound 81

[1364]

[1365] Step 1: Preparation of (3S,4R)-N-(4-fluorophenyl)-3-methyl-piperidin-4-amine

[1366]

[1367] Trifluoroacetic acid (36.97 mg, 324.26 μmol, 1 equivalent) was added to a solution of (3S,4R)-4-(4-fluoroaniline)-3-methyl-piperidin-1-carboxylic acid tert-butyl ester (100.00 mg, 324.26 μmol, 1 equivalent) in dichloromethane (5 mL), and the reaction mixture was stirred at 25 °C for 1 hour. The reaction mixture was concentrated under reduced pressure to give (3S,4R)-N-(4-fluorophenyl)-3-methyl-piperidin-4-amine (100 mg, 310.27 mol, 96% yield, TFA salt) as a brown oil.

[1368] Step 2: 6-Chloro-4-[(3S,4R)-4-(4-fluoroanilino)-3-methyl-1-piperidinyl]-1-methyl-2-oxo- Preparation of 1,5-naphthidine-3-carboxynitrile (compound 81)

[1369]

[1370] The title compound was prepared from (3S,4R)-N-(4-fluorophenyl)-3-methylpiperidin-4-amine in a manner similar to that of 6-chloro-4-[4-(4-chloroanilino)-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthidium-3-carboxynitrile. (Yellow solid). LC / MS (ESI) m / z: 426.1 [M+H] + . 1 HNMR(400MHz,DMSO-d6)δ8.06(d,J=9.2Hz,1H),7.80(d,J=8.8Hz,1H),6.90 (t,J=8.8Hz,2H),6.76-6.65(m,2H),5.60(d,J=8.8Hz,1H),4.01(d,J=2.4Hz ,1H),3.85(d,J=4.8Hz,2H),3.77-3.59(m,2H),3.52(s,3H),2.41-2.21(m, 1H), 2.13-2.04 (m, 1H), 1.84 (ddd, J=3.2, 9.6Hz, 1H), 0.86 (d, J=6.8Hz, 3H).

[1371] Synthesis of Compound 82

[1372] 6-Chloro-4-[(3R,4R)-4-(4-fluoroanilino)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthalene Preparation of pyridine-3-carboxynitrile (compound 82)

[1373]

[1374] The title compound was prepared from (3R,4R)-4-(4-fluoroanilino)-3-methyl-piperidin-1-carboxylate tert-butyl ester in a manner similar to that of 6-chloro-4-[(3S,4R)-4-(4-fluoroanilino)-3-methyl-1-piperidinyl]-1-methyl-2-oxo-1,5-naphthyl-3-carboxynitrile (yellow solid). LC / MS (ESI) m / z: 426.1 [M+H] + . 1 HNMR(400MHz,DMSO-d6)δ8.06(d,J=9.2Hz,1H),7.81(d,J=9.2Hz,1H),6.95-6.85(m,2H),6.68-6.56(m,2H),5.48(d,J=9.2Hz,1H),4.32-4.1 5(m,2H),3.65-3.54(m,1H),3.52(s,3H),3.26-3.09(m,2H),2.20-2.0 9(m,1H),2.08-1.92(m,1H),1.57-1.40(m,1H),0.98(d,J=6.4Hz,3H).

[1375] Synthesis of Compound 83

[1376]

[1377] Step 1: Preparation of tert-butyl 4-[(4-chloro-2-hydroxy-phenyl)methyl-methyl-amino]piperidine-1-carboxylate

[1378]

[1379] Acetic acid (560 mg, 9.33 mmol, 1.0 equivalent) was added to a mixture of tert-butyl 4-(methylamino)piperidine-1-carboxylate (500 mg, 2.33 mmol, 1.0 equivalent) and 4-chloro-2-hydroxybenzaldehyde (365 mg, 2.33 mmol, 1.0 equivalent) in dichloroethane (5 mL) and CH3OH (5 mL), and the resulting mixture was stirred at 25 °C for 5 h. Then, NaBH(OAc)3 (2.47 g, 11.67 mmol, 5.0 equivalent) was added,...

Claims

1. A compound having the structure of formula (A): or a pharmaceutically acceptable salt thereof, wherein: Ring A is a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaromatic ring fused to ring B; Ring C is a heterocyclic ring, except R 3 and R 4 Besides, it can also be replaced; R 1 is a C1-C4 alkyl group; R 2 is H or an electron-withdrawing functional group; Each R 3 Independently NR 5 R 6 ; Each R 4 are independently C1-C4 alkyl or C1-C4 alkoxy, or One R 3 and an R 4 Together with the atoms of the ring C to which they are attached, they form a substituted or unsubstituted ring; R 5 and R 6 are each independently H, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, or R 5 and R 6 Together with the nitrogen to which they are attached, they form a substituted or unsubstituted ring; m and n are each independently 0, 1, 2, 3 or 4.

2. The compound according to claim 0 or a pharmaceutically acceptable salt thereof, wherein Ring A is a substituted or unsubstituted heteroaromatic ring fused to Ring B.

3. The compound according to claim 0 or 0, which has the structure of formula (II): or a pharmaceutically acceptable salt thereof, wherein R 9 It is H or a linear or branched C1-C4 alkyl group.

4. The compound as claimed in claim 3, wherein R 9 It's methyl.

5. The compound according to claim 1 or 2, which has the structure of formula (III): or a pharmaceutically acceptable salt thereof, wherein R 10 It is a straight chain or branched C1-C4 alkyl C1-C4 alkyl or an electron-withdrawing functional group.

6. The compound according to any one of claims 1, 2 and 5, which has the structure of formula (IIIa): or a pharmaceutically acceptable salt thereof.

7. The compound according to claim 5 or 6, wherein R 10 Selected from halogen, -CH3, -SO2CF3, -N(R 11 )2, -NO2, -SO2R 12 、-C≡N、-C(R 13 3. -COR 14 、-CO2R 16 、-CON(R17 )2 and -N=O, wherein: R 11 , R 12 , R 14 , R 16 or R 17 Each of is independently H or a linear or branched C1-C4 alkyl group; and Each R 13 It's a halogen.

8. A compound as claimed in any one of claims 5 to 7, wherein R 10 It is -Cl.

9. The compound of any one of claims 5 to 7, wherein R 10 Yes -C≡N.

10. The compound of any one of claims 1 to 9, wherein R 1 It is a straight chain or branched C1-C4 alkyl group.

11. The compound of any one of claims 1 to 10, wherein R 1 It's methyl.

12. A compound as described in any one of claims 1 to 11, wherein each R 4 is independently a linear or branched C1-C4 alkyl or C1-C4 alkoxy group, or one R 3 and an R 4 Together with the atoms of the ring C to which they are attached, they form a substituted or unsubstituted ring.

13. A compound as described in any one of claims 0 to 12, wherein R 2 Selected from H, halogen, -SO2CF3, -N(R 32 )2, -NO2, -SO2R 26 、-C≡N、-C(R 33 3. -COR 28 、-CHO、-COR 29 、-CO2R 30 、-CON(R 31 )2 and -N=O, wherein: R 32 , R 26 , R 28 , R 29 , R 30 or R 31 Each of is independently H or C1-C4 alkyl; and Each R 33 It's a halogen.

14. A compound as claimed in any one of claims 0 to 12, or wherein R 2 Selected from H, halogen, -SO2CF3, -N(R 32 )2, -NO2, -SO2R 26 、-C≡N、-C(R 33 3. -COR 28 、-CHO、-COR 29 、-CO2R 30 、-CON(R 31 )2 and -N=O, wherein: R 32 , R 26 , R 28 , R 29 , R 30 or R 31 Each of is independently H or a linear or branched C1-C4 alkyl group; and Each R 33 It's a halogen.

15. The compound of any one of claims 0 to 14, wherein R 2 It's H.

16. A compound as described in any one of claims 0 to 14, wherein R 2 Yes -C≡N.

17. The compound as claimed in any one of claims 0 to 16, wherein ring C is further replaced by one or more selected from R 15 , R 18 , R 19 , R 20 , R 21 and R 22 Substituents of R 15 is C1-C4 alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 18 and R 19 Each is independently H, OH, C1-C4 alkoxy, C1-C4 alkyl or -NR 23 R 24 , or R 18 and R 19 Together with the carbon atoms to which they are attached, they form a substituted or unsubstituted ring; R 20 is H, C1-C4 alkyl or electron withdrawing group, or R 18 and R 20 or R 19 and R 20 Together with the carbon atoms to which they are attached, they form a substituted or unsubstituted ring; R 21 is H, C1-C4 alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 22 is C1-C4 alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and R 23 and R 24 Each is independently H, C1-C4 alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

18. The compound according to any one of claims 0 to 16, wherein ring C is further replaced by one or more selected from R 15 , R 18 , R 19 , R 20 , R 21 and R 22 Substituents of R 15 is a linear or branched C1-C4 alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group; R 18 and R 19 Each independently represents H, OH, C1-C4 alkoxy, linear or branched C1-C4 alkyl or -NR 23 R 24 , or R 18 and R 19 Together with the carbon atoms to which they are attached, they form a substituted or unsubstituted ring; R 20 is H, a straight or branched C1-C4 alkyl group or an electron withdrawing group, or R 18 and R 20 or R 19 and R 20 Together with the carbon atoms to which they are attached, they form a substituted or unsubstituted ring; R 21 is H, linear or branched C1-C4 alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 22 is a linear or branched C1-C4 alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group; and R 23 and R 24 Each is independently H, a linear or branched C1-C4 alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group.

19. The compound as claimed in any one of claims 0 to 16, wherein ring C is further replaced by one or more selected from R 15 , R 18 , R 19 , R 20 , R 21 and R 22 Substituents of R 15 is a linear or branched C1-C4 alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group; R 18 and R 19 Each is independently C1-C4 alkoxy, C1-C4 alkyl or -NR 23 R 24 , or R 18 and R 19 Together with the carbon atoms to which they are attached, they form a substituted or unsubstituted ring; R 20 is a straight chain or branched C1-C4 alkyl group or an electron withdrawing group, or R 18 and R 20 or R 19 and R 20 Together with the carbon atoms to which they are attached, they form a substituted or unsubstituted ring; R 21 is a linear or branched C1-C4 alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group; R 22 is a linear or branched C1-C4 alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group; and R 23 and R 24 Each is independently a linear or branched C1-C4 alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group.

20. The compound of any one of claims 1 to 19, wherein ring C is selected from in: The point of attachment of ring C to ring B is indicated.

21. A compound as described in any one of claims 17 to 20, wherein R 21 It is a straight chain or branched C1-C4 alkyl group.

22. A compound as described in any one of claims 17 to 21, wherein R 22 It is a straight chain or branched C1-C4 alkyl group.

23. A compound as described in any one of claims 17 to 22, wherein R 15 It is a straight chain or branched C1-C4 alkyl group.

24. The compound of any one of claims 1 to 16, wherein ring C is Where R 18 and R 19 Together with the carbon atoms to which they are attached, they form a substituted or unsubstituted 5-membered or 6-membered carbocyclic ring or a substituted or unsubstituted 5-membered or 6-membered heterocyclic ring.

25. The compound of any one of claims 1 to 16, wherein ring C is Where R 18 and R 20 or R 19 and R 20 Together with the carbon atoms to which they are attached, they form a substituted or unsubstituted 5-membered, 6-membered or 7-membered carbocyclic ring or a substituted or unsubstituted 5-membered, 6-membered or 7-membered heterocyclic ring.

26. A compound as described in any one of claims 17 to 25, wherein R 20 It is a straight chain or branched C1-C4 alkyl group.

27. The compound of any one of claims 0 to 16, wherein ring C is selected from 28. A compound as described in any one of claims 1 to 16, wherein ring C is Where R 21 yes in Each R 25 independently selected from OH, halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, substituted and unsubstituted aryl, and substituted and unsubstituted heteroaryl; t is 0, 1, or 2; and ---Indicates R21 The connection point with N.

29. A compound as described in any one of claims 1 to 16, wherein ring C is Where R 21 yes in Each R 25 independently selected from OH, halogen, linear or branched C1-C4 alkyl, C1-C4 alkoxy, linear or branched C1-C4 haloalkyl, C1-C4 haloalkoxy, substituted and unsubstituted aryl, and substituted and unsubstituted heteroaryl; t is 0, 1, or 2; and Indicator R 21 The connection point with N.

30. The compound of claim 28 or 29, wherein each R 25 Independently selected from OH, halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, unsubstituted aryl and unsubstituted heteroaryl.

31. The compound of claim 28 or 29, wherein each R 25 Independently selected from OH, halogen, linear or branched C1-C4 alkyl, C1-C4 alkoxy, linear or branched C1-C4 haloalkyl, C1-C4 haloalkoxy, unsubstituted aryl and unsubstituted heteroaryl.

32. The compound of claim 29, wherein ring C is 33. A compound as described in any one of claims 017 to 20 and 27 to 32, wherein R 21 Selected from 34. A compound as described in any one of claims 17 to 19 and 22, wherein ring C is selected from 35. A compound as described in any one of claims 17 to 19, 27 and 34, wherein R 22 is C1-C4 alkyl, unsubstituted aryl or unsubstituted heteroaryl.

36. The compound of claim 35, wherein R 22 It is a straight chain or branched C1-C4 alkyl group.

37. A compound as described in any one of claims 1 to 16, wherein ring C is Where R 18 and R 19 Each is independently selected from -H, -OH, alkyl, and wherein: R 26 is H, C1-C4 alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; Each R 27 is -OH, C1-C4 alkyl, halogen, C1-C4 alkoxy or C1-C4 haloalkoxy, or Two adjacent R 27 The group and the two carbon atoms to which they are attached form a substituted or unsubstituted 5-membered or 6-membered ring; q is 0, 1, or 2; and Indicator R 18 and R 19 The point of attachment of one or both to ring C.

38. A compound as described in any one of claims 1 to 16, wherein ring C is Where R 18 and R 19 are each independently selected from -H, -OH, C1-C4 alkyl, and in: R 26 is H, C1-C4 alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; Each R 27 is -OH, C1-C4 alkyl, halogen, C1-C4 alkoxy or C1-C4 haloalkoxy, or Two adjacent R 27 The group and the two carbon atoms to which they are attached form a substituted or unsubstituted 5-membered or 6-membered ring; q is 0, 1, or 2; and Indicator R 18 and R 19 The point of attachment of one or both to ring C.

39. A compound as described in any one of claims 1 to 16, wherein ring C is or a pharmaceutically acceptable salt thereof, wherein R 18 and R 19 are each independently selected from -H, -OH, a linear or branched C1-C4 alkyl group, and in: R 26 is H, linear or branched C1-C4 alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; Each R 27 is -OH, linear or branched C1-C4 alkyl, halogen, C1-C4 alkoxy or C1-C4 haloalkoxy, or Two adjacent R 27 The group and the two carbon atoms to which they are attached form a substituted or unsubstituted 5-membered or 6-membered ring; q is 0, 1, or 2; and Indicator R 18 and R 19 The point of attachment of one or both to ring C.

40. A compound as described in any one of claims 37 to 39, wherein R 26 It is a straight chain or branched C1-C4 alkyl group.

41. The compound of any one of claims 1 to 19, wherein ring C is selected from 42. A compound as described in any one of claims 27 and 34 to 41, wherein R 18 and R 19 Together with the carbon atoms to which they are attached, they form in: X and Y are each independently CH2, NR 29 , O or C=O; Each R 28 independently selected from -OH, halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy and C1-C4 haloalkoxy; R 29 is H or C1-C4 alkyl; and w is 0, 1, or 2.

43. A compound as described in any one of claims 27 and 34 to 41, wherein R 18 and R 19 Together with the carbon atoms to which they are attached, they form in: X and Y are each independently CH2, NR 29 , O or C=O; Each R 28 Independently selected from -OH, halogen, linear or branched C1-C4 alkyl, linear or branched C1-C4 haloalkyl, C1-C4 alkoxy and C1-C4 haloalkoxy; R 29 is H or C1-C4 alkyl; and w is 0, 1, or 2.

44. A compound as described in any one of claims 0 to 16, wherein ring C is selected from 45. The compound of any one of claims 0 to 16, wherein ring C is selected from 46. ​​The compound of any one of claims 1 to 16, wherein ring C is selected from 47. A compound as described in any one of claims 1 to 16, wherein ring C is selected from Where R 34 It is a C1-C4 alkyl group.

48. A compound as described in any one of claims 1 to 16, wherein ring C is selected from Where R 34 It is a straight chain or branched C1-C4 alkyl group.

49. A compound as described in any one of claims 0 to 16 or a pharmaceutically acceptable salt thereof, wherein ring C is Where R 15 yes or 50. The compound of any one of claims 0 to 16, wherein ring C is selected from 51. A compound as described in any one of claims 0 to 16, wherein ring C is 52. A compound selected from: or a pharmaceutically acceptable salt thereof.

53. A compound selected from: or a pharmaceutically acceptable salt thereof, wherein: X is CH2, O or NR 29 ;as well as R 29 It is H or C1-C4 alkyl.

54. The compound of claim 53, wherein R 29 It is a straight chain or branched C1-C4 alkyl group.

55. A compound, wherein the compound is selected from: or a pharmaceutically acceptable salt thereof.

56. A pharmaceutical composition comprising a compound as described in any one of claims 0 to 55 and a pharmaceutically acceptable excipient.

57. The pharmaceutical composition of claim 56, further comprising one or more additional anticancer agents.

58. The pharmaceutical composition of claim 57, wherein at least one of the additional anti-cancer agents is an immune checkpoint inhibitor.

59. A method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a compound as described in any one of claims 1 to 55 or a pharmaceutical composition as described in any one of claims 56 to 58.

60. The method of claim 59, wherein the cancer is selected from the group consisting of colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, cervical cancer, kidney cancer, head and neck cancer, lymphoma, lymphoma, leukemia, and melanoma.

61. A method of inhibiting the activity of diacylglycerol kinase alpha (DGKα), comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof as described in any one of claims 1 to 55 or a pharmaceutical composition as described in any one of claims 56 to 58.